Document_and_Entity_Informatio
Document and Entity Information (USD $) | 3 Months Ended |
In Thousands, except Share data, unless otherwise specified | Mar. 31, 2014 |
Document and Entity Information [Abstract] | ' |
Document period end date | 31-Mar-14 |
Amendment flag | 'false |
Entity registrant name | 'FRESENIUS MEDICAL CARE AG & Co. KGaA |
Entity current reporting status | 'Yes |
Entity voluntary filers | 'Yes |
Entity central index key | '0001333141 |
Document type | '6-K |
Current fiscal year end date | '--12-31 |
Entity filer category | 'Large Accelerated Filer |
Entity well known seasoned issuer | 'Yes |
Entity common stock shares outstanding | 301,491,046 |
Entity public float | $17,790,161,435 |
Document Fiscal Year Focus | '2014 |
Document Fiscal Period Focus | 'Q1 |
Consolidated_Statements_of_Inc
Consolidated Statements of Income (USD $) | 3 Months Ended | |
In Thousands, except Per Share data, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Net revenue: | ' | ' |
Dialysis Care Revenue | $2,845,424 | $2,741,935 |
Valuation Allowances and Reserves, Adjustments | -63,237 | -63,749 |
Net Dialysis care revenue | 2,782,187 | 2,678,186 |
Dialysis Products Revenue | 781,405 | 785,735 |
Net revenue | 3,563,592 | 3,463,921 |
Costs of revenue: | ' | ' |
Dialysis Care Cost of Revenue | 2,117,604 | 1,984,224 |
Dialysis Products Cost of Revenue | 363,856 | 370,179 |
Cost of revenues | 2,481,460 | 2,354,403 |
Gross profit | 1,082,132 | 1,109,518 |
Operating expenses: | ' | ' |
Selling, general and administrative | 619,733 | 591,714 |
Research and development | 30,028 | 30,372 |
Income from equity method investees | -12,522 | -4,808 |
Gain on the sale of dialysis clinics | -2 | -1,073 |
Operating income | 444,895 | 493,313 |
Other (income) expense: | ' | ' |
Interest income | -15,415 | -10,589 |
Interest expense | 111,676 | 114,818 |
Income before income taxes | 348,634 | 389,084 |
Income tax expense | 101,284 | 129,001 |
Net Income | 247,350 | 260,083 |
Less: Net income attributable to noncontrolling interests | 41,888 | 34,584 |
Net Income attributable to the Company | $205,462 | $225,499 |
Basic income per Ordinary share | $0.68 | $0.74 |
Earning Per Share Diluted | $0.68 | $0.73 |
Consolidated_Statements_of_Com
Consolidated Statements of Comprehensive Income (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Consolidated Statements of Comprehensive Income | ' | ' |
Net Income | $247,350 | $260,083 |
Other comprehensive income loss derivatives qualifying as hedges before tax | 6,959 | 15,897 |
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax | 4,354 | 6,398 |
Other comprehensive income loss foreign currency transaction and translation adjustment before tax | -47,056 | -68,192 |
Other comprehensive income loss tax | -3,550 | -6,684 |
Other comprehensive income (loss), net of tax | -39,293 | -52,581 |
Total comprehensive income | 208,057 | 207,502 |
Comprehensive income attributable to Noncontrolling interests | 41,855 | 32,602 |
Comprehensive income attributable to the Company | $166,202 | $174,900 |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Current assets: | ' | ' |
Cash and cash equivalents | $574,127 | $682,777 |
Trade accounts receivable less allowance for doubtful accounts of $403,657 in 2014 and $413,165 in 2013 | 3,080,334 | 3,037,274 |
Accounts receivable from related parties | 171,186 | 153,118 |
Inventories | 1,206,772 | 1,097,104 |
Prepaid expenses and other current assets | 1,195,392 | 1,037,391 |
Deferred tax asset, current | 268,910 | 279,052 |
Total current assets | 6,496,721 | 6,286,716 |
Property, plant and equipment, net | 3,135,123 | 3,091,954 |
Intangible assets | 734,227 | 757,876 |
Goodwill | 11,646,157 | 11,658,187 |
Deferred tax asset, non-current | 108,480 | 104,167 |
Equity Method Investments | 733,912 | 664,446 |
Other assets | 568,057 | 556,560 |
Total assets | 23,422,677 | 23,119,906 |
Current liabilities: | ' | ' |
Accounts payable | 550,668 | 542,597 |
Accounts payable to related parties | 164,229 | 123,929 |
Accrued expenses and other current liabilities | 1,900,239 | 2,012,533 |
Short-term borrowings and other financial liabilities | 157,226 | 96,648 |
Short-term borrowings from related parties | 134,314 | 62,342 |
Current portion of long-term debt and capital lease obligations | 301,275 | 511,370 |
Income tax payable, current | 203,554 | 170,360 |
Deferred tax liability, current | 35,811 | 34,194 |
Total current liabilities | 3,447,316 | 3,553,973 |
Total long-term debt less current maturities | 8,016,155 | 7,746,920 |
Other liabilities | 333,220 | 329,561 |
Pension liabilities | 413,388 | 435,858 |
Income tax payable, non-current | 166,040 | 176,933 |
Deferred tax liability, non-current | 734,329 | 743,390 |
Total liabilities | 13,110,448 | 12,986,635 |
Noncontrolling interests subject to put provisions | 631,940 | 648,251 |
Company shareholders' equity: | ' | ' |
Common stock, no par value, 1.00 Euro nominal value, 392,462,972 shares authorized, 309,111,125 issued and 301,562,174 outstanding | 382,569 | 382,411 |
Treasury Stock | 505,014 | 505,014 |
Additional paid-in capital | 3,553,425 | 3,530,337 |
Retained earnings | 6,582,879 | 6,377,417 |
Accumulated other comprehensive (loss) | -589,847 | -550,587 |
Total Company shareholders' equity | 9,424,012 | 9,234,564 |
Minority interest | 256,277 | 250,456 |
Total equity | 9,680,289 | 9,485,020 |
Total liabilities and equity | $23,422,677 | $23,119,906 |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets (Parentheticals) | Mar. 31, 2014 | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, except Share data, unless otherwise specified | USD ($) | EUR (€) | USD ($) |
Consolidated Balance Sheets | ' | ' | ' |
Trade accounts receivable allowance for doubtful accounts | $403,657 | ' | $413,165 |
Preference shares, no par value (in Euros) | ' | € 1 | ' |
Common stock no par value (in Euros) | ' | € 1 | ' |
Common stock authorized | 392,462,972 | 392,462,972 | ' |
Common stock issued | 308,995,730 | 308,995,730 | ' |
Common stock outstanding | 301,446,779 | 301,446,779 | ' |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Operating Activities: | ' | ' |
Net Income | $247,350 | $260,083 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' |
Depreciation and amortization | 167,167 | 156,353 |
Change in deferred taxes, net | -3,459 | -22,455 |
(Gain) loss on sale of investments | -2 | -1,073 |
(Gain) loss on sale of fixed assets | 808 | 1,401 |
Stock Option Compensation Expense | 6,174 | 6,220 |
Dividend income from equity method investees | 32,399 | 18,582 |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' |
Trade accounts receivable, net | -62,915 | -40,702 |
Inventories, net | -111,648 | -56,173 |
Prepaid expenses, other current and non-current assets | -26,831 | 32,079 |
Accounts receivable, related parties | -18,215 | -24,934 |
Accounts payable, related parties | 41,018 | 23,459 |
Accounts payable, accrued expenses and other current and non-current liabilities | -180,308 | -99,671 |
Income tax payable | 20,756 | 62,249 |
Net cash provided by (used in) operating activities | 112,294 | 315,418 |
Investing Activities: | ' | ' |
Purchases of property, plant and equipment | -199,631 | -147,357 |
Proceeds from sale of property, plant and equipment | 2,480 | 1,327 |
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets | -137,157 | -72,214 |
Proceeds from divestitures | 2,381 | 1,036 |
Net cash (used in) provided by investing activities | -331,927 | -217,208 |
Financing Activities: | ' | ' |
Proceeds from short-term borrowings and other financial liabilities | 40,200 | 46,349 |
Repayments of short-term borrowings and other financial liabilities | -35,277 | -41,930 |
Proceeds from short-term borrowings from related parties | 72,178 | 4,226 |
Repayments of short-term borrowings from related parties | ' | -1,606 |
Proceeds from long-term debt and capital lease obligations (net of debt issuance costs and other hedging costs of $156,391 in 2012) | 271,544 | 598 |
Repayments of long-term debt and capital lease obligations | -267,486 | -32,915 |
Increase (decrease) of accounts receivable securitization program | 68,000 | -162,000 |
Proceeds from exercise of stock options | 5,807 | 4,635 |
Proceeds from conversion of preference shares into ordinary shares | -52,157 | ' |
Distributions to Noncontrolling interests | ' | -72,619 |
Contributions from noncontrolling interests | 13,402 | 8,795 |
Cash provided by (used in) financing activities | 116,211 | -246,467 |
Effect of exchange rate changes on cash and cash equivalents | -5,228 | -4,942 |
Cash and Cash Equivalents: | ' | ' |
Net (decrease) in cash and cash equivalents | -108,650 | -153,199 |
Cash and cash equivalents at beginning of period | 682,777 | 688,040 |
Cash and cash equivalents at end of period | $574,127 | ' |
Consolidated_Statements_of_Sha
Consolidated Statements of Shareholders' Equity (USD $) | Total | Preferred Stock, No par value [Member] | Common Stock, No par value [Member] | Treasury Stock Equity | Additional paid in capital [Member] | Retained earnings [Member] | Accumulated other comprehensive income (loss) [Member] | Total FMC-AG and Co. KGaA [Member] | Noncontrolling interests not subject to put provisions [Member] |
In Thousands, except Share data, unless otherwise specified | |||||||||
Shareholders equity at Dec. 31, 2012 | ' | ' | $374,915 | ' | $3,491,581 | $5,563,661 | ($492,113) | $8,942,506 | $264,754 |
Shares issued at Dec. 31, 2012 | ' | 3,973,333 | 302,739,758 | ' | ' | ' | ' | ' | ' |
Proceeds from exercise of options and related tax effects | 105,554 | 3 | ' | ' | 102,520 | ' | ' | 105,554 | ' |
Shares from exercise of options and related tax effects | ' | 2,200 | 2,280,439 | ' | ' | ' | ' | ' | ' |
Proceeds from conversion of preference shares | 34,784 | -4,465 | ' | ' | 34,784 | ' | ' | 34,784 | ' |
Preference share conversion | ' | -3,975,533 | 3,975,533 | ' | ' | ' | ' | ' | ' |
Compensation expense related to stock options | -13,593 | ' | ' | ' | -13,593 | ' | ' | -13,593 | ' |
Dividends paid | 296,134 | ' | ' | ' | ' | 296,134 | ' | 296,134 | ' |
treasury stock value | -505,014 | ' | ' | -505,014 | ' | ' | ' | -505,014 | ' |
treasury stock shares | ' | ' | ' | -7,548,951 | ' | ' | ' | ' | ' |
Minority interest increase from stock issuance | -15,173 | ' | ' | ' | -3,566 | ' | ' | -3,566 | -11,607 |
Minority interest decrease from distributions to noncontrolling interest holders | -32,275 | ' | ' | ' | ' | ' | ' | ' | -32,275 |
Changes in fair value of noncontrolling interests | -108,575 | ' | ' | ' | -108,575 | ' | ' | -108,575 | ' |
Comprehensive income net of tax including portion attributable to noncontrolling interest abstract | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other comprehensive income loss net of tax period increase decrease less amounts attributable to noncontrolling interests subject to put provisions | -61,467 | ' | ' | ' | ' | ' | -58,474 | -58,474 | -2,993 |
Profit loss less amounts attributable to noncontrolling interests subject to put provisions | 1,142,467 | ' | ' | ' | ' | 1,109,890 | ' | 1,109,890 | 32,577 |
Comprehensive income net of tax including portion attributable to noncontrolling interest less amounts attributable to noncontrolling interests subject to put provisions | 1,081,000 | ' | ' | ' | ' | ' | ' | 1,051,416 | 29,584 |
Shareholders equity at Dec. 31, 2013 | 9,485,020 | ' | ' | -505,014 | ' | 6,377,417 | -550,587 | 9,234,564 | 250,456 |
Shares issued at Dec. 31, 2013 | ' | ' | ' | -7,548,951 | ' | ' | ' | ' | ' |
Proceeds from exercise of options and related tax effects | 5,801 | ' | 158 | ' | 5,643 | ' | ' | 5,801 | ' |
Shares from exercise of options and related tax effects | ' | ' | 115,395 | ' | ' | ' | ' | ' | ' |
Compensation expense related to stock options | 6,174 | ' | ' | ' | 6,174 | ' | ' | 6,174 | ' |
Minority interest increase from stock issuance | -2,879 | ' | ' | ' | -2,576 | ' | ' | -2,576 | -303 |
Minority interest decrease from distributions to noncontrolling interest holders | -8,951 | ' | ' | ' | ' | ' | ' | ' | -8,951 |
Changes in fair value of noncontrolling interests | 13,847 | ' | ' | ' | 13,847 | ' | ' | 13,847 | ' |
Comprehensive income net of tax including portion attributable to noncontrolling interest abstract | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other comprehensive income loss net of tax period increase decrease less amounts attributable to noncontrolling interests subject to put provisions | -39,305 | ' | ' | ' | ' | ' | -39,260 | -39,260 | -45 |
Profit loss less amounts attributable to noncontrolling interests subject to put provisions | 220,582 | ' | ' | ' | ' | 205,462 | ' | 205,462 | 15,120 |
Comprehensive income net of tax including portion attributable to noncontrolling interest less amounts attributable to noncontrolling interests subject to put provisions | 181,277 | ' | ' | ' | ' | ' | ' | 166,202 | 15,075 |
Shareholders equity at Mar. 31, 2014 | $9,680,289 | ' | ' | ($505,014) | $3,553,425 | $6,582,879 | ($589,847) | $9,424,012 | $256,277 |
Shares issued at Mar. 31, 2014 | ' | ' | ' | -7,548,951 | ' | ' | ' | ' | ' |
The_Company_Basis_of_Presentat
The Company, Basis of Presentation, Healthcare Reform and Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2014 | |
Notes to Consolidated Financial Statements [Abstract] | ' |
The Company and Basis of Presentation | ' |
1. The Company and Basis of Presentation | |
The Company | |
Fresenius Medical Care AG & Co. KGaA (“FMC-AG & Co. KGaA” or the “Company”), a German partnership limited by shares (Kommanditgesellschaft auf Aktien), is the world's largest kidney dialysis company, operating in both the field of dialysis care and the field of dialysis products for the treatment of end-stage renal disease (“ESRD”). The Company's dialysis care business, in addition to providing dialysis treatments to patients with ESRD, includes pharmacy services, vascular access surgery services and laboratory services (together, “Care Coordination”). The Company's dialysis products business includes manufacturing and distributing products for the treatment of ESRD. The Company's dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a broad range of products. In addition, the Company sells dialysis products to other dialysis service providers. In the United States (“U.S.”), the Company also provides inpatient dialysis services as well as other services under contract to hospitals. | |
In these unaudited consolidated financial statements, “FMC-AG & Co. KGaA,” or the “Company,” “we,” “us” or “our” refers to the Company or the Company and its subsidiaries on a consolidated basis, as the context requires. The term “North America Segment” refers to the North America operating segment. The term “International Segment” refers to the combined Europe, Middle East, Africa and Latin America (“EMEALA”) operating segment and the Asia-Pacific operating segment. For further discussion of our operating segments, see Note 13 “Segment and Corporate Information.” | |
Basis of Presentation | |
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). | |
The consolidated financial statements at March 31, 2014 and for the three-months ended March 31, 2014 and 2013 contained in this report are unaudited and should be read in conjunction with the consolidated financial statements contained in the Company's 2013 Annual Report on Form 20-F. The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Such financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair presentation of the results of the periods presented. All such adjustments are of a normal recurring nature. | |
The accounting policies applied in the accompanying consolidated financial statements are the same as those applied in the consolidated financial statements at and for the year ended December 31, 2013, contained in the Company's 2013 Annual Report on Form 20-F. | |
Certain items, in the net aggregate amount of $5,006 relating to research and development, compensation expense, and income from equity method investees have been reclassified in the prior year's comparative consolidated financial statements between the North America Segment, the International Segment and Corporate, as applicable, to conform to the current year's presentation. | |
The results of operations for the three-months ended March 31, 2014 are not necessarily indicative of the results of operations for the year ending December 31, 2014. | |
Related_Party_Transactions
Related Party Transactions | 3 Months Ended |
Mar. 31, 2014 | |
Notes to Consolidated Financial Statements [Abstract] | ' |
Related Party Transactions | ' |
2. Related Party Transactions | |
The Company's parent, Fresenius SE & Co. KGaA (“Fresenius SE”), a German partnership limited by shares, owns 100% of the share capital of Fresenius Medical Care Management AG, the Company's general partner (“General Partner”). Fresenius SE is also the Company's largest shareholder and owns approximately 31.3% of the Company's outstanding shares at March 31, 2014. The Company has entered into certain arrangements for the purchase and sale of products and services with Fresenius SE or its subsidiaries and with certain of the Company's joint ventures as described in items a), b) and d) below. The Company's terms related to the receivables or payables for these products and services are generally consistent with the normal terms of the Company's business. Financing arrangements as described in item c) below normally have agreed upon terms which are determined at the time such financing transactions occur and usually reflect market rates at the time of the transaction. Our related party transactions are settled through Fresenius SE's cash management system where appropriate. | |
a) Service and Lease Agreements | |
The Company is party to service agreements with Fresenius SE and certain of its affiliates (collectively the “Fresenius SE Companies”) to receive services, including, but not limited to: administrative services, management information services, employee benefit administration, insurance, information technology services, tax services and treasury management services. During the three-months ended March 31, 2014 and 2013, amounts charged by Fresenius SE Companies to the Company under the terms of these agreements were $27,467 and $23,973, respectively. The Company also provides certain services to the Fresenius SE Companies, including research and development, central purchasing and warehousing. The Company charged $1,848 and $1,719 for services rendered to the Fresenius SE Companies during the first three months of 2014 and 2013 respectively. | |
Under real estate operating lease agreements entered into with the Fresenius SE Companies, which are leases for the corporate headquarters in Bad Homburg, Germany and production sites in Schweinfurt and St. Wendel, Germany, the Company paid the Fresenius SE Companies $7,038 and $6,569 during the three months ended March 31, 2014 and 2013, respectively. The majority of the leases expire in 2016 and contain renewal options. | |
The Company's Articles of Association provide that the General Partner shall be reimbursed for any and all expenses in connection with management of the Company's business, including remuneration of the members of the General Partner's supervisory board and the members of the General Partner's management board. The aggregate amount reimbursed to the General Partner was $8,172 and $4,511, respectively, for its management services during the three months ended March 31, 2014 and 2013. | |
b) Products | |
For the first three months of 2014 and 2013, the Company sold products to the Fresenius SE Companies for $7,481 and $7,215, respectively. During the same periods, the Company made purchases from the Fresenius SE Companies in the amount of $5,907 and $10,364, respectively. | |
In addition to the purchases noted above, Fresenius Medical Care Holdings, Inc. (“FMCH”) currently purchases heparin supplied by Fresenius Kabi USA, Inc. (“Kabi USA”), through an independent group purchasing organization (“GPO”). Kabi USA is wholly-owned by Fresenius Kabi AG, a wholly-owned subsidiary of Fresenius SE. The Company has no direct supply agreement with Kabi USA and does not submit purchase orders directly to Kabi USA. During the three-months ended March 31, 2014 and 2013, FMCH acquired approximately $5,348 and $4,560, respectively, of heparin from Kabi USA, through the GPO contract, which was negotiated by the GPO at arm's length on behalf of all members of the GPO. | |
c) Financing | |
The Company receives short-term financing from and provides short-term financing to Fresenius SE. The Company also utilizes Fresenius SE's cash management system for the settlement of certain intercompany receivables and payables with its subsidiaries and other related parties. As of March 31, 2014 and December 31, 2013, the Company had accounts receivables from Fresenius SE in the amount of $149,350 and $112,568, respectively. As of March 31, 2014 and December 31, 2013, the Company had accounts payables to Fresenius SE in the amount of $134,817 and $102,731, respectively. The interest rates for these cash management arrangements are set on a daily basis and are based on the then-prevailing overnight reference rate for the respective currencies. | |
At March 31, 2014, the Company borrowed from Fresenius SE €52,700 ($72,663 at March 31, 2014) at an interest rate of 1.612%. This loan was renewed and increased to €142,300 ($197,350) at an interest rate of 1.644% and is due on May 31, 2014. | |
On August 19, 2009, the Company borrowed €1,500 ($2,068 at March 31, 2014) from the General Partner at 1.335%. The loan repayment has been extended periodically and is currently due August 20, 2014 with an interest rate of 1.796%. On November 28, 2013, the Company borrowed an additional €1,500 ($2,068 at March 31, 2014) from the General Partner at 1.875%. This loan is due on November 28, 2014. | |
At March 31, 2014, the Company had a Chinese Yuan Renminbi (“CNY”) loan of 357,710 ($57,515 at March 31, 2014) outstanding with a subsidiary of Fresenius SE at an interest rate of 6.1% and a maturity date of May 23, 2014. | |
d) Other | |
The Company performs clinical studies for certain of its joint ventures for which services the Company received $657 and $1,348 for the three months ended March 31, 2014 and 2013, respectively. In addition, the Company also performs marketing and distribution services for a joint venture for which services the Company received $4,349 and $4,006 for the three months ended March 31, 2014 and 2013, respectively. | |
At March 31, 2014 and December 31, 2013, a subsidiary of Fresenius SE held Senior Notes issued by the Company in the amount of €11,800 and €11,800 ($16,270 and $16,273), respectively. The Senior Notes were issued in 2011 and 2012 and have a coupon rate of 5.25% with interest payable semiannually. |
Inventories
Inventories | 3 Months Ended | ||||||
Mar. 31, 2014 | |||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||
Inventories | ' | ||||||
3. Inventories | |||||||
At March 31, 2014 and December 31, 2013, inventories consisted of the following: | |||||||
31-Mar-14 | 31-Dec-13 | ||||||
Finished goods | $ | 751,027 | $ | 640,355 | |||
Raw materials and purchased components | 194,808 | 185,146 | |||||
Health care supplies | 186,687 | 195,519 | |||||
Work in process | 74,250 | 76,084 | |||||
Inventories | $ | 1,206,772 | $ | 1,097,104 |
ShortTerm_Borrowings_and_Other
Short-Term Borrowings and Other Financial Liabilities, and Short-Term Borrowings from Related Parties | 3 Months Ended | ||||||
Mar. 31, 2014 | |||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||
Short-Term Borrowings and Other Financial Liabilities, and Short-Term Borrowings from Related Parties | ' | ||||||
Short-Term Borrowings, Other Financial Liabilities and Short-Term Borrowings from Related Parties | |||||||
At March 31, 2014 and December 31, 2013, short-term borrowings, other financial liabilities and short-term borrowings from related parties consisted of the following: | |||||||
31-Mar-14 | 31-Dec-13 | ||||||
Borrowings under lines of credit | $ | 100,429 | $ | 95,690 | |||
Other financial liabilities | 56,797 | 958 | |||||
Short-term borrowings and other financial liabilities | 157,226 | 96,648 | |||||
Short-term borrowings from related parties (see Note 2.c) | 134,314 | 62,342 | |||||
Short-term borrowings, other financial liabilities and short-term borrowings from related parties | $ | 291,540 | $ | 158,990 | |||
31-Mar-14 | 31-Dec-13 | ||||||
Borrowings under lines of credit | $ | 100,429 | $ | 95,690 | |||
Other financial liabilities | 56,797 | 958 | |||||
Short-term borrowings and other financial liabilities | 157,226 | 96,648 | |||||
Short-term borrowings from related parties (see Note 2.c) | 134,314 | 62,342 | |||||
Short-term borrowings, other financial liabilities and short-term borrowings from related parties | $ | 291,540 | $ | 158,990 | |||
Longterm_Debt_and_Capital_Leas
Long-term Debt and Capital Lease Obligations | 3 Months Ended | |||||||||||||||||||
Mar. 31, 2014 | ||||||||||||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | |||||||||||||||||||
Long-term Debt and Capital Lease Obligations | ' | |||||||||||||||||||
5. Long-Term Debt and Capital Lease Obligations | ||||||||||||||||||||
At March 31, 2014 and December 31, 2013, long-term debt and capital lease obligations consisted of the following: | ||||||||||||||||||||
31-Mar-14 | 31-Dec-13 | |||||||||||||||||||
2012 Credit Agreement | $ | 2,910,561 | $ | 2,707,145 | ||||||||||||||||
Senior Notes | 4,825,384 | 4,824,753 | ||||||||||||||||||
Euro Notes | 46,535 | 46,545 | ||||||||||||||||||
European Investment Bank Agreements (1) | - | 193,074 | ||||||||||||||||||
Accounts receivable facility | 419,250 | 351,250 | ||||||||||||||||||
Capital lease obligations | 24,875 | 24,264 | ||||||||||||||||||
Other | 90,825 | 111,259 | ||||||||||||||||||
Long-term debt and capital lease obligations | 8,317,430 | 8,258,290 | ||||||||||||||||||
Less current maturities | -301,275 | -511,370 | ||||||||||||||||||
Long-term debt and capital lease obligations, less current portion | $ | 8,016,155 | $ | 7,746,920 | ||||||||||||||||
(1) The remaining two loans under the European Investment Bank Agreements were repaid on their maturity in February 2014. | ||||||||||||||||||||
31-Mar-14 | 31-Dec-13 | |||||||||||||||||||
2012 Credit Agreement | $ | 2,910,561 | $ | 2,707,145 | ||||||||||||||||
Senior Notes | 4,825,384 | 4,824,753 | ||||||||||||||||||
Euro Notes | 46,535 | 46,545 | ||||||||||||||||||
European Investment Bank Agreements (1) | - | 193,074 | ||||||||||||||||||
Accounts receivable facility | 419,250 | 351,250 | ||||||||||||||||||
Capital lease obligations | 24,875 | 24,264 | ||||||||||||||||||
Other | 90,825 | 111,259 | ||||||||||||||||||
Long-term debt and capital lease obligations | 8,317,430 | 8,258,290 | ||||||||||||||||||
Less current maturities | -301,275 | -511,370 | ||||||||||||||||||
Long-term debt and capital lease obligations, less current portion | $ | 8,016,155 | $ | 7,746,920 | ||||||||||||||||
(1) The remaining two loans under the European Investment Bank Agreements were repaid on their maturity in February 2014. | ||||||||||||||||||||
2012 Credit Agreement | ||||||||||||||||||||
The following table shows the available and outstanding amounts under the 2012 Credit Agreement at March 31, 2014 and at December 31, 2013: | ||||||||||||||||||||
Maximum Amount Available March 31, 2014 | Balance Outstanding March 31, 2014 | |||||||||||||||||||
Revolving Credit USD | $ | 600,000 | $ | 600,000 | $ | 336,469 | $ | 336,469 | ||||||||||||
Revolving Credit EUR | € | 500,000 | $ | 689,400 | € | 90,000 | $ | 124,092 | ||||||||||||
Term Loan A | $ | 2,450,000 | $ | 2,450,000 | $ | 2,450,000 | $ | 2,450,000 | ||||||||||||
$ | 3,739,400 | $ | 2,910,561 | |||||||||||||||||
Maximum Amount Available December 31, 2013 | Balance Outstanding December 31, 2013 | |||||||||||||||||||
Revolving Credit USD | $ | 600,000 | $ | 600,000 | $ | 138,190 | $ | 138,190 | ||||||||||||
Revolving Credit EUR | € | 500,000 | $ | 689,550 | € | 50,000 | $ | 68,955 | ||||||||||||
Term Loan A | $ | 2,500,000 | $ | 2,500,000 | $ | 2,500,000 | $ | 2,500,000 | ||||||||||||
$ | 3,789,550 | $ | 2,707,145 | |||||||||||||||||
Accounts Receivable Facility | ||||||||||||||||||||
The following table shows the available and outstanding amounts under the account receivable facility at March 31, 2014 and at December 31, 2013: | ||||||||||||||||||||
Maximum Amount Available(1) | Balance Outstanding | |||||||||||||||||||
31-Mar-14 | 31-Dec-13 | 31-Mar-14 | 31-Dec-13 | |||||||||||||||||
Accounts Receivable Facility | $ | 800,000 | $ | 800,000 | $ | 419,250 | $ | 351,250 | ||||||||||||
(1) Subject to availability of sufficient accounts receivable meeting funding criteria. | ||||||||||||||||||||
The Company also had letters of credit outstanding under the accounts receivable facility in the amount of $65,622 as of March 31, 2014 and December 31, 2013. These letters of credit are not included above as part of the balance outstanding at March 31, 2014 and December 31, 2013; however, they reduce available borrowings under the accounts receivable facility. |
Earnings_Per_Share
Earnings Per Share | 3 Months Ended | ||||||||||
Mar. 31, 2014 | |||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||||||
Earnings Per Share | ' | ||||||||||
6. Earnings Per Ordinary Share | |||||||||||
The following table contains reconciliations of the numerators and denominators of the basic and diluted earnings per ordinary share computations for the three-months ended March 31, 2014 and 2013: | |||||||||||
For the three months ended March 31, | |||||||||||
2014 | 2013 | ||||||||||
Numerators: | |||||||||||
Net income attributable to shareholders of FMC-AG & Co. KGaA | $ | 205,462 | $ | 225,499 | |||||||
less: | |||||||||||
Dividend preference on Preference shares(1) | - | 26 | |||||||||
Income available to all classes of shares | $ | 205,462 | $ | 225,473 | |||||||
Denominators: | |||||||||||
Weighted average number of: | |||||||||||
Ordinary shares outstanding | 301,491,046 | 302,773,218 | |||||||||
Preference shares outstanding(1) | - | 3,973,333 | |||||||||
Total weighted average shares outstanding | 301,491,046 | 306,746,551 | |||||||||
Potentially dilutive Ordinary shares | 378,831 | 1,131,149 | |||||||||
Potentially dilutive Preference shares(1) | - | 13,681 | |||||||||
Total weighted average Ordinary shares outstanding assuming dilution | 301,869,877 | 303,904,367 | |||||||||
Total weighted average Preference shares outstanding assuming dilution(1) | - | 3,987,014 | |||||||||
Basic income per Ordinary share | $ | 0.68 | $ | 0.74 | |||||||
Fully diluted income per Ordinary share | 0.68 | 0.73 | |||||||||
(1) As of the preference share conversion on June 28th, 2013, the Company no longer has two classes of shares outstanding. |
Employee_Benefit_Plans
Employee Benefit Plans | 3 Months Ended | |||||||||
Mar. 31, 2014 | ||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | |||||||||
Employee Benefit Plans | ' | |||||||||
7. Employee Benefit Plans | ||||||||||
The Company currently has two principal pension plans, one for German employees, the other covering employees in the United States, the latter of which was curtailed in 2002. Plan benefits are generally based on years of service and final salary. As there is no legal requirement in Germany to fund defined benefit plans, the Company's pension obligations in Germany are unfunded. Each year FMCH contributes to the plan covering United States employees at least the minimum required by the Employee Retirement Income Security Act of 1974, as amended. | ||||||||||
The following table provides the calculations of net periodic benefit cost for the three-months ended March 31, 2014 and 2013, respectively. | ||||||||||
For the three months ended March 31, | ||||||||||
2014 | 2013 | |||||||||
Components of net periodic benefit cost: | ||||||||||
Service cost | $ | 4,739 | $ | 3,913 | ||||||
Interest cost | 7,404 | 6,784 | ||||||||
Expected return on plan assets | -3,925 | -3,400 | ||||||||
Amortization of unrealized losses | 4,354 | 6,398 | ||||||||
Net periodic benefit costs | $ | 12,572 | $ | 13,695 |
Noncontrolling_Interests_Subje
Noncontrolling Interests Subject to Put Provisions | 3 Months Ended | ||||||
Mar. 31, 2014 | |||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||
Noncontrolling Interests Subject to Put Provisions | ' | ||||||
8. Noncontrolling Interests Subject to Put Provisions | |||||||
The Company has potential obligations to purchase the noncontrolling interests held by third parties in certain of its consolidated subsidiaries. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase all or part of third-party owners' noncontrolling interests at the appraised fair value at the time of exercise. The methodology the Company uses to estimate the fair values of the noncontrolling interest subject to put provisions assumes the greater of net book value or a multiple of earnings, based on historical earnings, development stage of the underlying business and other factors. The estimated fair values of the noncontrolling interests subject to these put provisions can also fluctuate and the implicit multiple of earnings at which these noncontrolling interest obligations may ultimately be settled could vary significantly from our current estimates depending upon market conditions. | |||||||
At March 31, 2014 and December 31, 2013, the Company's potential obligations under these put options were $631,940 and $648,251, respectively, of which, at March 31, 2014, put options with an aggregate purchase obligation of $251,453 were exercisable. No put options were exercised during the first three months of 2014. | |||||||
The following is a roll forward of noncontrolling interests subject to put provisions for the three months ended March 31, 2014 and the year ended December 31, 2013: | |||||||
31-Mar-14 | 31-Dec-13 | ||||||
Beginning balance as of January 1, | $ | 648,251 | $ | 523,260 | |||
Contributions to noncontrolling interests | -29,121 | -122,179 | |||||
Purchase/ sale of noncontrolling interests | -4,452 | 6,723 | |||||
Contributions from noncontrolling interests | 4,329 | 17,767 | |||||
Changes in fair value of noncontrolling interests | -13,847 | 108,575 | |||||
Net income | 26,768 | 113,156 | |||||
Other comprehensive income (loss) | 12 | 949 | |||||
Ending balance as of March 31, 2014 and December 31, 2013 | $ | 631,940 | $ | 648,251 |
Patient_Service_Revenue
Patient Service Revenue | 3 Months Ended | |||||
Mar. 31, 2014 | ||||||
Notes to Consolidated Financial Statements [Abstract] | ' | |||||
Patient Service Revenue Text Block 1 [Text Block] | ' | |||||
9. Sources of Revenue | ||||||
Below is a table showing the sources of our U.S. patient service revenue (net of contractual allowance and discounts but before patient service bad debt provision), included in the Company's dialysis care revenue, for the three-months ended March 31, 2014 and 2013. Outside of the U.S., the Company does not recognize patient service revenue at the time the services are rendered without assessing the patient's ability to pay. Accordingly, the additional disclosure requirements introduced with ASU 2011-07 only apply to the U.S. patient service revenue. | ||||||
For the three months ended March 31, | ||||||
2014 | 2013 | |||||
Medicare ESRD program | $ | 1,094,338 | $ | 1,055,056 | ||
Private/alternative payors | 947,477 | 914,397 | ||||
Medicaid and other government sources | 109,486 | 91,026 | ||||
Hospitals | 112,701 | 106,931 | ||||
Total patient service revenue | $ | 2,264,002 | $ | 2,167,410 |
Financial_Instruments
Financial Instruments | 3 Months Ended | ||||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||||||||||||||||||
Financial Instruments | ' | ||||||||||||||||||||||
11. Financial Instruments | |||||||||||||||||||||||
Non-derivative Financial Instruments | |||||||||||||||||||||||
The following table presents the carrying amounts and fair values of the Company's non-derivative financial instruments at March 31, 2014, and December 31, 2013. | |||||||||||||||||||||||
March 31, | December 31, | ||||||||||||||||||||||
2014 | 2013 | ||||||||||||||||||||||
Fair Value | Carrying | Fair | Carrying | Fair | |||||||||||||||||||
Hierarchy | Amount | Value | Amount | Value | |||||||||||||||||||
Assets | |||||||||||||||||||||||
Cash and cash equivalents | 1 | $ | 574,127 | 574,127 | $ | 682,777 | 682,777 | ||||||||||||||||
Accounts Receivable(1) | 2 | 3,251,520 | 3,251,520 | 3,190,392 | 3,190,392 | ||||||||||||||||||
Notes Receivable | 3 | 166,631 | 184,242 | 165,807 | 175,768 | ||||||||||||||||||
Liabilities | |||||||||||||||||||||||
Accounts payable(1) | 2 | 714,897 | 714,897 | 666,526 | 666,526 | ||||||||||||||||||
Short-term borrowings(1) | 2 | 291,540 | 291,540 | 158,990 | 158,990 | ||||||||||||||||||
Long term debt, excluding 2012 Credit Agreement, Euro Notes and Senior Notes | 2 | 534,950 | 534,950 | 679,847 | 679,847 | ||||||||||||||||||
2012 Credit Agreement | 2 | 2,910,561 | 2,910,561 | 2,707,145 | 2,710,270 | ||||||||||||||||||
Senior Notes | 2 | 4,825,384 | 5,332,253 | 4,824,753 | 5,348,679 | ||||||||||||||||||
Euro Notes | 2 | 46,535 | 46,722 | 46,545 | 47,423 | ||||||||||||||||||
Noncontrolling interests subject to put provisions | 3 | 631,940 | 631,940 | 648,251 | 648,251 | ||||||||||||||||||
(1) Also includes amounts receivable from or payable to related parties. | |||||||||||||||||||||||
The carrying amounts in the table are included in the consolidated balance sheet under the indicated captions or in the case of long-term debt, in the captions shown in Note 5. | |||||||||||||||||||||||
The significant methods and assumptions used in estimating the fair values of non-derivative financial instruments are as follows: | |||||||||||||||||||||||
Cash and cash equivalents are stated at nominal value which equals the fair value. | |||||||||||||||||||||||
Short-term financial instruments such as accounts receivable, accounts payable and short-term borrowings are valued at their carrying amounts, which are reasonable estimates of the fair value due to the relatively short period to maturity of these instruments. | |||||||||||||||||||||||
The valuation of notes receivable was determined using significant unobservable inputs. They were valued using a constructed index based upon similar instruments with comparable credit ratings, terms, tenor, interest rates and that are within the Company's industry. The Company tracked the prices of the constructed index from the note issuance date to the reporting date to determine fair value. | |||||||||||||||||||||||
The fair values of major long-term financial liabilities are calculated on the basis of market information. Instruments for which market quotes are available are measured using these quotes. The fair values of the other long-term financial liabilities are calculated at the present value of the respective future cash flows. To determine these present values, the prevailing interest rates and credit spreads for the Company as of the balance sheet date are used. | |||||||||||||||||||||||
The valuation of noncontrolling interests subject to put provisions is determined using significant unobservable inputs. See Note 8 for a discussion of the Company's methodology for estimating the fair value of these noncontrolling interests subject to put obligations. | |||||||||||||||||||||||
Currently, there is no indication that a decrease in the value of the Company's financing receivables is probable. Therefore, the allowances on credit losses of financing receivables are immaterial. | |||||||||||||||||||||||
Derivative Financial Instruments | |||||||||||||||||||||||
The Company is exposed to market risk from changes in foreign exchange rates and interest rates. In order to manage the risk of currency exchange rate and interest rate fluctuations, the Company enters into various hedging transactions by means of derivative instruments with highly rated financial institutions as authorized by the Company's General Partner. On a quarterly basis the Company performs an assessment of its counterparty credit risk. The Company currently considers this risk to be low. The Company's policy, which has been consistently followed, is that financial derivatives be used only for the purpose of hedging foreign currency and interest rate exposure. | |||||||||||||||||||||||
In certain instances, the Company enters into derivative contracts that do not qualify for hedge accounting but are utilized for economic purposes (“economic hedges”). The Company does not use financial instruments for trading purposes. | |||||||||||||||||||||||
The Company established guidelines for risk assessment procedures and controls for the use of financial instruments. They include a clear segregation of duties with regard to execution on one side and administration, accounting and controlling on the other. | |||||||||||||||||||||||
To reduce the credit risk arising from derivatives the Company concluded Master Netting Agreements with banks. Through such agreements, positive and negative fair values of the derivative contracts could be offset against one another if a partner becomes insolvent. This offsetting is valid for transactions where the aggregate amount of obligations owed to and receivable from are not equal. If insolvency occurs, the party which owes the larger amount is obliged to pay the other party the difference between the amounts owed in the form of one net payment. | |||||||||||||||||||||||
The Company elects not to offset the fair values of derivative financial instruments subject to master netting agreements in its Consolidated Balance Sheets. | |||||||||||||||||||||||
At March 31, 2014 and December 31, 2013, the Company had $19,048 and $18,334 of derivative financial assets subject to netting arrangements and $14,044 and $16,371 of derivative financial liabilities subject to netting arrangements. Offsetting these derivative financial instruments would have resulted in net assets of $11,996 and $12,169 as well as net liabilities of $6,992 and $10,207 at March 31, 2014 and December 31, 2013, respectively. | |||||||||||||||||||||||
Foreign Exchange Risk Management | |||||||||||||||||||||||
The Company conducts business on a global basis in various currencies, though a majority of its operations are in Germany and the United States. For financial reporting purposes, the Company has chosen the U.S. dollar as its reporting currency. Therefore, changes in the rate of exchange between the U.S. dollar and the local currencies in which the financial statements of the Company's international operations are maintained affect its results of operations and financial position as reported in its consolidated financial statements. | |||||||||||||||||||||||
The Company's exposure to market risk for changes in foreign exchange rates relates to transactions such as sales and purchases. The Company has significant amounts of sales of products invoiced in euro from its European manufacturing facilities to its other international operations and, to a lesser extent, sales of products invoiced in other non-functional currencies. This exposes the subsidiaries to fluctuations in the rate of exchange between the euro and the currency in which their local operations are conducted. For the purpose of hedging existing and foreseeable foreign exchange transaction exposures the Company enters into foreign exchange forward contracts and, on a small scale, foreign exchange options. At March 31, 2014 and December 31, 2013, the Company had no foreign exchange options. | |||||||||||||||||||||||
Changes in the fair value of the effective portion of foreign exchange forward contracts designated and qualifying as cash flow hedges of forecasted product purchases and sales are reported in Accumulated Other Comprehensive Income (“AOCI”). Additionally, in connection with intercompany loans in foreign currency, the Company uses foreign exchange swaps thus assuring that no foreign exchange risks arise from those loans, which, if they qualify for cash flow hedge accounting, are also reported in AOCI. These amounts recorded in AOCI are subsequently reclassified into earnings as a component of cost of revenues for those contracts that hedge product purchases or as an adjustment of interest income/expense for those contracts that hedge loans, in the same period in which the hedged transaction affects earnings. The notional amounts of foreign exchange contracts in place that are designated and qualify as cash flow hedges totaled $174,918 and $238,983 at March 31, 2014 and December 31, 2013, respectively. | |||||||||||||||||||||||
The Company also enters into derivative contracts for forecasted product purchases and sales and for intercompany loans in foreign currency that do not qualify for hedge accounting but are utilized for economic hedges as defined above. In these two cases, the change in value of the economic hedge is recorded in the income statement and usually offsets the change in value recorded in the income statement for the underlying asset or liability. The notional amounts of economic hedges that do not qualify for hedge accounting totaled $1,685,750 and $1,512,559 at March 31, 2014 and December 31, 2013, respectively. | |||||||||||||||||||||||
Interest Rate Risk Management | |||||||||||||||||||||||
The Company enters into derivatives, particularly interest rate swaps and to a certain extent, interest rate options, to protect against the risk of rising interest rates. These interest rate derivatives are designated as cash flow hedges and have been entered into in order to effectively convert payments based on variable interest rates into payments at a fixed interest rate. The euro-denominated interest rate swaps expire in 2016 and have an interest rate of 1.73%. Interest payable and receivable under the swap agreements is accrued and recorded as an adjustment to interest expense. | |||||||||||||||||||||||
At March 31, 2014 and December 31, 2013, the notional amount of the euro-denominated interest rate swaps in place was €100,000 and €100,000 ($137,880 and $137,910 at March 31, 2014 and December 31, 2013, respectively). | |||||||||||||||||||||||
In addition, the Company also enters into interest rate hedges (“pre-hedges”) in anticipation of future debt issuance to effectively convert the variable interest rate related to the future debt to a fixed interest rate. These pre-hedges are settled at the issuance date of the corresponding debt with the settlement amount recorded in AOCI amortized to interest expense over the life of the pre-hedges. At March 31, 2014 and December 31, 2013, the Company had $113,570 and $118,844, respectively, related to such settlements of pre-hedges deferred in AOCI, net of tax. | |||||||||||||||||||||||
Derivative Financial Instruments Valuation | |||||||||||||||||||||||
The following table shows the carrying amounts of the Company's derivatives at March 31, 2014 and December 31, 2013. | |||||||||||||||||||||||
31-Mar-14 | 31-Dec-13 | ||||||||||||||||||||||
Assets(2) | Liabilities(2) | Assets(2) | Liabilities(2) | ||||||||||||||||||||
Derivatives in cash flow hedging relationships (1) | |||||||||||||||||||||||
Current | |||||||||||||||||||||||
Foreign exchange contracts | 3,235 | -2,856 | 4,985 | -2,719 | |||||||||||||||||||
Non-current | |||||||||||||||||||||||
Foreign exchange contracts | 204 | - | 759 | -374 | |||||||||||||||||||
Interest rate contracts | - | -4,553 | - | -4,392 | |||||||||||||||||||
Total | $ | 3,439 | $ | -7,409 | $ | 5,744 | $ | -7,485 | |||||||||||||||
Derivatives not designated as hedging instruments (1) | |||||||||||||||||||||||
Current | |||||||||||||||||||||||
Foreign exchange contracts | 15,373 | -15,449 | 11,679 | -22,982 | |||||||||||||||||||
Non-current | |||||||||||||||||||||||
Foreign exchange contracts | 556 | -648 | 1,060 | -820 | |||||||||||||||||||
Total | $ | 15,929 | $ | -16,097 | $ | 12,739 | $ | -23,802 | |||||||||||||||
(1) At March 31, 2014 and December 31, 2013, the valuation of the Company's derivatives was determined using Significant Other Observable Inputs (Level 2) in accordance with the fair value hierarchy levels established in U.S. GAAP. | |||||||||||||||||||||||
(2) Derivative instruments are marked to market each reporting period resulting in carrying amounts being equal to fair values at the reporting date. | |||||||||||||||||||||||
The carrying amounts for the current portion of derivatives indicated as assets in the table above are included in Prepaid expenses and other current assets in the Consolidated Balance Sheets while the current portion of those indicated as liabilities are included in Accrued expenses and other current liabilities. The non-current portions indicated as assets or liabilities are included in the Consolidated Balance Sheets in Other assets or Other liabilities, respectively. | |||||||||||||||||||||||
The significant methods and assumptions used in estimating the fair values of derivative financial instruments are as follows: | |||||||||||||||||||||||
The fair value of interest rate swaps is calculated by discounting the future cash flows on the basis of the market interest rates applicable for the remaining term of the contract as of the balance sheet date. To determine the fair value of foreign exchange forward contracts, the contracted forward rate is compared to the current forward rate for the remaining term of the contract as of the balance sheet date. The result is then discounted on the basis of the market interest rates prevailing at the balance sheet date for the applicable currency. | |||||||||||||||||||||||
The Company includes its own credit risk for financial instruments deemed liabilities and counterparty-credit risks for financial instruments deemed assets when measuring the fair value of derivative financial instruments. | |||||||||||||||||||||||
The Effect of Derivatives on the Consolidated Financial Statements | |||||||||||||||||||||||
Amount of Gain or (Loss) Recognized in OCI on Derivatives | Location of (Gain) or Loss Reclassified from AOCI in Income | Amount of (Gain) or Loss Reclassified from AOCI in Income | |||||||||||||||||||||
Derivatives in Cash Flow Hedging Relationships | |||||||||||||||||||||||
(Effective Portion) for the three months ended March 31, | (Effective Portion) for the three months ended March 31, | ||||||||||||||||||||||
2014 | 2013 | (Effective Portion) | 2014 | 2013 | |||||||||||||||||||
Interest rate contracts | $ | -125 | $ | 6,470 | Interest income/expense | $ | 7,358 | $ | 6,365 | ||||||||||||||
Foreign exchange contracts | -845 | 3,991 | Costs of Revenue | 571 | -1,345 | ||||||||||||||||||
Foreign exchange contracts | Interest income/expense | - | 416 | ||||||||||||||||||||
$ | -970 | $ | 10,461 | $ | 7,929 | $ | 5,436 | ||||||||||||||||
Derivatives not Designated as Hedging Instruments | Amount of (Gain) or Loss Recognized in Income on Derivatives for the three months ended March 31, | ||||||||||||||||||||||
Location of (Gain) or Loss Recognized in Income on Derivative | |||||||||||||||||||||||
2014 | 2013 | ||||||||||||||||||||||
Foreign exchange contracts | Selling, general and administrative expense | $ | -2,298 | $ | -21,812 | ||||||||||||||||||
Foreign exchange contracts | Interest income/expense | 1,226 | 1,966 | ||||||||||||||||||||
$ | -1,072 | $ | -19,846 | ||||||||||||||||||||
For foreign exchange derivatives, the Company expects to recognize $372 of losses deferred in AOCI at March 31, 2014, in earnings during the next twelve months. | |||||||||||||||||||||||
The Company expects to incur additional interest expense of $23,303 over the next twelve months which is currently deferred in AOCI. At March 31, 2014, this amount reflects the projected amortization of the settlement amount of the terminated swaps and the current fair value of the additional interest payments resulting from the remaining interest rate swap maturing in 2016. | |||||||||||||||||||||||
At March 31, 2014, the Company had foreign exchange derivatives with maturities of up to 20 months and interest rate swaps with maturities of up to 31 months. |
Commitments_and_Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2014 | |
Notes to Consolidated Financial Statements [Abstract] | ' |
Commitments and Contingencies | ' |
Legal and Regulatory Matters | |
The Company is routinely involved in numerous claims, lawsuits, regulatory and tax audits, investigations and other legal matters arising, for the most part, in the ordinary course of its business of providing healthcare services and products. Legal matters that the Company currently deems to be material are described below. For the matters described below in which the Company believes a loss is both reasonably possible and estimable, an estimate of the loss or range of loss exposure is provided. For the other matters described below, the Company believes that the loss probability is remote and/or the loss or range of possible losses cannot be reasonably estimated at this time. The outcome of litigation and other legal matters is always difficult to predict accurately and outcomes that are not consistent with the Company's view of the merits can occur. The Company believes that it has valid defenses to the legal matters pending against it and is defending itself vigorously. Nevertheless, it is possible that the resolution of one or more of the legal matters currently pending or threatened could have a material adverse effect on its business, results of operations and financial condition. | |
Commercial Litigation | |
On April 4, 2003, FMCH filed a suit in the U. S. District Court for the Northern District of California, styled Fresenius USA, Inc., et al., v. Baxter International Inc., et al., Case No. C 03-1431, seeking a declaratory judgment that FMCH does not infringe patents held by Baxter International Inc. and its subsidiaries and affiliates (“Baxter”), that the patents are invalid, and that Baxter is without right or authority to threaten or maintain suit against FMCH for alleged infringement of Baxter's patents. In general, the asserted patents concern the use of touch screen interfaces for hemodialysis machines. Baxter filed counterclaims against FMCH seeking more than $140,000 in monetary damages and injunctive relief, and alleging that FMCH willfully infringed on Baxter's patents. On July 17, 2006, the court entered judgment on a jury verdict in favor of FMCH finding all asserted claims of Baxter patents invalid as obvious and/or anticipated in light of prior art. | |
On February 13, 2007, the court granted Baxter's motion to set aside the jury's verdict in favor of FMCH and reinstated the patents and entered judgment of infringement. Following a trial on damages, the court entered judgment on November 6, 2007 in favor of Baxter on a jury award of $14,300. On April 4, 2008, the court denied Baxter's motion for a new trial, established a royalty payable to Baxter of 10% of the sales price for continuing sales of FMCH's 2008K hemodialysis machines and 7% of the sales price of related disposables, parts and service beginning November 7, 2007, and enjoined sales of the touchscreen-equipped 2008K machine effective January 1, 2009. The Company appealed the court's rulings to the United States Court of Appeals for the Federal Circuit (“Federal Circuit”). On September 10, 2009, the Federal Circuit reversed the district court's decision and determined that the asserted claims in two of the three patents at issue are invalid. As to the third patent, the Federal Circuit affirmed the district court's decision; however, the Court also vacated the injunction and award of damages. These issues were remanded to the District Court for reconsideration in light of the invalidity ruling on most of the claims. Upon remand, the district court reduced the post-verdict damages award to $10,000. Separately, the U.S. Patent and Trademark Office (“USPTO”) and the Board of Patent Appeals and Interferences ruled that the remaining Baxter patent is invalid. On May 17, 2012 the Federal Circuit affirmed the USPTO's ruling and invalidated the final remaining Baxter patent. Baxter appealed to the Federal Circuit claiming that approximately $20,000 of damages awarded to it by the District Court before the Federal Circuit affirmed the USPTO ruling constituted a final judgment that may be collected. On July 2, 2013, the Federal Circuit denied Baxter's appeal and ordered the District Court to dismiss the case. The court-approved escrow account has been terminated and the escrow funds have been returned to FMCH. On March 5, 2014, Baxter petitioned the United States Supreme Court to review the decisions of the Federal Circuit. | |
On August 27, 2012, Baxter filed suit in the U.S. District Court for the Northern District of Illinois, styled Baxter International Inc., et al., v. Fresenius Medical Care Holdings, Inc., Case No. 12-cv-06890, alleging that the Company's LibertyTM cycler infringes certain U.S. patents that were issued to Baxter between October 2010 and June 2012. The Company believes it has valid defenses to these claims, and will defend this litigation vigorously. | |
On April 5, 2013, the U.S. Judicial Panel on Multidistrict Litigation ordered that the numerous lawsuits filed and anticipated to be filed in various federal courts alleging wrongful death and personal injury claims against FMCH and certain of its affiliates relating to FMCH's acid concentrate products NaturaLyte® and Granuflo® be transferred and consolidated for pretrial management purposes into a consolidated multidistrict litigation in the United States District Court for the District of Massachusetts, styled In Re: Fresenius Granuflo/Naturalyte Dialysate Products Liability Litigation, Case No. 2013-md-02428. The Massachusetts state courts subsequently established a similar consolidated litigation for such cases filed in Massachusetts county courts, styled In Re: Consolidated Fresenius Cases, Case No. MICV 2013-03400-O (Massachusetts Superior Court, Middlesex County). These lawsuits allege generally that inadequate labeling and warnings for these products caused harm to patients. In addition, similar cases have been filed in state courts outside Massachusetts, in some of which the judicial authorities have established consolidated proceedings for their disposition. FMCH believes that these lawsuits are without merit, and will defend them vigorously. | |
Other Litigation and Potential Exposures | |
On February 15, 2011, a qui tam relator's complaint under the False Claims Act against FMCH was unsealed by order of the United States District Court for the District of Massachusetts and served by the relator. The United States has not intervened in the case United States ex rel. Chris Drennen v. Fresenius Medical Care Holdings, Inc., 2009 Civ. 10179 (D. Mass.). The relator's complaint, which was first filed under seal in February 2009, alleges that the Company seeks and receives reimbursement from government payors for serum ferritin and hepatitis B laboratory tests that are medically unnecessary or not properly ordered by a physician. On March 6, 2011, the United States Attorney for the District of Massachusetts issued a subpoena seeking the production of documents related to the same laboratory tests that are the subject of the relator's complaint. FMCH has cooperated fully in responding to the subpoena, and will vigorously contest the relator's complaint. | |
Subpoenas or search warrants have been issued by federal and state law enforcement authorities under the supervision of the United States Attorneys for the Districts of Connecticut, Southern Florida, Eastern Virginia and Rhode Island to American Access Care LLC (AAC), which the Company acquired in October 2011, and to the Company's Fresenius Vascular Access subsidiary which now operates former AAC centers as well as its own original facilities. Subpoenas have also been issued to certain of the Company's outpatient hemodialysis facilities for records relating to vascular access treatment and monitoring. The Company is cooperating fully in these investigations. Communications with certain of the investigating United States Attorney Offices indicate that the inquiry encompasses invoicing and coding for procedures commonly performed in vascular access centers and the documentary support for the medical necessity of such procedures. The AAC acquisition agreement contains customary indemnification obligations with respect to breaches of representations, warranties or covenants and certain other specified matters. As of October 18, 2013, a group of the prior owners of AAC exercised their right pursuant to the terms of the acquisition agreement to assume responsibility for responding to certain of the subpoenas. Pursuant to the AAC acquisition agreement the prior owners are obligated to indemnify the Company for certain liabilities that might arise from those subpoenas. | |
The Company has received communications alleging certain conduct in certain countries outside the U.S. and Germany that may violate the U.S. Foreign Corrupt Practices Act (“FCPA”) or other anti-bribery laws. The Audit and Corporate Governance Committee of the Company's Supervisory Board is conducting an internal review with the assistance of independent counsel retained for such purpose. The Company voluntarily advised the U.S. Securities and Exchange Commission (“SEC”) and the U.S. Department of Justice (“DOJ”) that allegations have been made and of the Company's internal review. The Company's review and dialogue with the SEC and DOJ are ongoing. | |
The review has identified conduct that raises concerns under the FCPA or other anti-bribery laws that may result in monetary penalties or other sanctions. In addition, the Company's ability to conduct business in certain jurisdictions could be negatively impacted. The Company has recorded a non-material accrual for an identified matter. Given the current status of the internal review, the Company cannot reasonably estimate the range of possible loss that may result from additional identified matters or from the final outcome of the continuing internal review. | |
The Company's independent counsel, in conjunction with the Company's Compliance Department, have reviewed the Company's anti-corruption compliance program, including internal controls related to compliance with international anti-bribery laws, and appropriate enhancements are being implemented. The Company is fully committed to FCPA compliance. | |
In December 2012 and January 2013, FMCH received subpoenas from the United States Attorneys for the District of Massachusetts and the Western District of Louisiana requesting production of a broad range of documents. Communications with the investigating United States Attorney Offices indicate that the inquiry relates to products manufactured by FMCH, which encompasses the Granuflo® and Naturalyte® acid concentrate products that are also the subject of personal injury litigation described above, as well as electron-beam sterilization of dialyzers, the Liberty peritoneal dialysis cycler, and 2008 series hemodialysis machines as related to the use of Granuflo® and Naturalyte®. FMCH is cooperating fully in the government's investigation. | |
The Company filed claims for refunds contesting the Internal Revenue Service's (“IRS”) disallowance of FMCH's deductions for civil settlement payments taken by FMCH in prior year tax returns. As a result of a settlement agreement with the IRS, the Company received a partial refund in September 2008 of $37,000, inclusive of interest and preserved its right to pursue claims in the United States Courts for refunds of all other disallowed deductions, which totaled approximately $126,000. On December 22, 2008, the Company filed a complaint for complete refund in the United States District Court for the District of Massachusetts, styled as Fresenius Medical Care Holdings, Inc. v. United States. On August 15, 2012, a jury entered a verdict for FMCH granting additional deductions of $95,000. On May 31, 2013, the District Court entered final judgment for FMCH in the amount of $50,400. On September 18, 2013, the IRS appealed the District Court's ruling to the United States Court of Appeals for the First Circuit (Boston). | |
From time to time, the Company is a party to or may be threatened with other litigation or arbitration, claims or assessments arising in the ordinary course of its business. Management regularly analyzes current information including, as applicable, the Company's defenses and insurance coverage and, as necessary, provides accruals for probable liabilities for the eventual disposition of these matters. | |
The Company, like other healthcare providers, conducts its operations under intense government regulation and scrutiny. It must comply with regulations which relate to or govern the safety and efficacy of medical products and supplies, the marketing and distribution of such products, the operation of manufacturing facilities, laboratories and dialysis clinics, and environmental and occupational health and safety. With respect to its development, manufacture, marketing and distribution of medical products, if such compliance is not maintained, the Company could be subject to significant adverse regulatory actions by the FDA and comparable regulatory authorities outside the U.S. These regulatory actions could include warning letters or other enforcement notices from the FDA, and/or comparable foreign regulatory authority which may require the Company to expend significant time and resources in order to implement appropriate corrective actions. If the Company does not address matters raised in warning letters or other enforcement notices to the satisfaction of the FDA and/or comparable regulatory authorities outside the U.S., these regulatory authorities could take additional actions, including product recalls, injunctions against the distribution of products or operation of manufacturing plants, civil penalties, seizures of the Company's products and/or criminal prosecution. FMCH is currently engaged in remediation efforts with respect to three pending FDA warning letters. See “Regulatory and Legal Matters – Product Regulation” section of the 2013 Annual Report on Form 20-F for additional information. The Company must also comply with the laws of the United States, including the federal Anti-Kickback Statute, the federal False Claims Act, the federal Stark Law and the federal Foreign Corrupt Practices Act as well as other federal and state fraud and abuse laws. Applicable laws or regulations may be amended, or enforcement agencies or courts may make interpretations that differ from the Company's interpretations or the manner in which it conducts its business. Enforcement has become a high priority for the federal government and some states. In addition, the provisions of the False Claims Act authorizing payment of a portion of any recovery to the party bringing the suit encourage private plaintiffs to commence “qui tam” or “whistle blower” actions. In May 2009, the scope of the False Claims Act was expanded and additional protections for whistle blowers and procedural provisions to aid whistle blowers' ability to proceed in a False Claims Act case were added. By virtue of this regulatory environment, the Company's business activities and practices are subject to extensive review by regulatory authorities and private parties, and continuing audits, subpoenas, other inquiries, claims and litigation relating to the Company's compliance with applicable laws and regulations. The Company may not always be aware that an inquiry or action has begun, particularly in the case of “whistle blower” actions, which are initially filed under court seal. | |
The Company operates many facilities throughout the United States and other parts of the world. In such a decentralized system, it is often difficult to maintain the desired level of oversight and control over the thousands of individuals employed by many affiliated companies. The Company relies upon its management structure, regulatory and legal resources, and the effective operation of its compliance program to direct, manage and monitor the activities of these employees. On occasion, the Company may identify instances where employees or other agents deliberately, recklessly or inadvertently contravene the Company's policies or violate applicable law. The actions of such persons may subject the Company and its subsidiaries to liability under the Anti-Kickback Statute, the Stark Law, the False Claims Act and the Foreign Corrupt Practices Act, among other laws and comparable laws of other countries. | |
Physicians, hospitals and other participants in the healthcare industry are also subject to a large number of lawsuits alleging professional negligence, malpractice, product liability, worker's compensation or related claims, many of which involve large claims and significant defense costs. The Company has been and is currently subject to these suits due to the nature of its business and expects that those types of lawsuits may continue. Although the Company maintains insurance at a level which it believes to be prudent, it cannot assure that the coverage limits will be adequate or that insurance will cover all asserted claims. A successful claim against the Company or any of its subsidiaries in excess of insurance coverage could have a material adverse effect upon it and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company's reputation and business. | |
The Company has also had claims asserted against it and has had lawsuits filed against it relating to alleged patent infringements or businesses that it has acquired or divested. These claims and suits relate both to operation of the businesses and to the acquisition and divestiture transactions. The Company has, when appropriate, asserted its own claims, and claims for indemnification. A successful claim against the Company or any of its subsidiaries could have a material adverse effect upon its business, financial condition, and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company's reputation and business |
Business_Segment_Information
Business Segment Information | 3 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||||||||||||
Business Segment Information | ' | ||||||||||||||||
13. Segment and Corporate Information | |||||||||||||||||
The Company has identified three operating segments, North America Segment, EMEALA and Asia-Pacific, which were determined based upon how the Company manages its businesses. All segments are primarily engaged in providing dialysis care services and the distribution of products and equipment for the treatment of ESRD. For reporting purposes, the Company has aggregated the EMEALA and Asia-Pacific operating segments as the “International Segment.” The segments are aggregated due to their similar economic characteristics. These characteristics include same services provided and same products sold, the same type of patient population, similar methods of distribution of products and services and similar economic environments. The General Partner's management board member responsible for the profitability and cash flow of each segment's various businesses supervises the management of each operating segment. The accounting policies of the segments are the same as those the Company applies in preparing the consolidated financial statements under U.S. GAAP. | |||||||||||||||||
Management evaluates each segment using measures that reflect all of the segment's controllable revenues and expenses. With respect to the performance of business operations, management believes that the most appropriate U.S. GAAP measures are revenue, operating income and operating income margin. The Company does not include income taxes as it believes this is outside the segments' control. Financing is a corporate function, which the Company's segments do not control. Therefore, the Company does not include interest expense relating to financing as a segment measurement. Similarly, the Company does not allocate certain costs, which relate primarily to certain headquarters overhead charges, including accounting and finance, etc. (“Corporate”), because the Company believes that these costs are also not within the control of the individual segments. Production of products, production asset management, quality management and procurement are centrally managed at Corporate by Global Manufacturing Operations. The Company's global research and development is also centrally managed at Corporate. These Corporate activities do not fulfill the definition of a segment. Products are transferred to the segments at cost; therefore no internal profit is generated. The associated internal revenues for the product transfers and their elimination are recorded as Corporate activities. Capital expenditures for production are based on the expected demand of the segments and consolidated profitability considerations. In addition, certain revenues, investments and intangible assets, as well as any related expenses, are not allocated to a segment but accounted for as Corporate. | |||||||||||||||||
Information pertaining to the Company's segment and Corporate activities for the three-months periods ended March 31, 2014 and 2013 is set forth below. | |||||||||||||||||
North America Segment | International Segment | Segment Totals | Corporate | Total | |||||||||||||
Three months ended March 31, 2014 | |||||||||||||||||
Net revenue external customers | $ | 2,392,907 | $ | 1,160,898 | $ | 3,553,805 | $ | 9,787 | $ | 3,563,592 | |||||||
Inter - segment revenue | 1,280 | - | 1,280 | -1,280 | - | ||||||||||||
Revenue | 2,394,187 | 1,160,898 | 3,555,085 | 8,507 | 3,563,592 | ||||||||||||
Depreciation and amortization | -87,649 | -45,021 | -132,670 | -34,497 | -167,167 | ||||||||||||
Operating income | 335,562 | 180,446 | 516,008 | -71,113 | 444,895 | ||||||||||||
Income (loss) from equity method investees | 10,551 | 1,971 | 12,522 | - | 12,522 | ||||||||||||
Segment assets | 14,860,218 | 6,267,649 | 21,127,867 | 2,294,810 | 23,422,677 | ||||||||||||
thereof investments in equity method investees | 300,110 | 433,802 | 733,912 | - | 733,912 | ||||||||||||
Capital expenditures, acquisitions and investments (1) | 204,899 | 64,637 | 269,536 | 67,252 | 336,788 | ||||||||||||
Three months ended March 31, 2013 | |||||||||||||||||
Net revenue external customers | $ | 2,287,250 | $ | 1,168,652 | $ | 3,455,902 | $ | 8,019 | $ | 3,463,921 | |||||||
Inter - segment revenue | 1,075 | - | 1,075 | -1,075 | - | ||||||||||||
Revenue | 2,288,325 | 1,168,652 | 3,456,977 | 6,944 | 3,463,921 | ||||||||||||
Depreciation and amortization(2) | -80,407 | -45,900 | -126,307 | -30,046 | -156,353 | ||||||||||||
Operating income (3) | 366,048 | 191,617 | 557,665 | -64,352 | 493,313 | ||||||||||||
Income (loss) from equity method investees(4) | 3,118 | 1,690 | 4,808 | - | 4,808 | ||||||||||||
Segment assets | 14,044,466 | 5,896,442 | 19,940,908 | 2,198,755 | 22,139,663 | ||||||||||||
thereof investments in equity method investees | 239,689 | 361,738 | 601,427 | - | 601,427 | ||||||||||||
Capital expenditures, acquisitions and investments (5) | 112,332 | 82,702 | 195,034 | 24,537 | 219,571 | ||||||||||||
(1) International acquisitions exclude $7,569 of non-cash acquisitions for 2014. | |||||||||||||||||
(2) Depreciation in the amount of $895 relating to research and development has been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation. | |||||||||||||||||
(3) Certain items, in the net aggregate amount of $5,006, relating to research and development, compensation expense and income from equity method investees have been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation as applicable. | |||||||||||||||||
(4) Income (loss) from equity method investees in the amount of $396 has been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation. | |||||||||||||||||
(5) International acquisitions exclude $3,690 of non-cash acquisitions for 2013. |
Other_Comprehensive_Income
Other Comprehensive Income | 3 Months Ended | ||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||||||||||||||
Other Comprehensive Income | ' | ||||||||||||||||||
12. Other Comprehensive Income (Loss), net of tax | |||||||||||||||||||
Changes in AOCI, net of tax, by component for the three months ended March 31, 2014 and 2013 are as follows: | |||||||||||||||||||
Gain (Loss) related to cash flow hedges | Actuarial gain (loss) on defined benefit pension plans | Gain (Loss) related to foreign-currency translation | Total, before non-controlling interests | Non-controlling interests | Total | ||||||||||||||
Balance at December 31, 2012 | $ | -138,341 | $ | -179,423 | $ | -174,349 | $ | -492,113 | $ | 2,869 | $ | -489,244 | |||||||
Other comprehensive income (loss) before reclassifications | 8,031 | - | -66,210 | -58,179 | -1,982 | -60,161 | |||||||||||||
Amounts reclassified from AOCI | 3,639 | 3,941 | - | 7,580 | - | 7,580 | |||||||||||||
Other comprehensive income (loss) after reclassifications | 11,670 | 3,941 | -66,210 | -50,599 | -1,982 | -52,581 | |||||||||||||
Balance at March 31, 2013 | $ | -126,671 | $ | -175,482 | $ | -240,559 | $ | -542,712 | $ | 887 | $ | -541,825 | |||||||
Balance at December 31, 2013 | $ | -121,856 | $ | -141,987 | $ | -286,744 | $ | -550,587 | $ | 825 | $ | -549,762 | |||||||
Other comprehensive income (loss) before reclassifications | -556 | - | -47,023 | -47,579 | -33 | -47,612 | |||||||||||||
Amounts reclassified from AOCI | 5,579 | 2,740 | - | 8,319 | - | 8,319 | |||||||||||||
Other comprehensive income (loss) after reclassifications | 5,023 | 2,740 | -47,023 | -39,260 | -33 | -39,293 | |||||||||||||
Balance at March 31, 2014 | $ | -116,833 | $ | -139,247 | $ | -333,767 | $ | -589,847 | $ | 792 | $ | -589,055 | |||||||
Reclassifications out of AOCI for the three months ended March 31, 2014 and 2013 are as follows: | |||||||||||||||||||
Details about AOCI Components | Amount of (Gain) Loss reclassified from AOCI in Income | Location of (Gain) Loss reclassified from AOCI in Income | |||||||||||||||||
For the three months ended March 31, | |||||||||||||||||||
2014 | 2013 | ||||||||||||||||||
(Gain) Loss related to cash flow hedges | |||||||||||||||||||
Interest rate contracts | $ | 7,358 | $ | 6,365 | Interest income/expense | ||||||||||||||
Foreign exchange contracts | 571 | -1,345 | Costs of Revenue | ||||||||||||||||
Foreign exchange contracts | - | 416 | Interest income/expense | ||||||||||||||||
7,929 | 5,436 | Total before tax | |||||||||||||||||
-2,350 | -1,797 | Tax expense or benefit | |||||||||||||||||
$ | 5,579 | $ | 3,639 | Net of tax | |||||||||||||||
Actuarial (Gain) Loss on defined benefit pension plans | |||||||||||||||||||
Amortization of unrealized (gain) /loss | 4,354 | 6,398 | -1 | ||||||||||||||||
4,354 | 6,398 | Total before tax | |||||||||||||||||
-1,614 | -2,457 | Tax expense or benefit | |||||||||||||||||
$ | 2,740 | $ | 3,941 | Net of tax | |||||||||||||||
Total reclassifications for the period | $ | 8,319 | $ | 7,580 | Net of tax | ||||||||||||||
(1) Included in the computation of net periodic pension cost (see Note 7 for additional details). |
Supplementary_Cash_Flow_Inform
Supplementary Cash Flow Information | 3 Months Ended | ||||||
Mar. 31, 2014 | |||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||
Cash Flow Supplemental Disclosures [Text Block] | ' | ||||||
14. Supplementary Cash Flow Information | |||||||
The following additional information is provided with respect to the consolidated statements of cash flows: | |||||||
Three months ended March 31, | |||||||
2014 | 2013 | ||||||
Supplementary cash flow information: | |||||||
Cash paid for interest | $ | 164,393 | $ | 165,596 | |||
Cash paid for income taxes (1) | $ | 83,138 | $ | 59,708 | |||
Cash inflow for income taxes from stock option exercises | $ | 545 | $ | 522 | |||
Supplemental disclosures of cash flow information: | |||||||
Details for acquisitions: | |||||||
Assets acquired | $ | -31,589 | $ | -69,485 | |||
Liabilities assumed | 2,251 | 3,334 | |||||
Noncontrolling interest subject to put provisions | - | 6,294 | |||||
Noncontrolling interest | 288 | 4,527 | |||||
Obligations assumed in connection with acquisition | 7,569 | 3,690 | |||||
Cash paid | -21,481 | -51,640 | |||||
Less cash acquired | 105 | 2,530 | |||||
Net cash paid for acquisitions | -21,376 | -49,110 | |||||
Cash paid for investments | -112,848 | -22,185 | |||||
Cash paid for intangible assets | -2,933 | -919 | |||||
Total cash paid for acquisitions and investments, net of cash acquired, and purchases of intangible assets | $ | -137,157 | $ | -72,214 | |||
(1) Net of tax refund. |
Supplemental_Condensed_Combini
Supplemental Condensed Combining Information | 3 Months Ended | ||||||||||||||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||||||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||||||||||||||||||||||||||||
Supplemental Condensed Combining Information | ' | ||||||||||||||||||||||||||||||||
16. Supplemental Condensed Combining Information | |||||||||||||||||||||||||||||||||
FMC Finance III, a former wholly-owned subsidiary of the Company, issued 6⅞% Senior Notes due 2017 in July 2007. On June 20, 2011, Fresenius Medical Care US Finance, Inc. (“US Finance”) acquired substantially all of the assets of FMC Finance III and assumed its obligations, including the 6⅞% Senior Notes and the related indenture. The 6⅞% Senior Notes are fully and unconditionally guaranteed, jointly and severally on a senior basis, by the Company and by FMCH and Fresenius Medical Care Deutschland GmbH (“D-GmbH”), together the (“Guarantor Subsidiaries”). The 6⅞% Senior Notes and related guarantees were issued in an exchange offer registered under the Securities Act of 1933. The financial statements in this report present the financial condition, results of operations and cash flows of the Company, on a consolidated basis at March 31, 2014 and December 31, 2013 and for the three-months periods ended March 31, 2014 and 2013. The following combining financial information for the Company is at March 31, 2014 and December 31, 2013 and for the three-months periods ended March 31, 2014 and 2013, segregated between FMC US Finance as issuer, the Company, D-GmbH and FMCH as guarantors, and the Company's other businesses (the “Non-Guarantor Subsidiaries”). For purposes of the condensed combining information, the Company and the Guarantor Subsidiaries carry their investments under the equity method. Other (income) expense includes income (loss) related to investments in consolidated subsidiaries recorded under the equity method for purposes of the condensed combining information. In addition, other (income) expense includes income and losses from profit and loss transfer agreements as well as dividends received. | |||||||||||||||||||||||||||||||||
For the three months ended March 31, 2014 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | ||||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||
Net revenue | $ | - | $ | - | $ | 531,730 | $ | - | $ | 3,896,574 | $ | -864,712 | $ | 3,563,592 | |||||||||||||||||||
Cost of revenue | - | - | 332,156 | - | 2,995,003 | -845,699 | 2,481,460 | ||||||||||||||||||||||||||
Gross profit | - | - | 199,574 | - | 901,571 | -19,013 | 1,082,132 | ||||||||||||||||||||||||||
Operating expenses (income): | |||||||||||||||||||||||||||||||||
Selling, general and administrative(1) | - | 47,374 | 28,650 | -26,380 | 569,452 | -11,887 | 607,209 | ||||||||||||||||||||||||||
Research and development | - | - | 19,297 | - | 10,731 | - | 30,028 | ||||||||||||||||||||||||||
Operating (loss) income | - | -47,374 | 151,627 | 26,380 | 321,388 | -7,126 | 444,895 | ||||||||||||||||||||||||||
Other (income) expense: | |||||||||||||||||||||||||||||||||
Interest, net | -1,731 | 60,526 | -1,031 | 45,462 | -7,015 | 50 | 96,261 | ||||||||||||||||||||||||||
Other, net | - | -330,870 | 111,665 | -154,698 | - | 373,903 | - | ||||||||||||||||||||||||||
Income (loss) before income taxes | 1,731 | 222,970 | 40,993 | 135,616 | 328,403 | -381,079 | 348,634 | ||||||||||||||||||||||||||
Income tax expense (benefit) | 628 | 17,508 | 37,172 | -7,528 | 148,579 | -95,075 | 101,284 | ||||||||||||||||||||||||||
Net Income (loss) | 1,103 | 205,462 | 3,821 | 143,144 | 179,824 | -286,004 | 247,350 | ||||||||||||||||||||||||||
Net Income attributable to noncontrolling interests | - | - | - | - | - | 41,888 | 41,888 | ||||||||||||||||||||||||||
Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA | $ | 1,103 | $ | 205,462 | $ | 3,821 | $ | 143,144 | $ | 179,824 | $ | -327,892 | $ | 205,462 | |||||||||||||||||||
(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees. | |||||||||||||||||||||||||||||||||
For the three months ended March 31, 2013 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | ||||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||
Net revenue | $ | - | $ | - | $ | 495,497 | $ | - | $ | 3,758,626 | $ | -790,202 | $ | 3,463,921 | |||||||||||||||||||
Cost of revenue | - | - | 335,779 | - | 2,796,879 | -778,255 | 2,354,403 | ||||||||||||||||||||||||||
Gross profit | - | - | 159,718 | - | 961,747 | -11,947 | 1,109,518 | ||||||||||||||||||||||||||
Operating expenses (income): | |||||||||||||||||||||||||||||||||
Selling, general and administrative (1) | - | 6,423 | 49,086 | -7,180 | 511,647 | 25,857 | 585,833 | ||||||||||||||||||||||||||
Research and development | - | - | 17,969 | - | 12,572 | -169 | 30,372 | ||||||||||||||||||||||||||
Operating (loss) income | - | -6,423 | 92,663 | 7,180 | 437,528 | -37,635 | 493,313 | ||||||||||||||||||||||||||
Other (income) expense: | |||||||||||||||||||||||||||||||||
Interest, net | -1,697 | 46,193 | 2,251 | 40,298 | 17,184 | - | 104,229 | ||||||||||||||||||||||||||
Other, net | - | -263,397 | 96,047 | -181,689 | - | 349,039 | - | ||||||||||||||||||||||||||
Income (loss) before income taxes | 1,697 | 210,781 | -5,635 | 148,571 | 420,344 | -386,674 | 389,084 | ||||||||||||||||||||||||||
Income tax expense (benefit) | 616 | -14,718 | 6,076 | -13,065 | 116,077 | 34,015 | 129,001 | ||||||||||||||||||||||||||
Net Income (loss) | 1,081 | 225,499 | -11,711 | 161,636 | 304,267 | -420,689 | 260,083 | ||||||||||||||||||||||||||
Net Income attributable to noncontrolling interests | - | - | - | - | - | 34,584 | 34,584 | ||||||||||||||||||||||||||
Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA | $ | 1,081 | $ | 225,499 | $ | -11,711 | $ | 161,636 | $ | 304,267 | $ | -455,273 | $ | 225,499 | |||||||||||||||||||
(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees. | |||||||||||||||||||||||||||||||||
For the three months ended March 31, 2014 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | ||||||||||||||||||||||||||||||
Net Income | $ | 1,103 | $ | 205,462 | $ | 3,821 | $ | 143,144 | $ | 179,824 | $ | -286,004 | $ | 247,350 | |||||||||||||||||||
Gain (loss) related to cash flow hedges | - | 7,234 | - | - | -275 | - | 6,959 | ||||||||||||||||||||||||||
Actuarial gain (loss) on defined benefit pension plans | - | 50 | 947 | 3,262 | 95 | - | 4,354 | ||||||||||||||||||||||||||
Gain (loss) related to foreign currency translation | - | 833 | -145 | - | -50,268 | 2,524 | -47,056 | ||||||||||||||||||||||||||
Income tax (expense) benefit related to components of other comprehensive income | - | -2,097 | -276 | -1,287 | 110 | - | -3,550 | ||||||||||||||||||||||||||
Other comprehensive income (loss), net of tax | - | 6,020 | 526 | 1,975 | -50,338 | 2,524 | -39,293 | ||||||||||||||||||||||||||
Total comprehensive income | $ | 1,103 | $ | 211,482 | $ | 4,347 | $ | 145,119 | $ | 129,486 | $ | -283,480 | $ | 208,057 | |||||||||||||||||||
Comprehensive income attributable to noncontrolling interests | - | - | - | - | - | 41,855 | 41,855 | ||||||||||||||||||||||||||
Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA | $ | 1,103 | $ | 211,482 | $ | 4,347 | $ | 145,119 | $ | 129,486 | $ | -325,335 | $ | 166,202 | |||||||||||||||||||
For the three months ended March 31, 2013 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | ||||||||||||||||||||||||||||||
Net Income | $ | 1,081 | $ | 225,499 | $ | -11,711 | $ | 161,636 | $ | 304,267 | $ | -420,689 | $ | 260,083 | |||||||||||||||||||
Gain (loss) related to cash flow hedges | - | 12,864 | - | - | 3,033 | - | 15,897 | ||||||||||||||||||||||||||
Actuarial gain (loss) on defined benefit pension plans | - | 32 | 637 | 5,668 | 61 | - | 6,398 | ||||||||||||||||||||||||||
Gain (loss) related to foreign currency translation | - | 67,232 | -22,010 | - | -115,710 | 2,296 | -68,192 | ||||||||||||||||||||||||||
Income tax (expense) benefit related to components of other comprehensive income | - | -3,707 | -186 | -2,236 | -555 | - | -6,684 | ||||||||||||||||||||||||||
Other comprehensive income (loss), net of tax | - | 76,421 | -21,559 | 3,432 | -113,171 | 2,296 | -52,581 | ||||||||||||||||||||||||||
Total comprehensive income | $ | 1,081 | $ | 301,920 | $ | -33,270 | $ | 165,068 | $ | 191,096 | $ | -418,393 | $ | 207,502 | |||||||||||||||||||
Comprehensive income attributable to noncontrolling interests | - | - | - | - | - | 32,602 | 32,602 | ||||||||||||||||||||||||||
Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA | $ | 1,081 | $ | 301,920 | $ | -33,270 | $ | 165,068 | $ | 191,096 | $ | -450,995 | $ | 174,900 | |||||||||||||||||||
At March 31, 2014 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | ||||||||||||||||||||||||||||||
Current assets: | |||||||||||||||||||||||||||||||||
Cash and cash equivalents | $ | 0 | $ | 293 | $ | 5,198 | $ | - | $ | 569,325 | $ | -689 | $ | 574,127 | |||||||||||||||||||
Trade accounts receivable, less allowance for doubtful accounts | - | - | 141,776 | - | 2,936,792 | 1,766 | 3,080,334 | ||||||||||||||||||||||||||
Accounts receivable from related parties | 1,251,652 | 1,082,152 | 925,520 | 1,654,727 | 4,395,927 | -9,138,792 | 171,186 | ||||||||||||||||||||||||||
Inventories | - | - | 314,500 | - | 1,046,933 | -154,661 | 1,206,772 | ||||||||||||||||||||||||||
Prepaid expenses and other current assets | - | 47,005 | 70,159 | 117 | 1,041,383 | 36,728 | 1,195,392 | ||||||||||||||||||||||||||
Deferred taxes | - | - | - | - | 312,758 | -43,848 | 268,910 | ||||||||||||||||||||||||||
Total current assets | 1,251,652 | 1,129,450 | 1,457,153 | 1,654,844 | 10,303,118 | -9,299,496 | 6,496,721 | ||||||||||||||||||||||||||
Property, plant and equipment, net | - | 679 | 255,385 | - | 3,003,849 | -124,790 | 3,135,123 | ||||||||||||||||||||||||||
Intangible assets | - | 387 | 71,527 | - | 662,404 | -91 | 734,227 | ||||||||||||||||||||||||||
Goodwill | - | - | 62,815 | - | 11,583,342 | - | 11,646,157 | ||||||||||||||||||||||||||
Deferred taxes | - | 83,365 | 14,762 | - | 119,945 | -109,592 | 108,480 | ||||||||||||||||||||||||||
Other assets and notes receivables(1) | - | 14,313,281 | 48,249 | 12,851,806 | 5,211,198 | -31,122,565 | 1,301,969 | ||||||||||||||||||||||||||
Total assets | $ | 1,251,652 | $ | 15,527,162 | $ | 1,909,891 | $ | 14,506,650 | $ | 30,883,856 | $ | -40,656,534 | $ | 23,422,677 | |||||||||||||||||||
Current liabilities: | |||||||||||||||||||||||||||||||||
Accounts payable | $ | - | $ | 726 | $ | 32,836 | $ | - | $ | 517,106 | $ | - | $ | 550,668 | |||||||||||||||||||
Accounts payable to related parties | - | 2,199,883 | 665,432 | 1,571,744 | 5,126,683 | -9,399,513 | 164,229 | ||||||||||||||||||||||||||
Accrued expenses and other current liabilities | 11,833 | 83,607 | 143,998 | 8,948 | 1,642,610 | 9,243 | 1,900,239 | ||||||||||||||||||||||||||
Short-term borrowings | - | 56,536 | - | - | 100,690 | - | 157,226 | ||||||||||||||||||||||||||
Short-term borrowings from related parties | - | - | - | - | 134,314 | - | 134,314 | ||||||||||||||||||||||||||
Current portion of long-term debt and capital lease obligations | - | 78,195 | - | 200,000 | 23,080 | - | 301,275 | ||||||||||||||||||||||||||
Income tax payable | - | 123,187 | - | - | 85,921 | -5,554 | 203,554 | ||||||||||||||||||||||||||
Deferred taxes | - | 1,869 | 10,567 | - | 66,021 | -42,646 | 35,811 | ||||||||||||||||||||||||||
Total current liabilities | 11,833 | 2,544,003 | 852,833 | 1,780,692 | 7,696,425 | -9,438,470 | 3,447,316 | ||||||||||||||||||||||||||
Long term debt and capital lease obligations, less current portion | 1,166,233 | 152,002 | - | 2,586,469 | 7,681,126 | -3,569,675 | 8,016,155 | ||||||||||||||||||||||||||
Long term borrowings from related parties | - | 3,359,322 | - | 2,092,452 | 6,491 | -5,458,265 | - | ||||||||||||||||||||||||||
Other liabilities | - | 5,557 | 5,837 | 267,855 | 30,366 | 23,605 | 333,220 | ||||||||||||||||||||||||||
Pension liabilities | - | 11,426 | 260,023 | - | 142,892 | -953 | 413,388 | ||||||||||||||||||||||||||
Income tax payable | 2,915 | 30,840 | - | - | 21,549 | 110,736 | 166,040 | ||||||||||||||||||||||||||
Deferred taxes | - | - | - | - | 759,967 | -25,638 | 734,329 | ||||||||||||||||||||||||||
Total liabilities | 1,180,981 | 6,103,150 | 1,118,693 | 6,727,468 | 16,338,816 | -18,358,660 | 13,110,448 | ||||||||||||||||||||||||||
Noncontrolling interests subject to put provisions | - | - | 0 | - | 631,940 | - | 631,940 | ||||||||||||||||||||||||||
Total FMC-AG & Co. KGaA shareholders' equity | 70,671 | 9,424,012 | 791,198 | 7,779,182 | 13,656,823 | -22,297,874 | 9,424,012 | ||||||||||||||||||||||||||
Noncontrolling interests not subject to put provisions | - | - | - | - | 256,277 | - | 256,277 | ||||||||||||||||||||||||||
Total equity | 70,671 | 9,424,012 | 791,198 | 7,779,182 | 13,913,100 | -22,297,874 | 9,680,289 | ||||||||||||||||||||||||||
Total liabilities and equity | $ | 1,251,652 | $ | 15,527,162 | $ | 1,909,891 | $ | 14,506,650 | $ | 30,883,856 | $ | -40,656,534 | $ | 23,422,677 | |||||||||||||||||||
(1) Other Assets and notes receivables are presented net of investment in equity method investees. | |||||||||||||||||||||||||||||||||
At December 31, 2013 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | ||||||||||||||||||||||||||||||
Current assets: | |||||||||||||||||||||||||||||||||
Cash and cash equivalents | $ | 0 | $ | 13 | $ | 4,490 | $ | - | $ | 672,206 | $ | 6,068 | $ | 682,777 | |||||||||||||||||||
Trade accounts receivable, less allowance for doubtful accounts | - | - | 152,480 | - | 2,882,736 | 2,058 | 3,037,274 | ||||||||||||||||||||||||||
Accounts receivable from related parties | 1,269,092 | 960,137 | 815,748 | 1,643,394 | 4,073,975 | -8,609,228 | 153,118 | ||||||||||||||||||||||||||
Inventories | - | - | 287,625 | - | 946,790 | -137,311 | 1,097,104 | ||||||||||||||||||||||||||
Prepaid expenses and other current assets | - | 71,939 | 41,240 | 167 | 879,085 | 44,960 | 1,037,391 | ||||||||||||||||||||||||||
Deferred taxes | - | - | - | - | 322,337 | -43,285 | 279,052 | ||||||||||||||||||||||||||
Total current assets | 1,269,092 | 1,032,089 | 1,301,583 | 1,643,561 | 9,777,129 | -8,736,738 | 6,286,716 | ||||||||||||||||||||||||||
Property, plant and equipment, net | - | 734 | 238,469 | - | 2,980,268 | -127,517 | 3,091,954 | ||||||||||||||||||||||||||
Intangible assets | - | 501 | 73,166 | - | 684,290 | -81 | 757,876 | ||||||||||||||||||||||||||
Goodwill | - | - | 62,829 | - | 11,595,358 | - | 11,658,187 | ||||||||||||||||||||||||||
Deferred taxes | - | 80,931 | 14,209 | - | 118,306 | -109,279 | 104,167 | ||||||||||||||||||||||||||
Other assets and notes receivables (1) | - | 13,955,933 | 47,661 | 12,583,246 | 5,234,132 | -30,599,966 | 1,221,006 | ||||||||||||||||||||||||||
Total assets | $ | 1,269,092 | $ | 15,070,188 | $ | 1,737,917 | $ | 14,226,807 | $ | 30,389,483 | $ | -39,573,581 | $ | 23,119,906 | |||||||||||||||||||
Current liabilities: | |||||||||||||||||||||||||||||||||
Accounts payable | $ | - | $ | 2,193 | $ | 28,689 | $ | - | $ | 511,715 | $ | - | $ | 542,597 | |||||||||||||||||||
Accounts payable to related parties | - | 1,896,712 | 522,719 | 1,600,480 | 4,931,344 | -8,827,326 | 123,929 | ||||||||||||||||||||||||||
Accrued expenses and other current liabilities | 29,770 | 45,897 | 129,727 | 9,403 | 1,786,709 | 11,027 | 2,012,533 | ||||||||||||||||||||||||||
Short-term borrowings | - | 60 | - | - | 96,588 | - | 96,648 | ||||||||||||||||||||||||||
Short-term borrowings from related parties | - | - | - | - | 62,342 | - | 62,342 | ||||||||||||||||||||||||||
Current portion of long-term debt and capital lease obligations | - | 271,090 | - | 200,000 | 40,280 | - | 511,370 | ||||||||||||||||||||||||||
Income tax payable | - | 114,197 | - | - | 56,163 | - | 170,360 | ||||||||||||||||||||||||||
Deferred taxes | - | 2,331 | 9,002 | - | 64,539 | -41,678 | 34,194 | ||||||||||||||||||||||||||
Total current liabilities | 29,770 | 2,332,480 | 690,137 | 1,809,883 | 7,549,680 | -8,857,977 | 3,553,973 | ||||||||||||||||||||||||||
Long term debt and capital lease obligations, less current portion | 1,167,466 | 96,699 | - | 2,438,189 | 7,478,944 | -3,434,378 | 7,746,920 | ||||||||||||||||||||||||||
Long term borrowings from related parties | - | 3,359,606 | - | 2,092,818 | 6,940 | -5,459,364 | - | ||||||||||||||||||||||||||
Other liabilities | - | 5,616 | 6,028 | 267,914 | 30,399 | 19,604 | 329,561 | ||||||||||||||||||||||||||
Pension liabilities | - | 10,377 | 254,233 | - | 171,248 | - | 435,858 | ||||||||||||||||||||||||||
Income tax payable | 2,287 | 30,846 | - | - | 20,262 | 123,538 | 176,933 | ||||||||||||||||||||||||||
Deferred taxes | - | - | - | - | 768,156 | -24,766 | 743,390 | ||||||||||||||||||||||||||
Total liabilities | 1,199,523 | 5,835,624 | 950,398 | 6,608,804 | 16,025,629 | -17,633,343 | 12,986,635 | ||||||||||||||||||||||||||
Noncontrolling interests subject to put provisions | - | - | 0 | - | 648,251 | - | 648,251 | ||||||||||||||||||||||||||
Total FMC-AG & Co. KGaA shareholders' equity | 69,569 | 9,234,564 | 787,519 | 7,618,003 | 13,465,147 | -21,940,238 | 9,234,564 | ||||||||||||||||||||||||||
Noncontrolling interests not subject to put provisions | - | - | - | - | 250,456 | - | 250,456 | ||||||||||||||||||||||||||
Total equity | 69,569 | 9,234,564 | 787,519 | 7,618,003 | 13,715,603 | -21,940,238 | 9,485,020 | ||||||||||||||||||||||||||
Total liabilities and equity | $ | 1,269,092 | $ | 15,070,188 | $ | 1,737,917 | $ | 14,226,807 | $ | 30,389,483 | $ | -39,573,581 | $ | 23,119,906 | |||||||||||||||||||
(1) Other Assets and notes receivables are presented net of investment in equity method investees. | |||||||||||||||||||||||||||||||||
For the three months ended March 31, 2014 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | ||||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||
Operating Activities: | |||||||||||||||||||||||||||||||||
Net income (loss) | $ | 1,103 | $ | 205,462 | $ | 3,821 | $ | 143,144 | $ | 179,824 | $ | -286,004 | $ | 247,350 | |||||||||||||||||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||||||||||||||||||||||||||||||||
Equity affiliate income | - | -124,293 | - | -154,698 | - | 278,991 | - | ||||||||||||||||||||||||||
Depreciation and amortization | - | 168 | 13,209 | - | 162,641 | -8,851 | 167,167 | ||||||||||||||||||||||||||
Change in deferred taxes, net | - | -5,141 | 1,004 | - | 6,310 | -5,632 | -3,459 | ||||||||||||||||||||||||||
(Gain) loss on sale of fixed assets and investments | - | - | -48 | - | 854 | - | 806 | ||||||||||||||||||||||||||
(Write Up) write-off loans from related parties | - | 54,513 | - | - | - | -54,513 | - | ||||||||||||||||||||||||||
Compensation expense related to stock options | - | 6,174 | - | - | - | - | 6,174 | ||||||||||||||||||||||||||
Investments in equity method investees, net | - | 43,389 | - | - | -10,990 | - | 32,399 | ||||||||||||||||||||||||||
Changes in assets and liabilities, net of amounts from businesses acquired: | |||||||||||||||||||||||||||||||||
Trade accounts receivable, net | - | - | 10,600 | - | -73,804 | 289 | -62,915 | ||||||||||||||||||||||||||
Inventories | - | - | -26,758 | - | -104,322 | 19,432 | -111,648 | ||||||||||||||||||||||||||
Prepaid expenses and other current and non-current assets | - | 27,932 | -28,285 | -25,230 | 5,543 | -6,791 | -26,831 | ||||||||||||||||||||||||||
Accounts receivable from / payable to related parties | 19,214 | 68,641 | 126,606 | -1,109 | -214,030 | 23,481 | 22,803 | ||||||||||||||||||||||||||
Accounts payable, accrued expenses and other current and non-current liabilities | -17,938 | -1,925 | 23,947 | -455 | -183,359 | -578 | -180,308 | ||||||||||||||||||||||||||
Income tax payable | 628 | 8,954 | - | -7,528 | 36,852 | -18,150 | 20,756 | ||||||||||||||||||||||||||
Net cash provided by (used in) operating activities | 3,007 | 283,874 | 124,096 | -45,876 | -194,481 | -58,326 | 112,294 | ||||||||||||||||||||||||||
Investing Activities: | |||||||||||||||||||||||||||||||||
Purchases of property, plant and equipment | - | - | -28,346 | - | -179,465 | 8,180 | -199,631 | ||||||||||||||||||||||||||
Proceeds from sale of property, plant and equipment | - | - | 128 | - | 2,352 | - | 2,480 | ||||||||||||||||||||||||||
Disbursement of loans to related parties | - | -88,773 | - | -63,712 | - | 152,485 | - | ||||||||||||||||||||||||||
Acquisitions and investments, net of cash acquired, and purchases of intangible assets | - | -63,444 | -1,216 | - | -136,985 | 64,488 | -137,157 | ||||||||||||||||||||||||||
Proceeds from divestitures | - | - | - | - | 2,381 | - | 2,381 | ||||||||||||||||||||||||||
Net cash provided by (used in) investing activities | - | -152,217 | -29,434 | -63,712 | -311,717 | 225,153 | -331,927 | ||||||||||||||||||||||||||
Financing Activities: | |||||||||||||||||||||||||||||||||
Short-term borrowings, net | - | -60 | -93,960 | - | 171,121 | - | 77,101 | ||||||||||||||||||||||||||
Long-term debt and capital lease obligations, net | -3,007 | -136,960 | - | 109,588 | 186,922 | -152,485 | 4,058 | ||||||||||||||||||||||||||
Increase (decrease) of accounts receivable securitization program | - | - | - | - | 68,000 | - | 68,000 | ||||||||||||||||||||||||||
Proceeds from exercise of stock options | - | 5,266 | - | - | 541 | - | 5,807 | ||||||||||||||||||||||||||
Capital increase (decrease) | - | - | - | - | 21,099 | -21,099 | - | ||||||||||||||||||||||||||
Distributions to noncontrolling interest | - | - | - | - | -52,157 | - | -52,157 | ||||||||||||||||||||||||||
Contributions from noncontrolling interest | - | - | - | - | 13,402 | - | 13,402 | ||||||||||||||||||||||||||
Net cash provided by (used in) financing activities | -3,007 | -131,754 | -93,960 | 109,588 | 408,928 | -173,584 | 116,211 | ||||||||||||||||||||||||||
Effect of exchange rate changes on cash and cash equivalents | - | 377 | 6 | - | -5,611 | - | -5,228 | ||||||||||||||||||||||||||
Cash and Cash Equivalents: | |||||||||||||||||||||||||||||||||
Net increase (decrease) in cash and cash equivalents | 0 | 280 | 708 | - | -102,881 | -6,757 | -108,650 | ||||||||||||||||||||||||||
Cash and cash equivalents at beginning of period | 0 | 13 | 4,490 | - | 672,206 | 6,068 | 682,777 | ||||||||||||||||||||||||||
Cash and cash equivalents at end of period | $ | 0 | $ | 293 | $ | 5,198 | $ | - | $ | 569,325 | $ | -689 | $ | 574,127 | |||||||||||||||||||
For the three months ended March 31, 2013 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | Non-Guarantor Subsidiaries | |||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Combining Adjustment | Combined Total | ||||||||||||||||||||||||||||
Operating Activities: | |||||||||||||||||||||||||||||||||
Net income (loss) | $ | 1,081 | $ | 225,499 | $ | -11,711 | $ | 161,636 | $ | 304,267 | $ | -420,689 | $ | 260,083 | |||||||||||||||||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||||||||||||||||||||||||||||||||
Equity affiliate income | - | -117,240 | - | -181,689 | - | 298,929 | - | ||||||||||||||||||||||||||
Depreciation and amortization | - | 169 | 12,184 | - | 151,774 | -7,774 | 156,353 | ||||||||||||||||||||||||||
Change in deferred taxes, net | - | -14,876 | 2,705 | - | -3,914 | -6,370 | -22,455 | ||||||||||||||||||||||||||
(Gain) loss on sale of fixed assets and investments | - | -12 | -115 | - | 455 | - | 328 | ||||||||||||||||||||||||||
Compensation expense related to stock options | - | 6,220 | - | - | - | - | 6,220 | ||||||||||||||||||||||||||
Investments in equity method investees, net | - | 22,816 | - | - | -4,234 | - | 18,582 | ||||||||||||||||||||||||||
Changes in assets and liabilities, net of amounts from businesses acquired: | |||||||||||||||||||||||||||||||||
Trade accounts receivable, net | - | - | -15,829 | - | -24,873 | - | -40,702 | ||||||||||||||||||||||||||
Inventories | - | - | -12,488 | - | -59,019 | 15,334 | -56,173 | ||||||||||||||||||||||||||
Prepaid expenses and other current and non-current assets | - | -19,210 | -9,435 | -6,047 | 66,903 | -132 | 32,079 | ||||||||||||||||||||||||||
Accounts receivable from / payable to related parties | 8,547 | -76,649 | 52,601 | 28,490 | -80,161 | 65,697 | -1,475 | ||||||||||||||||||||||||||
Accounts payable, accrued expenses and other current and non-current liabilities | -7,273 | 3,603 | 19,261 | -921 | -115,523 | 1,182 | -99,671 | ||||||||||||||||||||||||||
Income tax payable | 616 | -923 | - | -13,065 | 50,431 | 25,190 | 62,249 | ||||||||||||||||||||||||||
Net cash provided by (used in) operating activities | 2,971 | 29,397 | 37,173 | -11,596 | 286,106 | -28,633 | 315,418 | ||||||||||||||||||||||||||
Investing Activities: | |||||||||||||||||||||||||||||||||
Purchases of property, plant and equipment | - | -14 | -13,577 | - | -139,502 | 5,736 | -147,357 | ||||||||||||||||||||||||||
Proceeds from sale of property, plant and equipment | - | 17 | 180 | - | 1,130 | - | 1,327 | ||||||||||||||||||||||||||
Disbursement of loans to related parties | - | -22,515 | - | 83,644 | - | -61,129 | - | ||||||||||||||||||||||||||
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets | - | -23,152 | -1,424 | - | -69,095 | 21,457 | -72,214 | ||||||||||||||||||||||||||
Proceeds from divestitures | - | - | - | - | -63,452 | 64,488 | 1,036 | ||||||||||||||||||||||||||
Net cash provided by (used in) investing activities | - | -45,664 | -14,821 | 83,644 | -270,919 | 30,552 | -217,208 | ||||||||||||||||||||||||||
Financing Activities: | |||||||||||||||||||||||||||||||||
Short-term borrowings, net | - | 4,226 | -22,794 | - | 25,607 | - | 7,039 | ||||||||||||||||||||||||||
Long-term debt and capital lease obligations, net | -2,972 | - | - | 1,659,914 | -1,750,388 | 61,129 | -32,317 | ||||||||||||||||||||||||||
Increase (decrease) of accounts receivable securitization program | - | - | - | - | -162,000 | - | -162,000 | ||||||||||||||||||||||||||
Proceeds from exercise of stock options | - | 4,113 | - | - | 522 | - | 4,635 | ||||||||||||||||||||||||||
Capital increase (decrease) | - | - | - | -1,731,962 | 1,730,603 | 1,359 | - | ||||||||||||||||||||||||||
Distributions to noncontrolling interest | - | - | - | - | -72,619 | - | -72,619 | ||||||||||||||||||||||||||
Contributions from noncontrolling interest | - | - | - | - | 8,795 | - | 8,795 | ||||||||||||||||||||||||||
Net cash provided by (used in) financing activities | -2,972 | 8,339 | -22,794 | -72,048 | -219,480 | 62,488 | -246,467 | ||||||||||||||||||||||||||
Effect of exchange rate changes on cash and cash equivalents | - | 8,461 | -2 | - | -13,401 | - | -4,942 | ||||||||||||||||||||||||||
Cash and Cash Equivalents: | |||||||||||||||||||||||||||||||||
Net increase (decrease) in cash and cash equivalents | -1 | 533 | -444 | - | -217,694 | 64,407 | -153,199 | ||||||||||||||||||||||||||
Cash and cash equivalents at beginning of period | 1 | 78 | 501 | - | 686,457 | 1,003 | 688,040 | ||||||||||||||||||||||||||
Cash and cash equivalents at end of period | $ | 0 | $ | 611 | $ | 57 | $ | - | $ | 468,763 | $ | 65,410 | $ | 534,841 |
Inventories_Tables
Inventories (Tables) | 3 Months Ended | ||||||
Mar. 31, 2014 | |||||||
Inventories (Tables) [Abstract] | ' | ||||||
Inventory Disclosure Tables [Text Block] | ' | ||||||
31-Mar-14 | 31-Dec-13 | ||||||
Finished goods | $ | 751,027 | $ | 640,355 | |||
Raw materials and purchased components | 194,808 | 185,146 | |||||
Health care supplies | 186,687 | 195,519 | |||||
Work in process | 74,250 | 76,084 | |||||
Inventories | $ | 1,206,772 | $ | 1,097,104 |
Longterm_Debt_and_Capital_Leas1
Long-term Debt and Capital Lease Obligations (Tables) | 3 Months Ended | |||||||||||||||||||
Mar. 31, 2014 | ||||||||||||||||||||
Long Term Debt and Capital Lease Obligations (Tables) [Abstract] | ' | |||||||||||||||||||
Schedule of long-term debt | ' | |||||||||||||||||||
Maximum Amount Available(1) | Balance Outstanding | |||||||||||||||||||
31-Mar-14 | 31-Dec-13 | 31-Mar-14 | 31-Dec-13 | |||||||||||||||||
Accounts Receivable Facility | $ | 800,000 | $ | 800,000 | $ | 419,250 | $ | 351,250 | ||||||||||||
(1) Subject to availability of sufficient accounts receivable meeting funding criteria. | ||||||||||||||||||||
2006 Senior Credit Agreement Table | ' | |||||||||||||||||||
Maximum Amount Available March 31, 2014 | Balance Outstanding March 31, 2014 | |||||||||||||||||||
Revolving Credit USD | $ | 600,000 | $ | 600,000 | $ | 336,469 | $ | 336,469 | ||||||||||||
Revolving Credit EUR | € | 500,000 | $ | 689,400 | € | 90,000 | $ | 124,092 | ||||||||||||
Term Loan A | $ | 2,450,000 | $ | 2,450,000 | $ | 2,450,000 | $ | 2,450,000 | ||||||||||||
$ | 3,739,400 | $ | 2,910,561 | |||||||||||||||||
Maximum Amount Available December 31, 2013 | Balance Outstanding December 31, 2013 | |||||||||||||||||||
Revolving Credit USD | $ | 600,000 | $ | 600,000 | $ | 138,190 | $ | 138,190 | ||||||||||||
Revolving Credit EUR | € | 500,000 | $ | 689,550 | € | 50,000 | $ | 68,955 | ||||||||||||
Term Loan A | $ | 2,500,000 | $ | 2,500,000 | $ | 2,500,000 | $ | 2,500,000 | ||||||||||||
$ | 3,789,550 | $ | 2,707,145 |
Earning_Per_Share_Tables
Earning Per Share (Tables) | 3 Months Ended | ||||||||||
Mar. 31, 2014 | |||||||||||
Earnings Per Share (Tables) [Abstract] | ' | ||||||||||
Schedule of Earning per Share | ' | ||||||||||
For the three months ended March 31, | |||||||||||
2014 | 2013 | ||||||||||
Numerators: | |||||||||||
Net income attributable to shareholders of FMC-AG & Co. KGaA | $ | 205,462 | $ | 225,499 | |||||||
less: | |||||||||||
Dividend preference on Preference shares(1) | - | 26 | |||||||||
Income available to all classes of shares | $ | 205,462 | $ | 225,473 | |||||||
Denominators: | |||||||||||
Weighted average number of: | |||||||||||
Ordinary shares outstanding | 301,491,046 | 302,773,218 | |||||||||
Preference shares outstanding(1) | - | 3,973,333 | |||||||||
Total weighted average shares outstanding | 301,491,046 | 306,746,551 | |||||||||
Potentially dilutive Ordinary shares | 378,831 | 1,131,149 | |||||||||
Potentially dilutive Preference shares(1) | - | 13,681 | |||||||||
Total weighted average Ordinary shares outstanding assuming dilution | 301,869,877 | 303,904,367 | |||||||||
Total weighted average Preference shares outstanding assuming dilution(1) | - | 3,987,014 | |||||||||
Basic income per Ordinary share | $ | 0.68 | $ | 0.74 | |||||||
Fully diluted income per Ordinary share | 0.68 | 0.73 | |||||||||
(1) As of the preference share conversion on June 28th, 2013, the Company no longer has two classes of shares outstanding. |
Employee_Benefit_Plans_Tables
Employee Benefit Plans (Tables) | 3 Months Ended | |||||||||
Mar. 31, 2014 | ||||||||||
Employee Benefit Plans (Tables) [Abstract] | ' | |||||||||
Schedule of the components of net periodic benefit cost | ' | |||||||||
For the three months ended March 31, | ||||||||||
2014 | 2013 | |||||||||
Components of net periodic benefit cost: | ||||||||||
Service cost | $ | 4,739 | $ | 3,913 | ||||||
Interest cost | 7,404 | 6,784 | ||||||||
Expected return on plan assets | -3,925 | -3,400 | ||||||||
Amortization of unrealized losses | 4,354 | 6,398 | ||||||||
Net periodic benefit costs | $ | 12,572 | $ | 13,695 |
Noncontrolling_Interests_Subje1
Noncontrolling Interests Subject To Put Provisions (Tables) | 3 Months Ended | ||||||
Mar. 31, 2014 | |||||||
Noncontrolling Interests Subject To Put Provisions (Tables) [Abstract] | ' | ||||||
Noncontrolling Interests Subject to Put Provisions | ' | ||||||
8. Noncontrolling Interests Subject to Put Provisions | |||||||
The Company has potential obligations to purchase the noncontrolling interests held by third parties in certain of its consolidated subsidiaries. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase all or part of third-party owners' noncontrolling interests at the appraised fair value at the time of exercise. The methodology the Company uses to estimate the fair values of the noncontrolling interest subject to put provisions assumes the greater of net book value or a multiple of earnings, based on historical earnings, development stage of the underlying business and other factors. The estimated fair values of the noncontrolling interests subject to these put provisions can also fluctuate and the implicit multiple of earnings at which these noncontrolling interest obligations may ultimately be settled could vary significantly from our current estimates depending upon market conditions. | |||||||
At March 31, 2014 and December 31, 2013, the Company's potential obligations under these put options were $631,940 and $648,251, respectively, of which, at March 31, 2014, put options with an aggregate purchase obligation of $251,453 were exercisable. No put options were exercised during the first three months of 2014. | |||||||
The following is a roll forward of noncontrolling interests subject to put provisions for the three months ended March 31, 2014 and the year ended December 31, 2013: | |||||||
31-Mar-14 | 31-Dec-13 | ||||||
Beginning balance as of January 1, | $ | 648,251 | $ | 523,260 | |||
Contributions to noncontrolling interests | -29,121 | -122,179 | |||||
Purchase/ sale of noncontrolling interests | -4,452 | 6,723 | |||||
Contributions from noncontrolling interests | 4,329 | 17,767 | |||||
Changes in fair value of noncontrolling interests | -13,847 | 108,575 | |||||
Net income | 26,768 | 113,156 | |||||
Other comprehensive income (loss) | 12 | 949 | |||||
Ending balance as of March 31, 2014 and December 31, 2013 | $ | 631,940 | $ | 648,251 |
Patient_Service_Revenue_Tables
Patient Service Revenue (Tables) | 3 Months Ended | |||||
Mar. 31, 2014 | ||||||
Patient Service Revenue by Payor (Abstract) | ' | |||||
Patient Service Revenue [Text Block] | ' | |||||
For the three months ended March 31, | ||||||
2014 | 2013 | |||||
Medicare ESRD program | $ | 1,094,338 | $ | 1,055,056 | ||
Private/alternative payors | 947,477 | 914,397 | ||||
Medicaid and other government sources | 109,486 | 91,026 | ||||
Hospitals | 112,701 | 106,931 | ||||
Total patient service revenue | $ | 2,264,002 | $ | 2,167,410 |
Financial_Instrument_Tables
Financial Instrument (Tables) | 3 Months Ended | ||||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||||
Financial Instruments (Tables) [Abstract] | ' | ||||||||||||||||||||||
Non-Derivative Financial Instruments | ' | ||||||||||||||||||||||
March 31, | December 31, | ||||||||||||||||||||||
2014 | 2013 | ||||||||||||||||||||||
Fair Value | Carrying | Fair | Carrying | Fair | |||||||||||||||||||
Hierarchy | Amount | Value | Amount | Value | |||||||||||||||||||
Assets | |||||||||||||||||||||||
Cash and cash equivalents | 1 | $ | 574,127 | 574,127 | $ | 682,777 | 682,777 | ||||||||||||||||
Accounts Receivable(1) | 2 | 3,251,520 | 3,251,520 | 3,190,392 | 3,190,392 | ||||||||||||||||||
Notes Receivable | 3 | 166,631 | 184,242 | 165,807 | 175,768 | ||||||||||||||||||
Liabilities | |||||||||||||||||||||||
Accounts payable(1) | 2 | 714,897 | 714,897 | 666,526 | 666,526 | ||||||||||||||||||
Short-term borrowings(1) | 2 | 291,540 | 291,540 | 158,990 | 158,990 | ||||||||||||||||||
Long term debt, excluding 2012 Credit Agreement, Euro Notes and Senior Notes | 2 | 534,950 | 534,950 | 679,847 | 679,847 | ||||||||||||||||||
2012 Credit Agreement | 2 | 2,910,561 | 2,910,561 | 2,707,145 | 2,710,270 | ||||||||||||||||||
Senior Notes | 2 | 4,825,384 | 5,332,253 | 4,824,753 | 5,348,679 | ||||||||||||||||||
Euro Notes | 2 | 46,535 | 46,722 | 46,545 | 47,423 | ||||||||||||||||||
Noncontrolling interests subject to put provisions | 3 | 631,940 | 631,940 | 648,251 | 648,251 | ||||||||||||||||||
(1) Also includes amounts receivable from or payable to related parties. | |||||||||||||||||||||||
Derivative Financial Instruments Valuation | ' | ||||||||||||||||||||||
31-Mar-14 | 31-Dec-13 | ||||||||||||||||||||||
Assets(2) | Liabilities(2) | Assets(2) | Liabilities(2) | ||||||||||||||||||||
Derivatives in cash flow hedging relationships (1) | |||||||||||||||||||||||
Current | |||||||||||||||||||||||
Foreign exchange contracts | 3,235 | -2,856 | 4,985 | -2,719 | |||||||||||||||||||
Non-current | |||||||||||||||||||||||
Foreign exchange contracts | 204 | - | 759 | -374 | |||||||||||||||||||
Interest rate contracts | - | -4,553 | - | -4,392 | |||||||||||||||||||
Total | $ | 3,439 | $ | -7,409 | $ | 5,744 | $ | -7,485 | |||||||||||||||
Derivatives not designated as hedging instruments (1) | |||||||||||||||||||||||
Current | |||||||||||||||||||||||
Foreign exchange contracts | 15,373 | -15,449 | 11,679 | -22,982 | |||||||||||||||||||
Non-current | |||||||||||||||||||||||
Foreign exchange contracts | 556 | -648 | 1,060 | -820 | |||||||||||||||||||
Total | $ | 15,929 | $ | -16,097 | $ | 12,739 | $ | -23,802 | |||||||||||||||
(1) At March 31, 2014 and December 31, 2013, the valuation of the Company's derivatives was determined using Significant Other Observable Inputs (Level 2) in accordance with the fair value hierarchy levels established in U.S. GAAP. | |||||||||||||||||||||||
(2) Derivative instruments are marked to market each reporting period resulting in carrying amounts being equal to fair values at the reporting date. | |||||||||||||||||||||||
Effect of Derivatives on the Consolidated Financial Statements | ' | ||||||||||||||||||||||
The Effect of Derivatives on the Consolidated Financial Statements | |||||||||||||||||||||||
Amount of Gain or (Loss) Recognized in OCI on Derivatives | Location of (Gain) or Loss Reclassified from AOCI in Income | Amount of (Gain) or Loss Reclassified from AOCI in Income | |||||||||||||||||||||
Derivatives in Cash Flow Hedging Relationships | |||||||||||||||||||||||
(Effective Portion) for the three months ended March 31, | (Effective Portion) for the three months ended March 31, | ||||||||||||||||||||||
2014 | 2013 | (Effective Portion) | 2014 | 2013 | |||||||||||||||||||
Interest rate contracts | $ | -125 | $ | 6,470 | Interest income/expense | $ | 7,358 | $ | 6,365 | ||||||||||||||
Foreign exchange contracts | -845 | 3,991 | Costs of Revenue | 571 | -1,345 | ||||||||||||||||||
Foreign exchange contracts | Interest income/expense | - | 416 | ||||||||||||||||||||
$ | -970 | $ | 10,461 | $ | 7,929 | $ | 5,436 | ||||||||||||||||
Derivatives not Designated as Hedging Instruments | Amount of (Gain) or Loss Recognized in Income on Derivatives for the three months ended March 31, | ||||||||||||||||||||||
Location of (Gain) or Loss Recognized in Income on Derivative | |||||||||||||||||||||||
2014 | 2013 | ||||||||||||||||||||||
Foreign exchange contracts | Selling, general and administrative expense | $ | -2,298 | $ | -21,812 | ||||||||||||||||||
Foreign exchange contracts | Interest income/expense | 1,226 | 1,966 | ||||||||||||||||||||
$ | -1,072 | $ | -19,846 |
Other_Comprehensive_Income_Tab
Other Comprehensive Income (Tables) | 3 Months Ended | ||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||
Other Comprehensive Income (Tables) [Abstract] | ' | ||||||||||||||||||
Other Comprehensive Income Rollforward [Text Block] | ' | ||||||||||||||||||
Gain (Loss) related to cash flow hedges | Actuarial gain (loss) on defined benefit pension plans | Gain (Loss) related to foreign-currency translation | Total, before non-controlling interests | Non-controlling interests | Total | ||||||||||||||
Balance at December 31, 2012 | $ | -138,341 | $ | -179,423 | $ | -174,349 | $ | -492,113 | $ | 2,869 | $ | -489,244 | |||||||
Other comprehensive income (loss) before reclassifications | 8,031 | - | -66,210 | -58,179 | -1,982 | -60,161 | |||||||||||||
Amounts reclassified from AOCI | 3,639 | 3,941 | - | 7,580 | - | 7,580 | |||||||||||||
Other comprehensive income (loss) after reclassifications | 11,670 | 3,941 | -66,210 | -50,599 | -1,982 | -52,581 | |||||||||||||
Balance at March 31, 2013 | $ | -126,671 | $ | -175,482 | $ | -240,559 | $ | -542,712 | $ | 887 | $ | -541,825 | |||||||
Balance at December 31, 2013 | $ | -121,856 | $ | -141,987 | $ | -286,744 | $ | -550,587 | $ | 825 | $ | -549,762 | |||||||
Other comprehensive income (loss) before reclassifications | -556 | - | -47,023 | -47,579 | -33 | -47,612 | |||||||||||||
Amounts reclassified from AOCI | 5,579 | 2,740 | - | 8,319 | - | 8,319 | |||||||||||||
Other comprehensive income (loss) after reclassifications | 5,023 | 2,740 | -47,023 | -39,260 | -33 | -39,293 | |||||||||||||
Balance at March 31, 2014 | $ | -116,833 | $ | -139,247 | $ | -333,767 | $ | -589,847 | $ | 792 | $ | -589,055 | |||||||
Other Comprehensive Income Reclassifications [Text Block] | ' | ||||||||||||||||||
Details about AOCI Components | Amount of (Gain) Loss reclassified from AOCI in Income | Location of (Gain) Loss reclassified from AOCI in Income | |||||||||||||||||
For the three months ended March 31, | |||||||||||||||||||
2014 | 2013 | ||||||||||||||||||
(Gain) Loss related to cash flow hedges | |||||||||||||||||||
Interest rate contracts | $ | 7,358 | $ | 6,365 | Interest income/expense | ||||||||||||||
Foreign exchange contracts | 571 | -1,345 | Costs of Revenue | ||||||||||||||||
Foreign exchange contracts | - | 416 | Interest income/expense | ||||||||||||||||
7,929 | 5,436 | Total before tax | |||||||||||||||||
-2,350 | -1,797 | Tax expense or benefit | |||||||||||||||||
$ | 5,579 | $ | 3,639 | Net of tax | |||||||||||||||
Actuarial (Gain) Loss on defined benefit pension plans | |||||||||||||||||||
Amortization of unrealized (gain) /loss | 4,354 | 6,398 | -1 | ||||||||||||||||
4,354 | 6,398 | Total before tax | |||||||||||||||||
-1,614 | -2,457 | Tax expense or benefit | |||||||||||||||||
$ | 2,740 | $ | 3,941 | Net of tax | |||||||||||||||
Total reclassifications for the period | $ | 8,319 | $ | 7,580 | Net of tax | ||||||||||||||
(1) Included in the computation of net periodic pension cost (see Note 7 for additional details). |
Business_Segment_Information_T
Business Segment Information (Tables) | 3 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Business Segment Information (Tables) [Abstract] | ' | ||||||||||||||||
Schedule of segment reporting information by segment | ' | ||||||||||||||||
North America Segment | International Segment | Segment Totals | Corporate | Total | |||||||||||||
Three months ended March 31, 2014 | |||||||||||||||||
Net revenue external customers | $ | 2,392,907 | $ | 1,160,898 | $ | 3,553,805 | $ | 9,787 | $ | 3,563,592 | |||||||
Inter - segment revenue | 1,280 | - | 1,280 | -1,280 | - | ||||||||||||
Revenue | 2,394,187 | 1,160,898 | 3,555,085 | 8,507 | 3,563,592 | ||||||||||||
Depreciation and amortization | -87,649 | -45,021 | -132,670 | -34,497 | -167,167 | ||||||||||||
Operating income | 335,562 | 180,446 | 516,008 | -71,113 | 444,895 | ||||||||||||
Income (loss) from equity method investees | 10,551 | 1,971 | 12,522 | - | 12,522 | ||||||||||||
Segment assets | 14,860,218 | 6,267,649 | 21,127,867 | 2,294,810 | 23,422,677 | ||||||||||||
thereof investments in equity method investees | 300,110 | 433,802 | 733,912 | - | 733,912 | ||||||||||||
Capital expenditures, acquisitions and investments (1) | 204,899 | 64,637 | 269,536 | 67,252 | 336,788 | ||||||||||||
Three months ended March 31, 2013 | |||||||||||||||||
Net revenue external customers | $ | 2,287,250 | $ | 1,168,652 | $ | 3,455,902 | $ | 8,019 | $ | 3,463,921 | |||||||
Inter - segment revenue | 1,075 | - | 1,075 | -1,075 | - | ||||||||||||
Revenue | 2,288,325 | 1,168,652 | 3,456,977 | 6,944 | 3,463,921 | ||||||||||||
Depreciation and amortization(2) | -80,407 | -45,900 | -126,307 | -30,046 | -156,353 | ||||||||||||
Operating income (3) | 366,048 | 191,617 | 557,665 | -64,352 | 493,313 | ||||||||||||
Income (loss) from equity method investees(4) | 3,118 | 1,690 | 4,808 | - | 4,808 | ||||||||||||
Segment assets | 14,044,466 | 5,896,442 | 19,940,908 | 2,198,755 | 22,139,663 | ||||||||||||
thereof investments in equity method investees | 239,689 | 361,738 | 601,427 | - | 601,427 | ||||||||||||
Capital expenditures, acquisitions and investments (5) | 112,332 | 82,702 | 195,034 | 24,537 | 219,571 | ||||||||||||
(1) International acquisitions exclude $7,569 of non-cash acquisitions for 2014. | |||||||||||||||||
(2) Depreciation in the amount of $895 relating to research and development has been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation. | |||||||||||||||||
(3) Certain items, in the net aggregate amount of $5,006, relating to research and development, compensation expense and income from equity method investees have been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation as applicable. | |||||||||||||||||
(4) Income (loss) from equity method investees in the amount of $396 has been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation. | |||||||||||||||||
(5) International acquisitions exclude $3,690 of non-cash acquisitions for 2013. |
Supplementary_Cash_Flow_Inform1
Supplementary Cash Flow Information (Tables) | 3 Months Ended | ||||||
Mar. 31, 2014 | |||||||
Supplementary Cash Flow Information (Tables) [Abstract] | ' | ||||||
Schedule of supplemental Cash Flow information | ' | ||||||
Three months ended March 31, | |||||||
2014 | 2013 | ||||||
Supplementary cash flow information: | |||||||
Cash paid for interest | $ | 164,393 | $ | 165,596 | |||
Cash paid for income taxes (1) | $ | 83,138 | $ | 59,708 | |||
Cash inflow for income taxes from stock option exercises | $ | 545 | $ | 522 | |||
Supplemental disclosures of cash flow information: | |||||||
Details for acquisitions: | |||||||
Assets acquired | $ | -31,589 | $ | -69,485 | |||
Liabilities assumed | 2,251 | 3,334 | |||||
Noncontrolling interest subject to put provisions | - | 6,294 | |||||
Noncontrolling interest | 288 | 4,527 | |||||
Obligations assumed in connection with acquisition | 7,569 | 3,690 | |||||
Cash paid | -21,481 | -51,640 | |||||
Less cash acquired | 105 | 2,530 | |||||
Net cash paid for acquisitions | -21,376 | -49,110 | |||||
Cash paid for investments | -112,848 | -22,185 | |||||
Cash paid for intangible assets | -2,933 | -919 | |||||
Total cash paid for acquisitions and investments, net of cash acquired, and purchases of intangible assets | $ | -137,157 | $ | -72,214 | |||
(1) Net of tax refund. |
Supplemental_Condensed_Combini1
Supplemental Condensed Combining Information (Tables) | 3 Months Ended | ||||||||||||||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||||||||||||||
Supplemental Condensed Combining Information (Tables) [Abstract] | ' | ||||||||||||||||||||||||||||||||
Income statement information segregated by issuers and guarantors | ' | ||||||||||||||||||||||||||||||||
For the three months ended March 31, 2014 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | ||||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||
Net revenue | $ | - | $ | - | $ | 531,730 | $ | - | $ | 3,896,574 | $ | -864,712 | $ | 3,563,592 | |||||||||||||||||||
Cost of revenue | - | - | 332,156 | - | 2,995,003 | -845,699 | 2,481,460 | ||||||||||||||||||||||||||
Gross profit | - | - | 199,574 | - | 901,571 | -19,013 | 1,082,132 | ||||||||||||||||||||||||||
Operating expenses (income): | |||||||||||||||||||||||||||||||||
Selling, general and administrative(1) | - | 47,374 | 28,650 | -26,380 | 569,452 | -11,887 | 607,209 | ||||||||||||||||||||||||||
Research and development | - | - | 19,297 | - | 10,731 | - | 30,028 | ||||||||||||||||||||||||||
Operating (loss) income | - | -47,374 | 151,627 | 26,380 | 321,388 | -7,126 | 444,895 | ||||||||||||||||||||||||||
Other (income) expense: | |||||||||||||||||||||||||||||||||
Interest, net | -1,731 | 60,526 | -1,031 | 45,462 | -7,015 | 50 | 96,261 | ||||||||||||||||||||||||||
Other, net | - | -330,870 | 111,665 | -154,698 | - | 373,903 | - | ||||||||||||||||||||||||||
Income (loss) before income taxes | 1,731 | 222,970 | 40,993 | 135,616 | 328,403 | -381,079 | 348,634 | ||||||||||||||||||||||||||
Income tax expense (benefit) | 628 | 17,508 | 37,172 | -7,528 | 148,579 | -95,075 | 101,284 | ||||||||||||||||||||||||||
Net Income (loss) | 1,103 | 205,462 | 3,821 | 143,144 | 179,824 | -286,004 | 247,350 | ||||||||||||||||||||||||||
Net Income attributable to noncontrolling interests | - | - | - | - | - | 41,888 | 41,888 | ||||||||||||||||||||||||||
Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA | $ | 1,103 | $ | 205,462 | $ | 3,821 | $ | 143,144 | $ | 179,824 | $ | -327,892 | $ | 205,462 | |||||||||||||||||||
(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees. | |||||||||||||||||||||||||||||||||
For the three months ended March 31, 2013 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | ||||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||
Net revenue | $ | - | $ | - | $ | 495,497 | $ | - | $ | 3,758,626 | $ | -790,202 | $ | 3,463,921 | |||||||||||||||||||
Cost of revenue | - | - | 335,779 | - | 2,796,879 | -778,255 | 2,354,403 | ||||||||||||||||||||||||||
Gross profit | - | - | 159,718 | - | 961,747 | -11,947 | 1,109,518 | ||||||||||||||||||||||||||
Operating expenses (income): | |||||||||||||||||||||||||||||||||
Selling, general and administrative (1) | - | 6,423 | 49,086 | -7,180 | 511,647 | 25,857 | 585,833 | ||||||||||||||||||||||||||
Research and development | - | - | 17,969 | - | 12,572 | -169 | 30,372 | ||||||||||||||||||||||||||
Operating (loss) income | - | -6,423 | 92,663 | 7,180 | 437,528 | -37,635 | 493,313 | ||||||||||||||||||||||||||
Other (income) expense: | |||||||||||||||||||||||||||||||||
Interest, net | -1,697 | 46,193 | 2,251 | 40,298 | 17,184 | - | 104,229 | ||||||||||||||||||||||||||
Other, net | - | -263,397 | 96,047 | -181,689 | - | 349,039 | - | ||||||||||||||||||||||||||
Income (loss) before income taxes | 1,697 | 210,781 | -5,635 | 148,571 | 420,344 | -386,674 | 389,084 | ||||||||||||||||||||||||||
Income tax expense (benefit) | 616 | -14,718 | 6,076 | -13,065 | 116,077 | 34,015 | 129,001 | ||||||||||||||||||||||||||
Net Income (loss) | 1,081 | 225,499 | -11,711 | 161,636 | 304,267 | -420,689 | 260,083 | ||||||||||||||||||||||||||
Net Income attributable to noncontrolling interests | - | - | - | - | - | 34,584 | 34,584 | ||||||||||||||||||||||||||
Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA | $ | 1,081 | $ | 225,499 | $ | -11,711 | $ | 161,636 | $ | 304,267 | $ | -455,273 | $ | 225,499 | |||||||||||||||||||
(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees. | |||||||||||||||||||||||||||||||||
Balance sheet information segregated by issuers and guarantors | ' | ||||||||||||||||||||||||||||||||
At March 31, 2014 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | ||||||||||||||||||||||||||||||
Current assets: | |||||||||||||||||||||||||||||||||
Cash and cash equivalents | $ | 0 | $ | 293 | $ | 5,198 | $ | - | $ | 569,325 | $ | -689 | $ | 574,127 | |||||||||||||||||||
Trade accounts receivable, less allowance for doubtful accounts | - | - | 141,776 | - | 2,936,792 | 1,766 | 3,080,334 | ||||||||||||||||||||||||||
Accounts receivable from related parties | 1,251,652 | 1,082,152 | 925,520 | 1,654,727 | 4,395,927 | -9,138,792 | 171,186 | ||||||||||||||||||||||||||
Inventories | - | - | 314,500 | - | 1,046,933 | -154,661 | 1,206,772 | ||||||||||||||||||||||||||
Prepaid expenses and other current assets | - | 47,005 | 70,159 | 117 | 1,041,383 | 36,728 | 1,195,392 | ||||||||||||||||||||||||||
Deferred taxes | - | - | - | - | 312,758 | -43,848 | 268,910 | ||||||||||||||||||||||||||
Total current assets | 1,251,652 | 1,129,450 | 1,457,153 | 1,654,844 | 10,303,118 | -9,299,496 | 6,496,721 | ||||||||||||||||||||||||||
Property, plant and equipment, net | - | 679 | 255,385 | - | 3,003,849 | -124,790 | 3,135,123 | ||||||||||||||||||||||||||
Intangible assets | - | 387 | 71,527 | - | 662,404 | -91 | 734,227 | ||||||||||||||||||||||||||
Goodwill | - | - | 62,815 | - | 11,583,342 | - | 11,646,157 | ||||||||||||||||||||||||||
Deferred taxes | - | 83,365 | 14,762 | - | 119,945 | -109,592 | 108,480 | ||||||||||||||||||||||||||
Other assets and notes receivables(1) | - | 14,313,281 | 48,249 | 12,851,806 | 5,211,198 | -31,122,565 | 1,301,969 | ||||||||||||||||||||||||||
Total assets | $ | 1,251,652 | $ | 15,527,162 | $ | 1,909,891 | $ | 14,506,650 | $ | 30,883,856 | $ | -40,656,534 | $ | 23,422,677 | |||||||||||||||||||
Current liabilities: | |||||||||||||||||||||||||||||||||
Accounts payable | $ | - | $ | 726 | $ | 32,836 | $ | - | $ | 517,106 | $ | - | $ | 550,668 | |||||||||||||||||||
Accounts payable to related parties | - | 2,199,883 | 665,432 | 1,571,744 | 5,126,683 | -9,399,513 | 164,229 | ||||||||||||||||||||||||||
Accrued expenses and other current liabilities | 11,833 | 83,607 | 143,998 | 8,948 | 1,642,610 | 9,243 | 1,900,239 | ||||||||||||||||||||||||||
Short-term borrowings | - | 56,536 | - | - | 100,690 | - | 157,226 | ||||||||||||||||||||||||||
Short-term borrowings from related parties | - | - | - | - | 134,314 | - | 134,314 | ||||||||||||||||||||||||||
Current portion of long-term debt and capital lease obligations | - | 78,195 | - | 200,000 | 23,080 | - | 301,275 | ||||||||||||||||||||||||||
Income tax payable | - | 123,187 | - | - | 85,921 | -5,554 | 203,554 | ||||||||||||||||||||||||||
Deferred taxes | - | 1,869 | 10,567 | - | 66,021 | -42,646 | 35,811 | ||||||||||||||||||||||||||
Total current liabilities | 11,833 | 2,544,003 | 852,833 | 1,780,692 | 7,696,425 | -9,438,470 | 3,447,316 | ||||||||||||||||||||||||||
Long term debt and capital lease obligations, less current portion | 1,166,233 | 152,002 | - | 2,586,469 | 7,681,126 | -3,569,675 | 8,016,155 | ||||||||||||||||||||||||||
Long term borrowings from related parties | - | 3,359,322 | - | 2,092,452 | 6,491 | -5,458,265 | - | ||||||||||||||||||||||||||
Other liabilities | - | 5,557 | 5,837 | 267,855 | 30,366 | 23,605 | 333,220 | ||||||||||||||||||||||||||
Pension liabilities | - | 11,426 | 260,023 | - | 142,892 | -953 | 413,388 | ||||||||||||||||||||||||||
Income tax payable | 2,915 | 30,840 | - | - | 21,549 | 110,736 | 166,040 | ||||||||||||||||||||||||||
Deferred taxes | - | - | - | - | 759,967 | -25,638 | 734,329 | ||||||||||||||||||||||||||
Total liabilities | 1,180,981 | 6,103,150 | 1,118,693 | 6,727,468 | 16,338,816 | -18,358,660 | 13,110,448 | ||||||||||||||||||||||||||
Noncontrolling interests subject to put provisions | - | - | 0 | - | 631,940 | - | 631,940 | ||||||||||||||||||||||||||
Total FMC-AG & Co. KGaA shareholders' equity | 70,671 | 9,424,012 | 791,198 | 7,779,182 | 13,656,823 | -22,297,874 | 9,424,012 | ||||||||||||||||||||||||||
Noncontrolling interests not subject to put provisions | - | - | - | - | 256,277 | - | 256,277 | ||||||||||||||||||||||||||
Total equity | 70,671 | 9,424,012 | 791,198 | 7,779,182 | 13,913,100 | -22,297,874 | 9,680,289 | ||||||||||||||||||||||||||
Total liabilities and equity | $ | 1,251,652 | $ | 15,527,162 | $ | 1,909,891 | $ | 14,506,650 | $ | 30,883,856 | $ | -40,656,534 | $ | 23,422,677 | |||||||||||||||||||
(1) Other Assets and notes receivables are presented net of investment in equity method investees. | |||||||||||||||||||||||||||||||||
At December 31, 2013 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | ||||||||||||||||||||||||||||||
Current assets: | |||||||||||||||||||||||||||||||||
Cash and cash equivalents | $ | 0 | $ | 13 | $ | 4,490 | $ | - | $ | 672,206 | $ | 6,068 | $ | 682,777 | |||||||||||||||||||
Trade accounts receivable, less allowance for doubtful accounts | - | - | 152,480 | - | 2,882,736 | 2,058 | 3,037,274 | ||||||||||||||||||||||||||
Accounts receivable from related parties | 1,269,092 | 960,137 | 815,748 | 1,643,394 | 4,073,975 | -8,609,228 | 153,118 | ||||||||||||||||||||||||||
Inventories | - | - | 287,625 | - | 946,790 | -137,311 | 1,097,104 | ||||||||||||||||||||||||||
Prepaid expenses and other current assets | - | 71,939 | 41,240 | 167 | 879,085 | 44,960 | 1,037,391 | ||||||||||||||||||||||||||
Deferred taxes | - | - | - | - | 322,337 | -43,285 | 279,052 | ||||||||||||||||||||||||||
Total current assets | 1,269,092 | 1,032,089 | 1,301,583 | 1,643,561 | 9,777,129 | -8,736,738 | 6,286,716 | ||||||||||||||||||||||||||
Property, plant and equipment, net | - | 734 | 238,469 | - | 2,980,268 | -127,517 | 3,091,954 | ||||||||||||||||||||||||||
Intangible assets | - | 501 | 73,166 | - | 684,290 | -81 | 757,876 | ||||||||||||||||||||||||||
Goodwill | - | - | 62,829 | - | 11,595,358 | - | 11,658,187 | ||||||||||||||||||||||||||
Deferred taxes | - | 80,931 | 14,209 | - | 118,306 | -109,279 | 104,167 | ||||||||||||||||||||||||||
Other assets and notes receivables (1) | - | 13,955,933 | 47,661 | 12,583,246 | 5,234,132 | -30,599,966 | 1,221,006 | ||||||||||||||||||||||||||
Total assets | $ | 1,269,092 | $ | 15,070,188 | $ | 1,737,917 | $ | 14,226,807 | $ | 30,389,483 | $ | -39,573,581 | $ | 23,119,906 | |||||||||||||||||||
Current liabilities: | |||||||||||||||||||||||||||||||||
Accounts payable | $ | - | $ | 2,193 | $ | 28,689 | $ | - | $ | 511,715 | $ | - | $ | 542,597 | |||||||||||||||||||
Accounts payable to related parties | - | 1,896,712 | 522,719 | 1,600,480 | 4,931,344 | -8,827,326 | 123,929 | ||||||||||||||||||||||||||
Accrued expenses and other current liabilities | 29,770 | 45,897 | 129,727 | 9,403 | 1,786,709 | 11,027 | 2,012,533 | ||||||||||||||||||||||||||
Short-term borrowings | - | 60 | - | - | 96,588 | - | 96,648 | ||||||||||||||||||||||||||
Short-term borrowings from related parties | - | - | - | - | 62,342 | - | 62,342 | ||||||||||||||||||||||||||
Current portion of long-term debt and capital lease obligations | - | 271,090 | - | 200,000 | 40,280 | - | 511,370 | ||||||||||||||||||||||||||
Income tax payable | - | 114,197 | - | - | 56,163 | - | 170,360 | ||||||||||||||||||||||||||
Deferred taxes | - | 2,331 | 9,002 | - | 64,539 | -41,678 | 34,194 | ||||||||||||||||||||||||||
Total current liabilities | 29,770 | 2,332,480 | 690,137 | 1,809,883 | 7,549,680 | -8,857,977 | 3,553,973 | ||||||||||||||||||||||||||
Long term debt and capital lease obligations, less current portion | 1,167,466 | 96,699 | - | 2,438,189 | 7,478,944 | -3,434,378 | 7,746,920 | ||||||||||||||||||||||||||
Long term borrowings from related parties | - | 3,359,606 | - | 2,092,818 | 6,940 | -5,459,364 | - | ||||||||||||||||||||||||||
Other liabilities | - | 5,616 | 6,028 | 267,914 | 30,399 | 19,604 | 329,561 | ||||||||||||||||||||||||||
Pension liabilities | - | 10,377 | 254,233 | - | 171,248 | - | 435,858 | ||||||||||||||||||||||||||
Income tax payable | 2,287 | 30,846 | - | - | 20,262 | 123,538 | 176,933 | ||||||||||||||||||||||||||
Deferred taxes | - | - | - | - | 768,156 | -24,766 | 743,390 | ||||||||||||||||||||||||||
Total liabilities | 1,199,523 | 5,835,624 | 950,398 | 6,608,804 | 16,025,629 | -17,633,343 | 12,986,635 | ||||||||||||||||||||||||||
Noncontrolling interests subject to put provisions | - | - | 0 | - | 648,251 | - | 648,251 | ||||||||||||||||||||||||||
Total FMC-AG & Co. KGaA shareholders' equity | 69,569 | 9,234,564 | 787,519 | 7,618,003 | 13,465,147 | -21,940,238 | 9,234,564 | ||||||||||||||||||||||||||
Noncontrolling interests not subject to put provisions | - | - | - | - | 250,456 | - | 250,456 | ||||||||||||||||||||||||||
Total equity | 69,569 | 9,234,564 | 787,519 | 7,618,003 | 13,715,603 | -21,940,238 | 9,485,020 | ||||||||||||||||||||||||||
Total liabilities and equity | $ | 1,269,092 | $ | 15,070,188 | $ | 1,737,917 | $ | 14,226,807 | $ | 30,389,483 | $ | -39,573,581 | $ | 23,119,906 | |||||||||||||||||||
(1) Other Assets and notes receivables are presented net of investment in equity method investees. | |||||||||||||||||||||||||||||||||
Statement of cash flows information segregated by issuers and guarantors | ' | ||||||||||||||||||||||||||||||||
For the three months ended March 31, 2014 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | ||||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||
Operating Activities: | |||||||||||||||||||||||||||||||||
Net income (loss) | $ | 1,103 | $ | 205,462 | $ | 3,821 | $ | 143,144 | $ | 179,824 | $ | -286,004 | $ | 247,350 | |||||||||||||||||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||||||||||||||||||||||||||||||||
Equity affiliate income | - | -124,293 | - | -154,698 | - | 278,991 | - | ||||||||||||||||||||||||||
Depreciation and amortization | - | 168 | 13,209 | - | 162,641 | -8,851 | 167,167 | ||||||||||||||||||||||||||
Change in deferred taxes, net | - | -5,141 | 1,004 | - | 6,310 | -5,632 | -3,459 | ||||||||||||||||||||||||||
(Gain) loss on sale of fixed assets and investments | - | - | -48 | - | 854 | - | 806 | ||||||||||||||||||||||||||
(Write Up) write-off loans from related parties | - | 54,513 | - | - | - | -54,513 | - | ||||||||||||||||||||||||||
Compensation expense related to stock options | - | 6,174 | - | - | - | - | 6,174 | ||||||||||||||||||||||||||
Investments in equity method investees, net | - | 43,389 | - | - | -10,990 | - | 32,399 | ||||||||||||||||||||||||||
Changes in assets and liabilities, net of amounts from businesses acquired: | |||||||||||||||||||||||||||||||||
Trade accounts receivable, net | - | - | 10,600 | - | -73,804 | 289 | -62,915 | ||||||||||||||||||||||||||
Inventories | - | - | -26,758 | - | -104,322 | 19,432 | -111,648 | ||||||||||||||||||||||||||
Prepaid expenses and other current and non-current assets | - | 27,932 | -28,285 | -25,230 | 5,543 | -6,791 | -26,831 | ||||||||||||||||||||||||||
Accounts receivable from / payable to related parties | 19,214 | 68,641 | 126,606 | -1,109 | -214,030 | 23,481 | 22,803 | ||||||||||||||||||||||||||
Accounts payable, accrued expenses and other current and non-current liabilities | -17,938 | -1,925 | 23,947 | -455 | -183,359 | -578 | -180,308 | ||||||||||||||||||||||||||
Income tax payable | 628 | 8,954 | - | -7,528 | 36,852 | -18,150 | 20,756 | ||||||||||||||||||||||||||
Net cash provided by (used in) operating activities | 3,007 | 283,874 | 124,096 | -45,876 | -194,481 | -58,326 | 112,294 | ||||||||||||||||||||||||||
Investing Activities: | |||||||||||||||||||||||||||||||||
Purchases of property, plant and equipment | - | - | -28,346 | - | -179,465 | 8,180 | -199,631 | ||||||||||||||||||||||||||
Proceeds from sale of property, plant and equipment | - | - | 128 | - | 2,352 | - | 2,480 | ||||||||||||||||||||||||||
Disbursement of loans to related parties | - | -88,773 | - | -63,712 | - | 152,485 | - | ||||||||||||||||||||||||||
Acquisitions and investments, net of cash acquired, and purchases of intangible assets | - | -63,444 | -1,216 | - | -136,985 | 64,488 | -137,157 | ||||||||||||||||||||||||||
Proceeds from divestitures | - | - | - | - | 2,381 | - | 2,381 | ||||||||||||||||||||||||||
Net cash provided by (used in) investing activities | - | -152,217 | -29,434 | -63,712 | -311,717 | 225,153 | -331,927 | ||||||||||||||||||||||||||
Financing Activities: | |||||||||||||||||||||||||||||||||
Short-term borrowings, net | - | -60 | -93,960 | - | 171,121 | - | 77,101 | ||||||||||||||||||||||||||
Long-term debt and capital lease obligations, net | -3,007 | -136,960 | - | 109,588 | 186,922 | -152,485 | 4,058 | ||||||||||||||||||||||||||
Increase (decrease) of accounts receivable securitization program | - | - | - | - | 68,000 | - | 68,000 | ||||||||||||||||||||||||||
Proceeds from exercise of stock options | - | 5,266 | - | - | 541 | - | 5,807 | ||||||||||||||||||||||||||
Capital increase (decrease) | - | - | - | - | 21,099 | -21,099 | - | ||||||||||||||||||||||||||
Distributions to noncontrolling interest | - | - | - | - | -52,157 | - | -52,157 | ||||||||||||||||||||||||||
Contributions from noncontrolling interest | - | - | - | - | 13,402 | - | 13,402 | ||||||||||||||||||||||||||
Net cash provided by (used in) financing activities | -3,007 | -131,754 | -93,960 | 109,588 | 408,928 | -173,584 | 116,211 | ||||||||||||||||||||||||||
Effect of exchange rate changes on cash and cash equivalents | - | 377 | 6 | - | -5,611 | - | -5,228 | ||||||||||||||||||||||||||
Cash and Cash Equivalents: | |||||||||||||||||||||||||||||||||
Net increase (decrease) in cash and cash equivalents | 0 | 280 | 708 | - | -102,881 | -6,757 | -108,650 | ||||||||||||||||||||||||||
Cash and cash equivalents at beginning of period | 0 | 13 | 4,490 | - | 672,206 | 6,068 | 682,777 | ||||||||||||||||||||||||||
Cash and cash equivalents at end of period | $ | 0 | $ | 293 | $ | 5,198 | $ | - | $ | 569,325 | $ | -689 | $ | 574,127 | |||||||||||||||||||
For the three months ended March 31, 2013 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | Non-Guarantor Subsidiaries | |||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Combining Adjustment | Combined Total | ||||||||||||||||||||||||||||
Operating Activities: | |||||||||||||||||||||||||||||||||
Net income (loss) | $ | 1,081 | $ | 225,499 | $ | -11,711 | $ | 161,636 | $ | 304,267 | $ | -420,689 | $ | 260,083 | |||||||||||||||||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||||||||||||||||||||||||||||||||
Equity affiliate income | - | -117,240 | - | -181,689 | - | 298,929 | - | ||||||||||||||||||||||||||
Depreciation and amortization | - | 169 | 12,184 | - | 151,774 | -7,774 | 156,353 | ||||||||||||||||||||||||||
Change in deferred taxes, net | - | -14,876 | 2,705 | - | -3,914 | -6,370 | -22,455 | ||||||||||||||||||||||||||
(Gain) loss on sale of fixed assets and investments | - | -12 | -115 | - | 455 | - | 328 | ||||||||||||||||||||||||||
Compensation expense related to stock options | - | 6,220 | - | - | - | - | 6,220 | ||||||||||||||||||||||||||
Investments in equity method investees, net | - | 22,816 | - | - | -4,234 | - | 18,582 | ||||||||||||||||||||||||||
Changes in assets and liabilities, net of amounts from businesses acquired: | |||||||||||||||||||||||||||||||||
Trade accounts receivable, net | - | - | -15,829 | - | -24,873 | - | -40,702 | ||||||||||||||||||||||||||
Inventories | - | - | -12,488 | - | -59,019 | 15,334 | -56,173 | ||||||||||||||||||||||||||
Prepaid expenses and other current and non-current assets | - | -19,210 | -9,435 | -6,047 | 66,903 | -132 | 32,079 | ||||||||||||||||||||||||||
Accounts receivable from / payable to related parties | 8,547 | -76,649 | 52,601 | 28,490 | -80,161 | 65,697 | -1,475 | ||||||||||||||||||||||||||
Accounts payable, accrued expenses and other current and non-current liabilities | -7,273 | 3,603 | 19,261 | -921 | -115,523 | 1,182 | -99,671 | ||||||||||||||||||||||||||
Income tax payable | 616 | -923 | - | -13,065 | 50,431 | 25,190 | 62,249 | ||||||||||||||||||||||||||
Net cash provided by (used in) operating activities | 2,971 | 29,397 | 37,173 | -11,596 | 286,106 | -28,633 | 315,418 | ||||||||||||||||||||||||||
Investing Activities: | |||||||||||||||||||||||||||||||||
Purchases of property, plant and equipment | - | -14 | -13,577 | - | -139,502 | 5,736 | -147,357 | ||||||||||||||||||||||||||
Proceeds from sale of property, plant and equipment | - | 17 | 180 | - | 1,130 | - | 1,327 | ||||||||||||||||||||||||||
Disbursement of loans to related parties | - | -22,515 | - | 83,644 | - | -61,129 | - | ||||||||||||||||||||||||||
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets | - | -23,152 | -1,424 | - | -69,095 | 21,457 | -72,214 | ||||||||||||||||||||||||||
Proceeds from divestitures | - | - | - | - | -63,452 | 64,488 | 1,036 | ||||||||||||||||||||||||||
Net cash provided by (used in) investing activities | - | -45,664 | -14,821 | 83,644 | -270,919 | 30,552 | -217,208 | ||||||||||||||||||||||||||
Financing Activities: | |||||||||||||||||||||||||||||||||
Short-term borrowings, net | - | 4,226 | -22,794 | - | 25,607 | - | 7,039 | ||||||||||||||||||||||||||
Long-term debt and capital lease obligations, net | -2,972 | - | - | 1,659,914 | -1,750,388 | 61,129 | -32,317 | ||||||||||||||||||||||||||
Increase (decrease) of accounts receivable securitization program | - | - | - | - | -162,000 | - | -162,000 | ||||||||||||||||||||||||||
Proceeds from exercise of stock options | - | 4,113 | - | - | 522 | - | 4,635 | ||||||||||||||||||||||||||
Capital increase (decrease) | - | - | - | -1,731,962 | 1,730,603 | 1,359 | - | ||||||||||||||||||||||||||
Distributions to noncontrolling interest | - | - | - | - | -72,619 | - | -72,619 | ||||||||||||||||||||||||||
Contributions from noncontrolling interest | - | - | - | - | 8,795 | - | 8,795 | ||||||||||||||||||||||||||
Net cash provided by (used in) financing activities | -2,972 | 8,339 | -22,794 | -72,048 | -219,480 | 62,488 | -246,467 | ||||||||||||||||||||||||||
Effect of exchange rate changes on cash and cash equivalents | - | 8,461 | -2 | - | -13,401 | - | -4,942 | ||||||||||||||||||||||||||
Cash and Cash Equivalents: | |||||||||||||||||||||||||||||||||
Net increase (decrease) in cash and cash equivalents | -1 | 533 | -444 | - | -217,694 | 64,407 | -153,199 | ||||||||||||||||||||||||||
Cash and cash equivalents at beginning of period | 1 | 78 | 501 | - | 686,457 | 1,003 | 688,040 | ||||||||||||||||||||||||||
Cash and cash equivalents at end of period | $ | 0 | $ | 611 | $ | 57 | $ | - | $ | 468,763 | $ | 65,410 | $ | 534,841 | |||||||||||||||||||
Other comprehensive income statement segregated by issuers and guarantors | ' | ||||||||||||||||||||||||||||||||
For the three months ended March 31, 2014 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | ||||||||||||||||||||||||||||||
Net Income | $ | 1,103 | $ | 205,462 | $ | 3,821 | $ | 143,144 | $ | 179,824 | $ | -286,004 | $ | 247,350 | |||||||||||||||||||
Gain (loss) related to cash flow hedges | - | 7,234 | - | - | -275 | - | 6,959 | ||||||||||||||||||||||||||
Actuarial gain (loss) on defined benefit pension plans | - | 50 | 947 | 3,262 | 95 | - | 4,354 | ||||||||||||||||||||||||||
Gain (loss) related to foreign currency translation | - | 833 | -145 | - | -50,268 | 2,524 | -47,056 | ||||||||||||||||||||||||||
Income tax (expense) benefit related to components of other comprehensive income | - | -2,097 | -276 | -1,287 | 110 | - | -3,550 | ||||||||||||||||||||||||||
Other comprehensive income (loss), net of tax | - | 6,020 | 526 | 1,975 | -50,338 | 2,524 | -39,293 | ||||||||||||||||||||||||||
Total comprehensive income | $ | 1,103 | $ | 211,482 | $ | 4,347 | $ | 145,119 | $ | 129,486 | $ | -283,480 | $ | 208,057 | |||||||||||||||||||
Comprehensive income attributable to noncontrolling interests | - | - | - | - | - | 41,855 | 41,855 | ||||||||||||||||||||||||||
Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA | $ | 1,103 | $ | 211,482 | $ | 4,347 | $ | 145,119 | $ | 129,486 | $ | -325,335 | $ | 166,202 | |||||||||||||||||||
For the three months ended March 31, 2013 | |||||||||||||||||||||||||||||||||
Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | ||||||||||||||||||||||||||||||
Net Income | $ | 1,081 | $ | 225,499 | $ | -11,711 | $ | 161,636 | $ | 304,267 | $ | -420,689 | $ | 260,083 | |||||||||||||||||||
Gain (loss) related to cash flow hedges | - | 12,864 | - | - | 3,033 | - | 15,897 | ||||||||||||||||||||||||||
Actuarial gain (loss) on defined benefit pension plans | - | 32 | 637 | 5,668 | 61 | - | 6,398 | ||||||||||||||||||||||||||
Gain (loss) related to foreign currency translation | - | 67,232 | -22,010 | - | -115,710 | 2,296 | -68,192 | ||||||||||||||||||||||||||
Income tax (expense) benefit related to components of other comprehensive income | - | -3,707 | -186 | -2,236 | -555 | - | -6,684 | ||||||||||||||||||||||||||
Other comprehensive income (loss), net of tax | - | 76,421 | -21,559 | 3,432 | -113,171 | 2,296 | -52,581 | ||||||||||||||||||||||||||
Total comprehensive income | $ | 1,081 | $ | 301,920 | $ | -33,270 | $ | 165,068 | $ | 191,096 | $ | -418,393 | $ | 207,502 | |||||||||||||||||||
Comprehensive income attributable to noncontrolling interests | - | - | - | - | - | 32,602 | 32,602 | ||||||||||||||||||||||||||
Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA | $ | 1,081 | $ | 301,920 | $ | -33,270 | $ | 165,068 | $ | 191,096 | $ | -450,995 | $ | 174,900 | |||||||||||||||||||
Related_Party_Transactions_Det
Related Party Transactions (Details) | 3 Months Ended | 3 Months Ended | |||||||||||||||||||||||||
In Thousands, unless otherwise specified | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 |
USD ($) | USD ($) | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | General Partner [Member] | General Partner [Member] | General Partner [Member] | General Partner [Member] | APP Inc [Member] | APP Inc [Member] | Equity Method Investees [Member] | Fresenius SE Subsidiary [Member] | Fresenius SE Subsidiary [Member] | Fresenius SE Subsidiary [Member] | General partner extensions [Member] | |
USD ($) | EUR (€) | Services Provided By Related Party [Member] | Services Provided By Related Party [Member] | Services Provided To Related Party [Member] | Services Provided To Related Party [Member] | Operating Lease Agreements [Member] | Operating Lease Agreements [Member] | Sales To Related Party [Member] | Sales To Related Party [Member] | Purchases From Related Party [Member] | Purchases From Related Party [Member] | Taxes Receivable [Member] | Taxes Receivable [Member] | USD ($) | EUR (€) | Services Provided By Related Party [Member] | Services Provided By Related Party [Member] | Purchases From Related Party [Member] | Purchases From Related Party [Member] | Sales To Related Party [Member] | USD ($) | Senior notes held by related party [Member] | Senior notes held by related party [Member] | ||||
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | EUR (€) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | EUR (€) | |||||||||
Related Party Transactions [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
FSE ownership percentage | 31.38% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amount of transaction | ' | ' | ' | ' | $27,467 | $23,973 | $1,848 | $1,719 | $7,038 | $6,569 | $7,481 | $7,215 | $5,907 | $10,364 | ' | ' | ' | ' | $8,172 | $4,511 | $5,348 | $4,560 | $655 | ' | $16,270 | € 11,800 | ' |
Due to related parties | $164,229 | $123,929 | $72,663 | € 52,700 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2,068 | € 1,500 | ' | ' | ' | ' | ' | $57,515 | ' | ' | ' |
Interest rate | ' | ' | 1.61% | 1.61% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.34% | 1.34% | ' | ' | ' | ' | ' | 6.10% | 5.25% | 5.25% | 1.88% |
Date of repayment | ' | ' | 30-Apr-14 | 30-Apr-14 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 23-May-14 | ' | ' | ' |
Inventories_Details
Inventories (Details) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Inventories (Details) [Abstract] | ' | ' |
Raw materials and purchased components | $194,808 | $185,146 |
Work in process | 74,250 | 76,084 |
Finished goods | 751,027 | 640,355 |
Health care supplies | 186,687 | 195,519 |
Inventories | $1,206,772 | $1,097,104 |
Other_Assets_and_Notes_Receiva
Other Assets and Notes Receivable (Details) (USD $) | 3 Months Ended |
In Thousands, unless otherwise specified | Mar. 31, 2014 |
Accounts notes and loans receivable [LineItems] | ' |
Borrowings Available Under Notes Receivable | 200,000 |
Notes Receivable Maturity Date | 'date of July 4, 2020 (unless prepaid) |
Notes Receivable Cash Interest Rate | 10.75% |
Notes Receivable PIK Interest Rate | 11.75% |
Notes Receivable Balance | $170,000 |
Notes Receivable Net Payment | 165,542 |
Notes Receivable Interest Income | $2,538 |
Longterm_Debt_and_Capital_Leas2
Long-term Debt and Capital Lease Obligations (Details) (USD $) | 3 Months Ended | 12 Months Ended |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Dec. 31, 2013 |
Debt Instrument [Line Items] | ' | ' |
Senior Long Term Notes | $4,825,384 | $4,824,753 |
Capital lease obligations | 24,875 | 24,264 |
Other | 90,825 | 111,259 |
Long-term debt and capital lease obligations | 8,317,430 | 8,258,290 |
Less current maturities | 301,275 | 511,370 |
Total long-term debt less current maturities | 8,016,155 | 7,746,920 |
Revolving credit maximum amount available | 3,739,400 | 3,789,550 |
Revolving credit balance outstanding | 2,910,561 | 2,707,145 |
Accounts receivable facility | 419,250 | 351,250 |
Senior Credit Agreement 2012 Member [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Senior Credit Agreement | 2,910,561 | 2,707,145 |
Line of credit outstanding which reduces available borrowings under the revolving credit facility | 7,143 | 9,444 |
RevolvingCreditUSD [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Revolving credit maximum amount available | 600,000 | 600,000 |
Revolving credit balance outstanding | 336,469 | 138,190 |
RevolvingCreditEUR [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Revolving credit maximum amount available | 689,400 | 689,550 |
Revolving credit balance outstanding | 124,092 | 68,955 |
TermLoanA2012 [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Revolving credit maximum amount available | 2,450,000 | 2,500,000 |
Revolving credit balance outstanding | 2,450,000 | 2,500,000 |
Euro Notes [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Senior Long Term Notes | 46,535 | 46,545 |
EIB Agreements [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Senior Long Term Notes | ' | 193,074 |
Accounts Receivable Facility [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Maximum amount available | 800,000 | ' |
Balance outstanding | 351,250 | ' |
Line of credit outstanding which reduces available borrowings under the revolving credit facility | $65,622 | ' |
Recovered_Sheet1
Short-term Borrowings and Other Financial Liabilities and Short-term Borrowings from Related Parties (Details) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 |
In Thousands, unless otherwise specified | Fresenius SE [Member] | General Partner [Member] | ||
Short Term Borrowings Other Financial Liabilities And Short Term Borrowings From Related Parties (Details) [Abstract] | ' | ' | ' | ' |
Borrowings under lines of credit | $100,429 | $95,690 | ' | ' |
Accounts receivable facility | 419,250 | 351,250 | ' | ' |
Other financial liabilities | 56,797 | 958 | ' | ' |
Related Party Transaction [Line Items] | ' | ' | ' | ' |
Related Party Transaction Rate | ' | ' | 1.61% | 1.34% |
Short-term borrowings and other financial liabilities | 157,226 | 96,648 | ' | ' |
Short Term Borrowings Due To Related Parties Current Acquisitions | 134,314 | 62,342 | ' | ' |
Short-term borrowings, Other financial liabilities and Short-term borrowings from related parties | $291,540 | $158,990 | ' | ' |
Earnings_Per_Share_Details
Earnings Per Share (Details) (USD $) | 3 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Numerators: | ' | ' |
Income attributable to the Company | $205,462,000 | $225,499,000 |
Less: Dividend preference on Preference shares | ' | 26,000 |
Income available to all classes of shares | 205,462,000 | 225,473,000 |
Denominators: | ' | ' |
Weighted average number of ordinary shares outstanding | 301,491,046 | 302,773,218 |
Weighted average number of preference shares outstanding | 0 | 3,973,333 |
Total weighted average shares outstanding | 301,491,046 | 306,746,551 |
Potentially dilutive Ordinary shares | 378,831 | 1,131,149 |
Potentially dilutive Preference shares | 0 | 13,681 |
Total weighted average Ordinary shares outstanding assuming dilution | 301,869,877 | 303,904,367 |
Total weighted average Preference shares outstanding assuming dilution | 0 | 3,987,014 |
Basic income per Ordinary share | $0.68 | $0.74 |
Fully diluted income per Ordinary share | $0.68 | $0.73 |
Employee_Benefit_Plans_Details
Employee Benefit Plans (Details) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Components Of Net Periodic Benefit Cost [Abstract] | ' | ' |
Service cost | $4,739 | $3,913 |
Interest cost | 7,404 | 6,784 |
Expected return on plan assets | -3,925 | -3,400 |
Amortization of unrealized losses | 4,354 | 6,398 |
Net periodic benefit costs | $12,572 | $13,695 |
Noncontrolling_Interests_Subje2
Noncontrolling Interests Subject to Put Provisions (Details) (USD $) | 3 Months Ended | 12 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 |
Noncontrolling Interests Subject To Put Provisions (Details) [Abstract] | ' | ' | ' |
Potential obligations under the put provisions | $631,940 | ' | $648,251 |
Temporary Equity [Line Items] | ' | ' | ' |
Noncontrolling interests subject to put provisions beginning balance | 648,251 | ' | ' |
Dividends paid | ' | ' | 296,134 |
Minority interest increase from stock issuance | -2,879 | ' | -15,173 |
Minority interest decrease from distributions to noncontrolling interest holders | -8,951 | ' | -32,275 |
Changes in fair value of noncontrolling interests | 13,847 | ' | -108,575 |
Net Income | 247,350 | 260,083 | ' |
Other comprehensive income loss net of tax | -39,293 | -52,581 | ' |
Noncontrolling interests subject to put provisions ending balance | 631,940 | ' | 648,251 |
Put provisions exercisable | 251,453 | ' | ' |
Noncontrolling interests subject to put provisions [Member] | ' | ' | ' |
Temporary Equity [Line Items] | ' | ' | ' |
Noncontrolling interests subject to put provisions beginning balance | 523,260 | ' | ' |
Dividends paid | -29,121 | ' | -122,179 |
Minority interest increase from stock issuance | -4,452 | ' | 6,723 |
Minority interest decrease from distributions to noncontrolling interest holders | 4,329 | ' | 17,767 |
Changes in fair value of noncontrolling interests | -13,847 | ' | 108,575 |
Net Income | 26,768 | ' | 113,156 |
Other comprehensive income loss net of tax | 12 | ' | 949 |
Noncontrolling interests subject to put provisions ending balance | ' | ' | $523,260 |
Patient_Service_Revenue_Detail
Patient Service Revenue (Details) (USD $) | Mar. 31, 2014 | Mar. 31, 2013 |
In Thousands, unless otherwise specified | ||
Patient Service Revenue By Payor [Line Items] | ' | ' |
Patient Service Revenue by Payor | $2,264,002 | $2,167,410 |
Medicare ESRD program | ' | ' |
Patient Service Revenue By Payor [Line Items] | ' | ' |
Patient Service Revenue by Payor | 1,094,338 | 1,055,056 |
Hospitals | ' | ' |
Patient Service Revenue By Payor [Line Items] | ' | ' |
Patient Service Revenue by Payor | 112,701 | 106,931 |
Private | ' | ' |
Patient Service Revenue By Payor [Line Items] | ' | ' |
Patient Service Revenue by Payor | 947,477 | 914,397 |
Medicaid and other government sources | ' | ' |
Patient Service Revenue By Payor [Line Items] | ' | ' |
Patient Service Revenue by Payor | $109,486 | $91,026 |
Financial_Instruments_Details
Financial Instruments (Details) (USD $) | 3 Months Ended | ||
In Thousands, unless otherwise specified | Mar. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Assets: | ' | ' | ' |
Cash and cash equivalents | $574,127 | $682,777 | $688,040 |
Liabilities: | ' | ' | ' |
Short-term borrowings | 157,226 | 96,648 | ' |
Short-term borrowings from related parties | 134,314 | 62,342 | ' |
Senior Long Term Notes | 4,825,384 | 4,824,753 | ' |
Noncontrolling interests subject to put provisions | 631,940 | 648,251 | ' |
Notional amount of foreign currency cash flow hedge derivatives | 174,918 | 238,983 | ' |
Notional amount of interest rate derivatives | 1,685,750 | 1,512,559 | ' |
Amount estimated to be transferred in the future from accumulated OCI into earnings | 372 | ' | ' |
The time period estimated for the anticipated transfer of interest expense into earnings | '12 months | ' | ' |
Derivative assets subject to master netting agreements | 19,048 | 18,334 | ' |
Derivative liabilities subject to master netting agreements | 14,044 | 16,371 | ' |
Derivative net assets subject to master netting agreements | 11,996 | 12,169 | ' |
Derivative net liabiltiies subject to master netting agreements | 6,992 | 10,207 | ' |
Euro Notes [Member] | ' | ' | ' |
Liabilities: | ' | ' | ' |
Senior Long Term Notes | 46,535 | 46,545 | ' |
Carrying Reported Amount Fair Value Disclosure [Member] | ' | ' | ' |
Assets: | ' | ' | ' |
Cash and cash equivalents | 574,127 | 682,777 | ' |
Accounts receivable | 3,251,520 | 3,190,392 | ' |
Long-term notes receivable | 166,631 | 165,807 | ' |
Liabilities: | ' | ' | ' |
Accounts Payable | 714,897 | 666,526 | ' |
Short-term borrowings | 291,540 | 158,990 | ' |
Long term debt, excluding Amended 2006 Senior Credit Agreement, Euro Notes and Senior Notes | 534,950 | 679,847 | ' |
Senior Credit Agreement | 2,910,561 | 2,707,145 | ' |
Carrying Reported Amount Fair Value Disclosure [Member] | Euro Notes [Member] | ' | ' | ' |
Liabilities: | ' | ' | ' |
Senior Long Term Notes | 46,535 | 46,545 | ' |
Carrying Reported Amount Fair Value Disclosure [Member] | Senior Notes [Member] | ' | ' | ' |
Liabilities: | ' | ' | ' |
Senior Long Term Notes | 4,825,384 | 4,824,753 | ' |
Portion At Fair Value Fair Value Disclosure [Member] | ' | ' | ' |
Assets: | ' | ' | ' |
Cash and cash equivalents | 574,127 | 682,777 | ' |
Accounts receivable | 3,251,520 | 3,190,392 | ' |
Long-term notes receivable | 184,242 | 175,768 | ' |
Liabilities: | ' | ' | ' |
Accounts Payable | 714,897 | 666,526 | ' |
Short-term borrowings | 291,540 | 158,990 | ' |
Long term debt, excluding Amended 2006 Senior Credit Agreement, Euro Notes and Senior Notes | 534,950 | 679,847 | ' |
Senior Credit Agreement | 2,910,561 | 2,710,270 | ' |
Portion At Fair Value Fair Value Disclosure [Member] | Euro Notes [Member] | ' | ' | ' |
Liabilities: | ' | ' | ' |
Senior Long Term Notes | 46,722 | 47,423 | ' |
Portion At Fair Value Fair Value Disclosure [Member] | Senior Notes [Member] | ' | ' | ' |
Liabilities: | ' | ' | ' |
Senior Long Term Notes | $5,332,253 | $5,348,679 | ' |
Financial_Instruments_Details_
Financial Instruments (Details 1) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2) | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Assets | $3,439 | $5,744 |
Liabilities | -7,409 | -7,485 |
Nondesignated as Hedging Instrument [Member] | Significant Observable Inputs (Level 2) | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Assets | 15,929 | 12,739 |
Liabilities | -16,097 | -23,802 |
Foreign Exchange Contract Current [Member] | Designated As Hedging Instrument [Member] | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Liabilities | 0 | ' |
Foreign Exchange Contract Current [Member] | Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2) | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Assets | 3,235 | 4,985 |
Liabilities | -2,856 | -2,719 |
Foreign Exchange Contract Current [Member] | Nondesignated as Hedging Instrument [Member] | Significant Observable Inputs (Level 2) | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Assets | 15,373 | 11,679 |
Liabilities | -15,449 | -22,982 |
Foreign Exchange Contract Non Current [Member] | Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2) | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Assets | 204 | 759 |
Liabilities | ' | -374 |
Foreign Exchange Contract Non Current [Member] | Nondesignated as Hedging Instrument [Member] | Significant Observable Inputs (Level 2) | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Assets | 556 | 1,060 |
Liabilities | -648 | -820 |
Interest Rate Contract Non Current Dollar [Member] | Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2) | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Liabilities | ($4,553) | ($4,392) |
Financial_Instruments_Details_1
Financial Instruments (Details 2) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Designated As Hedging Instrument [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion) | ($970) | $10,461 |
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI | 7,929 | 5,436 |
Designated As Hedging Instrument [Member] | Interest Rate Contract [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion) | -125 | 6,470 |
Designated As Hedging Instrument [Member] | Foreign Exchange Contract [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion) | -845 | 3,991 |
Nondesignated as Hedging Instrument [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of (Gain) or Loss Recognized in Income on Derivatives | -1,072 | -19,846 |
Interest Income Expense [Member] | Designated As Hedging Instrument [Member] | Interest Rate Contract [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI | 7,358 | 6,365 |
Interest Income Expense [Member] | Designated As Hedging Instrument [Member] | Foreign Exchange Contract [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI | 0 | 416 |
Interest Income Expense [Member] | Nondesignated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of (Gain) or Loss Recognized in Income on Derivatives | 1,226 | 1,966 |
Cost Of Sale [Member] | Designated As Hedging Instrument [Member] | Foreign Exchange Contract [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI | 571 | -1,345 |
Selling, General and Administrative Expense [Member] | Nondesignated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of (Gain) or Loss Recognized in Income on Derivatives | ($2,298) | ($21,812) |
Other_Comprehensive_Income_Rol
Other Comprehensive Income - Rollforward (Details) (USD $) | 3 Months Ended | 12 Months Ended | ||
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 |
Balance | ' | ' | ($549,762) | ($489,244) |
Other comprehensive income (loss) before reclassifications | -47,612 | -60,161 | ' | ' |
AOCI reclassifications | 8,319 | 7,580 | ' | ' |
Other comprehensive income loss net of taxes | -39,293 | -52,581 | ' | ' |
Ending Balance OCI | -589,055 | -541,825 | ' | ' |
Accumulated Net Gain Loss From Designated Or Qualifying Cash Flow Hedges [Member] | ' | ' | ' | ' |
Balance | ' | ' | -121,856 | -138,341 |
Other comprehensive income (loss) before reclassifications | -556 | 8,031 | ' | ' |
AOCI reclassifications | 5,579 | 3,639 | ' | ' |
Other comprehensive income loss net of taxes | 5,023 | 11,670 | ' | ' |
Ending Balance OCI | -116,833 | -126,671 | ' | ' |
Accumulate benefit plans adjustment [Member] | ' | ' | ' | ' |
Balance | ' | ' | -141,987 | -179,423 |
AOCI reclassifications | 2,740 | 3,941 | ' | ' |
Other comprehensive income loss net of taxes | 2,740 | 3,941 | ' | ' |
Ending Balance OCI | -139,247 | -175,482 | ' | ' |
Accumulated translation adjustments (Domain) [Member] | ' | ' | ' | ' |
Balance | ' | ' | -286,744 | -174,349 |
Other comprehensive income (loss) before reclassifications | -47,023 | -66,210 | ' | ' |
Other comprehensive income loss net of taxes | -47,023 | -66,210 | ' | ' |
Ending Balance OCI | -333,767 | -240,559 | ' | ' |
Total, before non-controlling interests | ' | ' | ' | ' |
Balance | ' | ' | -550,587 | -492,113 |
Other comprehensive income (loss) before reclassifications | -47,579 | -58,179 | ' | ' |
AOCI reclassifications | 8,319 | 7,580 | ' | ' |
Other comprehensive income loss net of taxes | -39,260 | -50,599 | ' | ' |
Ending Balance OCI | -589,847 | -542,712 | ' | ' |
Noncontrolling interests not subject to put provisions [Member] | ' | ' | ' | ' |
Balance | ' | ' | 825 | 2,869 |
Other comprehensive income (loss) before reclassifications | -33 | -1,982 | ' | ' |
Other comprehensive income loss net of taxes | -33 | -1,982 | ' | ' |
Ending Balance OCI | $792 | $887 | ' | ' |
Other_Comprehensive_Income_Rec
Other Comprehensive Income - Reclassifications (Details) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Other comprehensive income derivatives qualifying as hedges net of tax period increase decrease abstract | ' | ' |
Interest rate contracts | $7,358 | $6,365 |
Foreign exchange contracts cost of revenue | 571 | -1,345 |
Foreign exchange contracts interest | 0 | 416 |
Total before tax | 7,929 | 5,436 |
Tax expense or benefit | -2,350 | -1,797 |
Net of tax | 5,579 | 3,639 |
Other comprehensive income defined benefit plans adjustment net of tax period increase decrease abstract | ' | ' |
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax | 4,354 | 6,398 |
Total before tax | 4,354 | 6,398 |
Benefit plans tax expense | -1,614 | -2,457 |
Benefit plans net of tax | 2,740 | 3,941 |
Total reclassifications for the period | $8,319 | $7,580 |
Business_Segment_Information_D
Business Segment Information (Details) (USD $) | 3 Months Ended | ||
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 |
Entity-Wide Information, Revenue from External Customer [Line Items] | ' | ' | ' |
Net revenue from external customers | $3,563,592 | $3,463,921 | ' |
Segment depreciation and amortization | -167,167 | -156,353 | ' |
Operating income | 444,895 | 493,313 | ' |
Income from equity method investees | 12,522 | 4,808 | ' |
Segment assets | 23,422,677 | ' | 23,119,906 |
thereof investment in equity method investees | 733,912 | ' | 664,446 |
Capital expenditures, acquisitions and investments | 336,788 | 219,571 | ' |
Segment Total [Member] | ' | ' | ' |
Entity-Wide Information, Revenue from External Customer [Line Items] | ' | ' | ' |
Net revenue from external customers | 3,553,805 | 3,455,902 | ' |
Inter - segment revenue | 1,280 | 1,075 | ' |
Segment revenue | 3,555,085 | 3,456,977 | ' |
Segment depreciation and amortization | -132,670 | -126,307 | ' |
Operating income | 516,008 | 557,665 | ' |
Income from equity method investees | 12,522 | 4,808 | ' |
Capital expenditures, acquisitions and investments | 269,536 | 195,034 | ' |
North America [Member] | ' | ' | ' |
Entity-Wide Information, Revenue from External Customer [Line Items] | ' | ' | ' |
Net revenue from external customers | 2,392,907 | 2,287,250 | ' |
Inter - segment revenue | 1,280 | 1,075 | ' |
Segment revenue | 2,394,187 | 2,288,325 | ' |
Segment depreciation and amortization | -87,649 | -80,407 | ' |
Operating income | 335,562 | 366,048 | ' |
Income from equity method investees | 10,551 | 3,118 | ' |
Capital expenditures, acquisitions and investments | 204,899 | 112,332 | ' |
Exclusion of non-cash acquisitions | 6,000 | ' | ' |
International [Member] | ' | ' | ' |
Entity-Wide Information, Revenue from External Customer [Line Items] | ' | ' | ' |
Net revenue from external customers | 1,160,898 | 1,168,652 | ' |
Segment revenue | 1,160,898 | 1,168,652 | ' |
Segment depreciation and amortization | -45,021 | -45,900 | ' |
Operating income | 180,446 | 191,617 | ' |
Income from equity method investees | 1,971 | 1,690 | ' |
Capital expenditures, acquisitions and investments | 64,637 | 82,702 | ' |
Exclusion of non-cash acquisitions | 1,731 | 8,884 | ' |
Corporate1 [Member] | ' | ' | ' |
Entity-Wide Information, Revenue from External Customer [Line Items] | ' | ' | ' |
Net revenue from external customers | 9,787 | 8,019 | ' |
Inter - segment revenue | -1,280 | -1,075 | ' |
Segment revenue | 8,507 | 6,944 | ' |
Segment depreciation and amortization | -34,497 | -30,046 | ' |
Operating income | -71,113 | -64,352 | ' |
Income from equity method investees | 0 | 0 | ' |
Capital expenditures, acquisitions and investments | 67,252 | 24,537 | ' |
Exclusion of non-cash acquisitions | ' | $2,125 | ' |
Supplemental_Condensed_Combini2
Supplemental Condensed Combining Information (Details) (USD $) | 3 Months Ended | |||
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 |
Consolidated Statements of Income | ' | ' | ' | ' |
Net revenue | $3,563,592 | $3,463,921 | ' | ' |
Cost of revenues | 2,481,460 | 2,354,403 | ' | ' |
Gross profit | 1,082,132 | 1,109,518 | ' | ' |
Research and development | 30,028 | 30,372 | ' | ' |
Operating income | 444,895 | 493,313 | ' | ' |
Other (income) expense: | ' | ' | ' | ' |
Gain on the sale of dialysis clinics | 2 | 1,073 | ' | ' |
Income before income taxes | 348,634 | 389,084 | ' | ' |
Income tax expense | 101,284 | 129,001 | ' | ' |
Net Income | 247,350 | 260,083 | ' | ' |
Other comprehensive income loss derivatives qualifying as hedges before tax | 6,959 | 15,897 | ' | ' |
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax | 4,354 | 6,398 | ' | ' |
Other comprehensive income loss foreign currency transaction and translation adjustment before tax | -47,056 | -68,192 | ' | ' |
Other comprehensive income loss tax | -3,550 | -6,684 | ' | ' |
Less: Net income attributable to noncontrolling interests | 41,888 | 34,584 | ' | ' |
Income attributable to the Company | 205,462 | 225,499 | ' | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 574,127 | ' | 682,777 | 688,040 |
Trade accounts receivable less allowance for doubtful accounts of $403,657 in 2014 and $413,165 in 2013 | 3,080,334 | ' | 3,037,274 | ' |
Accounts receivable from related parties | 171,186 | ' | 153,118 | ' |
Inventories | 1,206,772 | ' | 1,097,104 | ' |
Prepaid expenses and other current assets | 1,195,392 | ' | 1,037,391 | ' |
Deferred tax asset, current | 268,910 | ' | 279,052 | ' |
Total current assets | 6,496,721 | ' | 6,286,716 | ' |
Property, plant and equipment, net | 3,135,123 | ' | 3,091,954 | ' |
Intangible assets | 734,227 | ' | 757,876 | ' |
Goodwill | 11,646,157 | ' | 11,658,187 | ' |
Deferred tax asset, non-current | 108,480 | ' | 104,167 | ' |
Total assets | 23,422,677 | ' | 23,119,906 | ' |
Current liabilities: | ' | ' | ' | ' |
Accounts payable | 550,668 | ' | 542,597 | ' |
Accounts payable to related parties | 164,229 | ' | 123,929 | ' |
Accrued expenses and other current liabilities | 1,900,239 | ' | 2,012,533 | ' |
Short-term borrowings and other financial liabilities | 157,226 | ' | 96,648 | ' |
Short Term Borrowings Due To Related Parties Current Acquisitions | 134,314 | ' | 62,342 | ' |
Current portion of long-term debt and capital lease obligations | 301,275 | ' | 511,370 | ' |
Income tax payable, current | 203,554 | ' | 170,360 | ' |
Deferred tax liability, current | 35,811 | ' | 34,194 | ' |
Total current liabilities | 3,447,316 | ' | 3,553,973 | ' |
Total long-term debt less current maturities | 8,016,155 | ' | 7,746,920 | ' |
Other liabilities | 333,220 | ' | 329,561 | ' |
Pension liabilities | 413,388 | ' | 435,858 | ' |
Income tax payable, non-current | 166,040 | ' | 176,933 | ' |
Deferred tax liability, non-current | 734,329 | ' | 743,390 | ' |
Total liabilities | 13,110,448 | ' | 12,986,635 | ' |
Noncontrolling interests subject to put provisions | 631,940 | ' | 648,251 | ' |
Company shareholders' equity | 9,424,012 | ' | 9,234,564 | ' |
Minority interest | 256,277 | ' | 250,456 | ' |
Total equity | 9,680,289 | ' | 9,485,020 | ' |
Total liabilities and equity | 23,422,677 | ' | 23,119,906 | ' |
Consolidated Statements of Comprehensive Income | ' | ' | ' | ' |
Net Income | 247,350 | 260,083 | ' | ' |
Other comprehensive income loss derivatives qualifying as hedges before tax | 6,959 | 15,897 | ' | ' |
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax | 4,354 | 6,398 | ' | ' |
Other comprehensive income loss foreign currency transaction and translation adjustment before tax | -47,056 | -68,192 | ' | ' |
Other comprehensive income loss tax | -3,550 | -6,684 | ' | ' |
Other comprehensive income (loss), net of tax | -39,293 | -52,581 | ' | ' |
Total comprehensive income | 208,057 | 207,502 | ' | ' |
Comprehensive income attributable to noncontrolling interests | -41,855 | -32,602 | ' | ' |
Comprehensive income attributable to the Company | 166,202 | 174,900 | ' | ' |
Issuers [Member] | FMC US Finance [Member] | ' | ' | ' | ' |
Other (income) expense: | ' | ' | ' | ' |
Interest, net | ' | -1,697 | ' | ' |
Income before income taxes | 1,731 | 1,697 | ' | ' |
Income tax expense | 628 | 616 | ' | ' |
Net Income | 1,103 | 1,081 | ' | ' |
Income attributable to the Company | 1,103 | 1,081 | ' | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 0 | 0 | ' | 1 |
Accounts receivable from related parties | 1,251,652 | ' | 1,269,092 | ' |
Total current assets | 1,251,652 | ' | 1,269,092 | ' |
Total assets | 1,251,652 | ' | 1,269,092 | ' |
Current liabilities: | ' | ' | ' | ' |
Accrued expenses and other current liabilities | 11,833 | ' | 29,770 | ' |
Total current liabilities | 11,833 | ' | 29,770 | ' |
Total long-term debt less current maturities | 1,166,233 | ' | 1,167,466 | ' |
Income tax payable, non-current | 2,915 | ' | 2,287 | ' |
Total liabilities | 1,180,981 | ' | 1,199,523 | ' |
Noncontrolling interests subject to put provisions | 70,671 | ' | ' | ' |
Company shareholders' equity | ' | ' | 69,569 | ' |
Total equity | 70,671 | ' | 69,569 | ' |
Total liabilities and equity | 1,251,652 | ' | 1,269,092 | ' |
Consolidated Statements of Comprehensive Income | ' | ' | ' | ' |
Net Income | 1,103 | 1,081 | ' | ' |
Total comprehensive income | 1,103 | 1,081 | ' | ' |
Comprehensive income attributable to the Company | 1,103 | 1,081 | ' | ' |
Guarantors [Member] | Total FMC-AG and Co. KGaA [Member] | ' | ' | ' | ' |
Consolidated Statements of Income | ' | ' | ' | ' |
Selling, general and administrative | 47,374 | 6,423 | ' | ' |
Operating income | -47,374 | -6,423 | ' | ' |
Other (income) expense: | ' | ' | ' | ' |
Interest, net | 60,526 | 46,193 | ' | ' |
Other, net | -330,870 | -263,397 | ' | ' |
Income before income taxes | 222,970 | 210,781 | ' | ' |
Income tax expense | 17,508 | -14,718 | ' | ' |
Net Income | 205,462 | 225,499 | ' | ' |
Other comprehensive income loss derivatives qualifying as hedges before tax | 7,234 | 12,864 | ' | ' |
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax | 50 | 32 | ' | ' |
Other comprehensive income loss foreign currency transaction and translation adjustment before tax | 833 | 67,232 | ' | ' |
Other comprehensive income loss tax | -2,097 | -3,707 | ' | ' |
Income attributable to the Company | 205,462 | 225,499 | ' | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 293 | 611 | 13 | 78 |
Accounts receivable from related parties | 1,082,152 | ' | 960,137 | ' |
Prepaid expenses and other current assets | 47,005 | ' | 71,939 | ' |
Total current assets | 1,129,450 | ' | 1,032,089 | ' |
Property, plant and equipment, net | 679 | ' | 734 | ' |
Intangible assets | 387 | ' | 501 | ' |
Deferred tax asset, non-current | 83,365 | ' | 80,931 | ' |
Other assets | 14,313,281 | ' | 13,955,933 | ' |
Total assets | 15,527,162 | ' | 15,070,188 | ' |
Current liabilities: | ' | ' | ' | ' |
Accounts payable | 726 | ' | 2,193 | ' |
Accounts payable to related parties | 2,199,883 | ' | 1,896,712 | ' |
Accrued expenses and other current liabilities | 83,607 | ' | 45,897 | ' |
Short-term borrowings and other financial liabilities | 56,536 | ' | 60 | ' |
Current portion of long-term debt and capital lease obligations | 78,195 | ' | 271,090 | ' |
Income tax payable, current | 123,187 | ' | 114,197 | ' |
Deferred tax liability, current | 1,869 | ' | 2,331 | ' |
Total current liabilities | 2,544,003 | ' | 2,332,480 | ' |
Total long-term debt less current maturities | 152,002 | ' | 96,699 | ' |
Long term borrowings from related parties | 3,359,322 | ' | 3,359,606 | ' |
Other liabilities | 5,557 | ' | 5,616 | ' |
Pension liabilities | 11,426 | ' | 10,377 | ' |
Income tax payable, non-current | 30,840 | ' | 30,846 | ' |
Total liabilities | 6,103,150 | ' | 5,835,624 | ' |
Noncontrolling interests subject to put provisions | 9,424,012 | ' | ' | ' |
Company shareholders' equity | ' | ' | 9,234,564 | ' |
Total equity | 9,424,012 | ' | 9,234,564 | ' |
Total liabilities and equity | 15,527,162 | ' | 15,070,188 | ' |
Consolidated Statements of Comprehensive Income | ' | ' | ' | ' |
Net Income | 205,462 | 225,499 | ' | ' |
Other comprehensive income loss derivatives qualifying as hedges before tax | 7,234 | 12,864 | ' | ' |
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax | 50 | 32 | ' | ' |
Other comprehensive income loss foreign currency transaction and translation adjustment before tax | 833 | 67,232 | ' | ' |
Other comprehensive income loss tax | -2,097 | -3,707 | ' | ' |
Other comprehensive income (loss), net of tax | 6,020 | 76,421 | ' | ' |
Total comprehensive income | 211,482 | 301,920 | ' | ' |
Comprehensive income attributable to the Company | 211,482 | 301,920 | ' | ' |
Guarantors [Member] | D GmbH [Member] | ' | ' | ' | ' |
Consolidated Statements of Income | ' | ' | ' | ' |
Net revenue | 531,730 | 495,497 | ' | ' |
Cost of revenues | 332,156 | 335,779 | ' | ' |
Gross profit | 199,574 | 159,718 | ' | ' |
Selling, general and administrative | 28,650 | 49,086 | ' | ' |
Research and development | 19,297 | 17,969 | ' | ' |
Operating income | 151,627 | 92,663 | ' | ' |
Other (income) expense: | ' | ' | ' | ' |
Interest, net | -1,031 | 2,251 | ' | ' |
Other, net | 111,665 | 96,047 | ' | ' |
Income before income taxes | 40,993 | -5,635 | ' | ' |
Income tax expense | 37,172 | 6,076 | ' | ' |
Net Income | 3,821 | -11,711 | ' | ' |
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax | 947 | 637 | ' | ' |
Other comprehensive income loss foreign currency transaction and translation adjustment before tax | -145 | -22,010 | ' | ' |
Other comprehensive income loss tax | -276 | -186 | ' | ' |
Income attributable to the Company | 3,821 | -11,711 | ' | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 5,198 | 57 | 4,490 | 501 |
Trade accounts receivable less allowance for doubtful accounts of $403,657 in 2014 and $413,165 in 2013 | 141,776 | ' | 152,480 | ' |
Accounts receivable from related parties | 925,520 | ' | 815,748 | ' |
Inventories | 314,500 | ' | 287,625 | ' |
Prepaid expenses and other current assets | 70,159 | ' | 41,240 | ' |
Total current assets | 1,457,153 | ' | 1,301,583 | ' |
Property, plant and equipment, net | 255,385 | ' | 238,469 | ' |
Intangible assets | 71,527 | ' | 73,166 | ' |
Goodwill | 62,815 | ' | 62,829 | ' |
Deferred tax asset, non-current | 14,762 | ' | 14,209 | ' |
Other assets | 48,249 | ' | 47,661 | ' |
Total assets | 1,909,891 | ' | 1,737,917 | ' |
Current liabilities: | ' | ' | ' | ' |
Accounts payable | 32,836 | ' | 28,689 | ' |
Accounts payable to related parties | 665,432 | ' | 522,719 | ' |
Accrued expenses and other current liabilities | 143,998 | ' | 129,727 | ' |
Deferred tax liability, current | 10,567 | ' | 9,002 | ' |
Total current liabilities | 852,833 | ' | 690,137 | ' |
Other liabilities | 5,837 | ' | 6,028 | ' |
Pension liabilities | 260,023 | ' | 254,233 | ' |
Total liabilities | 1,118,693 | ' | 950,398 | ' |
Company shareholders' equity | 791,198 | ' | 787,519 | ' |
Total equity | 791,198 | ' | 787,519 | ' |
Total liabilities and equity | 1,909,891 | ' | 1,737,917 | ' |
Consolidated Statements of Comprehensive Income | ' | ' | ' | ' |
Net Income | 3,821 | -11,711 | ' | ' |
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax | 947 | 637 | ' | ' |
Other comprehensive income loss foreign currency transaction and translation adjustment before tax | -145 | -22,010 | ' | ' |
Other comprehensive income loss tax | -276 | -186 | ' | ' |
Other comprehensive income (loss), net of tax | 526 | -21,559 | ' | ' |
Total comprehensive income | 4,347 | -33,270 | ' | ' |
Comprehensive income attributable to the Company | 4,347 | -33,270 | ' | ' |
Guarantors [Member] | FMCH [Member] | ' | ' | ' | ' |
Consolidated Statements of Income | ' | ' | ' | ' |
Selling, general and administrative | -26,380 | -7,180 | ' | ' |
Operating income | 26,380 | 7,180 | ' | ' |
Other (income) expense: | ' | ' | ' | ' |
Interest, net | 45,462 | 40,298 | ' | ' |
Other, net | -154,698 | -181,689 | ' | ' |
Income before income taxes | 135,616 | 148,571 | ' | ' |
Income tax expense | -7,528 | -13,065 | ' | ' |
Net Income | 143,144 | 161,636 | ' | ' |
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax | 3,262 | 5,668 | ' | ' |
Other comprehensive income loss tax | -1,287 | -2,236 | ' | ' |
Income attributable to the Company | 143,144 | 161,636 | ' | ' |
Current assets: | ' | ' | ' | ' |
Accounts receivable from related parties | 1,654,727 | ' | 1,643,394 | ' |
Prepaid expenses and other current assets | 117 | ' | 167 | ' |
Total current assets | 1,654,844 | ' | 1,643,561 | ' |
Other assets | 12,851,806 | ' | 12,583,246 | ' |
Total assets | 14,506,650 | ' | 14,226,807 | ' |
Current liabilities: | ' | ' | ' | ' |
Accounts payable to related parties | 1,571,744 | ' | 1,600,480 | ' |
Accrued expenses and other current liabilities | 8,948 | ' | 9,403 | ' |
Current portion of long-term debt and capital lease obligations | 200,000 | ' | 200,000 | ' |
Total current liabilities | 1,780,692 | ' | 1,809,883 | ' |
Total long-term debt less current maturities | 2,586,469 | ' | 2,438,189 | ' |
Long term borrowings from related parties | 2,092,452 | ' | 2,092,818 | ' |
Other liabilities | 267,855 | ' | 267,914 | ' |
Total liabilities | 6,727,468 | ' | 6,608,804 | ' |
Company shareholders' equity | 7,779,182 | ' | 7,618,003 | ' |
Total equity | 7,779,182 | ' | 7,618,003 | ' |
Total liabilities and equity | 14,506,650 | ' | 14,226,807 | ' |
Consolidated Statements of Comprehensive Income | ' | ' | ' | ' |
Net Income | 143,144 | 161,636 | ' | ' |
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax | 3,262 | 5,668 | ' | ' |
Other comprehensive income loss tax | -1,287 | -2,236 | ' | ' |
Other comprehensive income (loss), net of tax | 1,975 | 3,432 | ' | ' |
Total comprehensive income | 145,119 | 165,068 | ' | ' |
Comprehensive income attributable to the Company | 145,119 | 165,068 | ' | ' |
Non Guarantor Subsidiaries [Member] | ' | ' | ' | ' |
Consolidated Statements of Income | ' | ' | ' | ' |
Net revenue | 3,896,574 | 3,758,626 | ' | ' |
Cost of revenues | 2,995,003 | 2,796,879 | ' | ' |
Gross profit | 901,571 | 961,747 | ' | ' |
Selling, general and administrative | 569,452 | 511,647 | ' | ' |
Research and development | 10,731 | 12,572 | ' | ' |
Operating income | 321,388 | 437,528 | ' | ' |
Other (income) expense: | ' | ' | ' | ' |
Interest, net | -7,015 | 17,184 | ' | ' |
Income before income taxes | 328,403 | 420,344 | ' | ' |
Income tax expense | 148,579 | 116,077 | ' | ' |
Net Income | 179,824 | 304,267 | ' | ' |
Other comprehensive income loss derivatives qualifying as hedges before tax | -275 | 3,033 | ' | ' |
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax | 95 | 61 | ' | ' |
Other comprehensive income loss foreign currency transaction and translation adjustment before tax | -50,268 | -115,710 | ' | ' |
Other comprehensive income loss tax | 110 | -555 | ' | ' |
Income attributable to the Company | 179,824 | 304,267 | ' | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 569,325 | 468,763 | 672,206 | 686,457 |
Trade accounts receivable less allowance for doubtful accounts of $403,657 in 2014 and $413,165 in 2013 | 2,936,792 | ' | 2,882,736 | ' |
Accounts receivable from related parties | 4,395,927 | ' | 4,073,975 | ' |
Inventories | 1,046,933 | ' | 946,790 | ' |
Prepaid expenses and other current assets | 1,041,383 | ' | 879,085 | ' |
Deferred tax asset, current | 312,758 | ' | 322,337 | ' |
Total current assets | 10,303,118 | ' | 9,777,129 | ' |
Property, plant and equipment, net | 3,003,849 | ' | 2,980,268 | ' |
Intangible assets | 662,404 | ' | 684,290 | ' |
Goodwill | 11,583,342 | ' | 11,595,358 | ' |
Deferred tax asset, non-current | 119,945 | ' | 118,306 | ' |
Other assets | 5,211,198 | ' | 5,234,132 | ' |
Total assets | 30,883,856 | ' | 30,389,483 | ' |
Current liabilities: | ' | ' | ' | ' |
Accounts payable | 517,106 | ' | 511,715 | ' |
Accounts payable to related parties | 5,126,683 | ' | 4,931,344 | ' |
Accrued expenses and other current liabilities | 1,642,610 | ' | 1,786,709 | ' |
Short-term borrowings and other financial liabilities | 100,690 | ' | 96,588 | ' |
Short Term Borrowings Due To Related Parties Current Acquisitions | 134,314 | ' | 62,342 | ' |
Current portion of long-term debt and capital lease obligations | 23,080 | ' | 40,280 | ' |
Income tax payable, current | 85,921 | ' | 56,163 | ' |
Deferred tax liability, current | 66,021 | ' | 64,539 | ' |
Total current liabilities | 7,696,425 | ' | 7,549,680 | ' |
Total long-term debt less current maturities | 7,681,126 | ' | 7,478,944 | ' |
Long term borrowings from related parties | 6,491 | ' | 6,940 | ' |
Other liabilities | 30,366 | ' | 30,399 | ' |
Pension liabilities | 142,892 | ' | 171,248 | ' |
Income tax payable, non-current | 21,549 | ' | 20,262 | ' |
Deferred tax liability, non-current | 759,967 | ' | 768,156 | ' |
Total liabilities | 16,338,816 | ' | 16,025,629 | ' |
Noncontrolling interests subject to put provisions | 631,940 | ' | 648,251 | ' |
Company shareholders' equity | 13,656,823 | ' | 13,465,147 | ' |
Minority interest | 256,277 | ' | 250,456 | ' |
Total equity | 13,913,100 | ' | 13,715,603 | ' |
Total liabilities and equity | 30,883,856 | ' | 30,389,483 | ' |
Consolidated Statements of Comprehensive Income | ' | ' | ' | ' |
Net Income | 179,824 | 304,267 | ' | ' |
Other comprehensive income loss derivatives qualifying as hedges before tax | -275 | 3,033 | ' | ' |
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax | 95 | 61 | ' | ' |
Other comprehensive income loss foreign currency transaction and translation adjustment before tax | -50,268 | -115,710 | ' | ' |
Other comprehensive income loss tax | 110 | -555 | ' | ' |
Other comprehensive income (loss), net of tax | -50,338 | -113,171 | ' | ' |
Total comprehensive income | 129,486 | 191,096 | ' | ' |
Comprehensive income attributable to the Company | 129,486 | 191,096 | ' | ' |
Combining Adjustment [Member] | ' | ' | ' | ' |
Consolidated Statements of Income | ' | ' | ' | ' |
Net revenue | -864,712 | -790,202 | ' | ' |
Cost of revenues | -845,699 | -778,255 | ' | ' |
Gross profit | -19,013 | -11,947 | ' | ' |
Selling, general and administrative | -11,887 | 25,857 | ' | ' |
Research and development | 0 | -169 | ' | ' |
Operating income | -7,126 | -37,635 | ' | ' |
Other (income) expense: | ' | ' | ' | ' |
Other, net | 373,903 | 349,039 | ' | ' |
Income before income taxes | -381,079 | -386,674 | ' | ' |
Income tax expense | -95,075 | 34,015 | ' | ' |
Net Income | -286,004 | -420,689 | ' | ' |
Other comprehensive income loss foreign currency transaction and translation adjustment before tax | 2,524 | 2,296 | ' | ' |
Less: Net income attributable to noncontrolling interests | 41,888 | 34,584 | ' | ' |
Income attributable to the Company | -327,892 | -455,273 | ' | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | -689 | 65,410 | 6,068 | 1,003 |
Trade accounts receivable less allowance for doubtful accounts of $403,657 in 2014 and $413,165 in 2013 | 1,766 | ' | 2,058 | ' |
Accounts receivable from related parties | -9,138,792 | ' | -8,609,228 | ' |
Inventories | -154,661 | ' | -137,311 | ' |
Prepaid expenses and other current assets | 36,728 | ' | 44,960 | ' |
Deferred tax asset, current | -43,848 | ' | -43,285 | ' |
Total current assets | -9,299,496 | ' | -8,736,738 | ' |
Property, plant and equipment, net | -124,790 | ' | -127,517 | ' |
Intangible assets | -91 | ' | -81 | ' |
Deferred tax asset, non-current | -109,592 | ' | -109,279 | ' |
Other assets | -31,122,565 | ' | -30,599,966 | ' |
Total assets | -40,656,534 | ' | -39,573,581 | ' |
Current liabilities: | ' | ' | ' | ' |
Accounts payable to related parties | -9,399,513 | ' | -8,827,326 | ' |
Accrued expenses and other current liabilities | 9,243 | ' | 11,027 | ' |
Income tax payable, current | -5,554 | ' | ' | ' |
Deferred tax liability, current | -42,646 | ' | -41,678 | ' |
Total current liabilities | -9,438,470 | ' | -8,857,977 | ' |
Total long-term debt less current maturities | -3,569,675 | ' | -3,434,378 | ' |
Long term borrowings from related parties | -5,458,265 | ' | -5,459,364 | ' |
Other liabilities | 23,605 | ' | 19,604 | ' |
Pension liabilities | -953 | ' | ' | ' |
Income tax payable, non-current | 110,736 | ' | 123,538 | ' |
Deferred tax liability, non-current | -25,638 | ' | -24,766 | ' |
Total liabilities | -18,358,660 | ' | -17,633,343 | ' |
Company shareholders' equity | -22,297,874 | ' | -21,940,238 | ' |
Total equity | -22,297,874 | ' | -21,940,238 | ' |
Total liabilities and equity | -40,656,534 | ' | -39,573,581 | ' |
Consolidated Statements of Comprehensive Income | ' | ' | ' | ' |
Net Income | -286,004 | -420,689 | ' | ' |
Other comprehensive income loss foreign currency transaction and translation adjustment before tax | 2,524 | 2,296 | ' | ' |
Other comprehensive income (loss), net of tax | 2,524 | 2,296 | ' | ' |
Total comprehensive income | -283,480 | -418,393 | ' | ' |
Comprehensive income attributable to noncontrolling interests | -41,855 | -32,602 | ' | ' |
Comprehensive income attributable to the Company | ($325,335) | ($450,995) | ' | ' |
Supplementary_Cash_Flow_Inform2
Supplementary Cash Flow Information (Details) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Supplementary cash flow information: | ' | ' |
Cash paid for interest | $164,393 | $165,596 |
Cash paid for income taxes, net of tax refund | 83,138 | 59,708 |
Cash inflow for income taxes from stock option exercises | 545 | 522 |
Supplemental disclosures of cash flow information, details for acquisitions: | ' | ' |
Assets acquired | -31,589 | -69,485 |
Liabilities assumed | 2,251 | 3,334 |
Noncontrolling interest | 288 | 4,527 |
Notes assumed in connection with acquisition | 7,569 | 3,690 |
Noncontrolling Interest Subject To Put Provisions | 0 | 6,294 |
Cash Paid | -21,481 | -51,640 |
Less cash acquired in acquisition | 105 | 2,530 |
Net cash paid for acquisitions | -21,376 | -49,110 |
CashPaidForInvestments | -112,848 | -22,185 |
Cash Paid For Intangible Assets | -2,933 | -919 |
Cash Paid For Acquisitions And Investments Net Of Cash Acquired And Purchases Of Intangible Assets | ($137,157) | ($72,214) |
Supplemental_Condensed_Combini3
Supplemental Condensed Combining Information (Details 1) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Operating Activities: | ' | ' |
Net Income | $247,350 | $260,083 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' |
Depreciation and amortization | 167,167 | 156,353 |
Change in deferred taxes, net | -3,459 | -22,455 |
Stock Option Compensation Expense | 6,174 | 6,220 |
Dividend income from equity method investees | 32,399 | 18,582 |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' |
Trade accounts receivable, net | -62,915 | -40,702 |
Inventories, net | -111,648 | -56,173 |
Prepaid expenses, other current and non-current assets | -26,831 | 32,079 |
Accounts payable, accrued expenses and other current and non-current liabilities | -180,308 | -99,671 |
Income tax payable | 20,756 | 62,249 |
Net cash provided by (used in) operating activities | 112,294 | 315,418 |
Investing Activities: | ' | ' |
Purchases of property, plant and equipment | -199,631 | -147,357 |
Proceeds from sale of property, plant and equipment | 2,480 | 1,327 |
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets | -137,157 | -72,214 |
Proceeds from divestitures | 2,381 | 1,036 |
Net cash (used in) provided by investing activities | -331,927 | -217,208 |
Financing Activities: | ' | ' |
Increase (decrease) of accounts receivable securitization program | 68,000 | -162,000 |
Proceeds from exercise of stock options | 5,807 | 4,635 |
Distributions to noncontrolling interests | ' | 72,619 |
Contributions from noncontrolling interests | 13,402 | 8,795 |
Net cash (used in) provided by financing activities | 116,211 | -246,467 |
Effect of exchange rate changes on cash and cash equivalents | -5,228 | -4,942 |
Cash and Cash Equivalents: | ' | ' |
(decrease) in cash and cash equivalents | -108,650 | -153,199 |
Cash and cash equivalents at beginning of period | 682,777 | 688,040 |
Cash and cash equivalents at end of period | 574,127 | ' |
Issuers [Member] | FMC US Finance [Member] | ' | ' |
Operating Activities: | ' | ' |
Net Income | 1,103 | 1,081 |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' |
Accounts receivable from/payable to related parties | 19,214 | -8,547 |
Accounts payable, accrued expenses and other current and non-current liabilities | -17,938 | -7,273 |
Income tax payable | 628 | 616 |
Net cash provided by (used in) operating activities | 3,007 | 2,971 |
Financing Activities: | ' | ' |
Long-term debt and capital lease obligations, net | -3,007 | -2,972 |
Net cash (used in) provided by financing activities | -3,007 | -2,972 |
Cash and Cash Equivalents: | ' | ' |
(decrease) in cash and cash equivalents | ' | -1 |
Cash and cash equivalents at beginning of period | ' | 1 |
Cash and cash equivalents at end of period | 0 | 0 |
Guarantors [Member] | Total FMC-AG and Co. KGaA [Member] | ' | ' |
Operating Activities: | ' | ' |
Net Income | 205,462 | 225,499 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' |
Income Loss From Equity Method Investments Net Of Dividends Or Distributions | -124,293 | -117,240 |
Depreciation and amortization | 168 | 169 |
Change in deferred taxes, net | -5,141 | -14,876 |
(Gain) loss on sale of fixed assets and investments | ' | -12 |
Write-off of loans from related parties | 54,513 | ' |
Stock Option Compensation Expense | 6,174 | 6,220 |
Dividend income from equity method investees | -43,389 | -22,816 |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' |
Prepaid expenses, other current and non-current assets | 27,932 | -19,210 |
Accounts receivable from/payable to related parties | 68,641 | 76,649 |
Accounts payable, accrued expenses and other current and non-current liabilities | -1,925 | 3,603 |
Income tax payable | 8,954 | -923 |
Net cash provided by (used in) operating activities | 283,874 | 29,397 |
Investing Activities: | ' | ' |
Purchases of property, plant and equipment | ' | 14 |
Proceeds from sale of property, plant and equipment | ' | 17 |
Disbursements of loans to related parties | -88,773 | 22,515 |
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets | 63,444 | 23,152 |
Net cash (used in) provided by investing activities | -152,217 | -45,664 |
Financing Activities: | ' | ' |
Short-term borrowings, net | -60 | 4,226 |
Long-term debt and capital lease obligations, net | -136,960 | ' |
Proceeds from exercise of stock options | -5,266 | -4,113 |
Net cash (used in) provided by financing activities | -131,754 | 8,339 |
Effect of exchange rate changes on cash and cash equivalents | 377 | 8,461 |
Cash and Cash Equivalents: | ' | ' |
(decrease) in cash and cash equivalents | 280 | 533 |
Cash and cash equivalents at beginning of period | 13 | 78 |
Cash and cash equivalents at end of period | 293 | 611 |
Guarantors [Member] | D GmbH [Member] | ' | ' |
Operating Activities: | ' | ' |
Net Income | 3,821 | -11,711 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' |
Depreciation and amortization | 13,209 | 12,184 |
Change in deferred taxes, net | 1,004 | 2,705 |
(Gain) loss on sale of fixed assets and investments | -48 | -115 |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' |
Trade accounts receivable, net | 10,600 | -15,829 |
Inventories, net | -26,758 | -12,488 |
Prepaid expenses, other current and non-current assets | -28,285 | -9,435 |
Accounts receivable from/payable to related parties | 126,606 | -52,601 |
Accounts payable, accrued expenses and other current and non-current liabilities | 23,947 | 19,261 |
Net cash provided by (used in) operating activities | 124,096 | 37,173 |
Investing Activities: | ' | ' |
Purchases of property, plant and equipment | 28,346 | 13,577 |
Proceeds from sale of property, plant and equipment | -128 | ' |
Disbursements of loans to related parties | ' | 180 |
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets | 1,216 | 1,424 |
Net cash (used in) provided by investing activities | -29,434 | -14,821 |
Financing Activities: | ' | ' |
Short-term borrowings, net | -93,960 | -22,794 |
Net cash (used in) provided by financing activities | -93,960 | -22,794 |
Effect of exchange rate changes on cash and cash equivalents | 6 | -2 |
Cash and Cash Equivalents: | ' | ' |
(decrease) in cash and cash equivalents | 708 | -444 |
Cash and cash equivalents at beginning of period | 4,490 | 501 |
Cash and cash equivalents at end of period | 5,198 | 57 |
Guarantors [Member] | FMCH [Member] | ' | ' |
Operating Activities: | ' | ' |
Net Income | 143,144 | 161,636 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' |
Income Loss From Equity Method Investments Net Of Dividends Or Distributions | -154,698 | -181,689 |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' |
Prepaid expenses, other current and non-current assets | -25,230 | -6,047 |
Accounts receivable from/payable to related parties | -1,109 | -28,490 |
Accounts payable, accrued expenses and other current and non-current liabilities | -455 | -921 |
Income tax payable | -7,528 | -13,065 |
Net cash provided by (used in) operating activities | -45,876 | -11,596 |
Investing Activities: | ' | ' |
Disbursements of loans to related parties | -63,712 | -83,644 |
Net cash (used in) provided by investing activities | -63,712 | 83,644 |
Financing Activities: | ' | ' |
Long-term debt and capital lease obligations, net | 109,588 | 1,659,914 |
Capital (decrease) increase | ' | 1,731,962 |
Net cash (used in) provided by financing activities | 109,588 | -72,048 |
Non Guarantor Subsidiaries [Member] | ' | ' |
Operating Activities: | ' | ' |
Net Income | 179,824 | 304,267 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' |
Depreciation and amortization | 162,641 | 151,774 |
Change in deferred taxes, net | 6,310 | -3,914 |
(Gain) loss on sale of fixed assets and investments | 854 | 455 |
Dividend income from equity method investees | 10,990 | 4,234 |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' |
Trade accounts receivable, net | -73,804 | -24,873 |
Inventories, net | -104,322 | -59,019 |
Prepaid expenses, other current and non-current assets | 5,543 | 66,903 |
Accounts receivable from/payable to related parties | -214,030 | 80,161 |
Accounts payable, accrued expenses and other current and non-current liabilities | -183,359 | -115,523 |
Income tax payable | 36,852 | 50,431 |
Net cash provided by (used in) operating activities | -194,481 | 286,106 |
Investing Activities: | ' | ' |
Purchases of property, plant and equipment | 179,465 | 139,502 |
Proceeds from sale of property, plant and equipment | -2,352 | 1,130 |
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets | 136,985 | 69,095 |
Proceeds from divestitures | -2,381 | -63,452 |
Net cash (used in) provided by investing activities | -311,717 | -270,919 |
Financing Activities: | ' | ' |
Short-term borrowings, net | 171,121 | 25,607 |
Long-term debt and capital lease obligations, net | 186,922 | -1,750,388 |
Increase (decrease) of accounts receivable securitization program | 68,000 | 162,000 |
Proceeds from exercise of stock options | -541 | -522 |
Capital (decrease) increase | -21,099 | -1,730,603 |
Distributions to noncontrolling interests | 52,157 | 72,619 |
Contributions from noncontrolling interests | 13,402 | 8,795 |
Net cash (used in) provided by financing activities | 408,928 | -219,480 |
Effect of exchange rate changes on cash and cash equivalents | -5,611 | -13,401 |
Cash and Cash Equivalents: | ' | ' |
(decrease) in cash and cash equivalents | -102,881 | -217,694 |
Cash and cash equivalents at beginning of period | 672,206 | 686,457 |
Cash and cash equivalents at end of period | 569,325 | 468,763 |
Combining Adjustment [Member] | ' | ' |
Operating Activities: | ' | ' |
Net Income | -286,004 | -420,689 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' |
Income Loss From Equity Method Investments Net Of Dividends Or Distributions | 278,991 | 298,929 |
Depreciation and amortization | -8,851 | -7,774 |
Change in deferred taxes, net | -5,632 | -6,370 |
Write-off of loans from related parties | -54,513 | ' |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' |
Trade accounts receivable, net | 289 | ' |
Inventories, net | 19,432 | 15,334 |
Prepaid expenses, other current and non-current assets | -6,791 | -132 |
Accounts receivable from/payable to related parties | 23,481 | -65,697 |
Accounts payable, accrued expenses and other current and non-current liabilities | -578 | 1,182 |
Income tax payable | -18,150 | 25,190 |
Net cash provided by (used in) operating activities | -58,326 | -28,633 |
Investing Activities: | ' | ' |
Purchases of property, plant and equipment | -8,180 | -5,736 |
Disbursements of loans to related parties | 152,485 | 61,129 |
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets | -64,488 | -21,457 |
Proceeds from divestitures | ' | 64,488 |
Net cash (used in) provided by investing activities | 225,153 | 30,552 |
Financing Activities: | ' | ' |
Long-term debt and capital lease obligations, net | -152,485 | 61,129 |
Capital (decrease) increase | 21,099 | -1,359 |
Net cash (used in) provided by financing activities | -173,584 | 62,488 |
Cash and Cash Equivalents: | ' | ' |
(decrease) in cash and cash equivalents | -6,757 | 64,407 |
Cash and cash equivalents at beginning of period | 6,068 | 1,003 |
Cash and cash equivalents at end of period | ($689) | $65,410 |